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Abstract
This thesis presents statistical modelling approaches and analyses for the filtration function of the
kidney in patients with cancer, using widely available clinical data.
The filtration function of the kidney is reported as the glomerular filtration rate (GFR). Many clinical
decisions, for example dose calculations for chemotherapy drugs, are based on a patient’s GFR. The
most accurate way to determine a patient’s GFR involves costly, time-consuming, and consequently
frequently unavailable methods. Therefore, GFR is commonly estimated using statistical models based
on routine clinical data. Although these models are used in patients with cancer, most of them have
been developed using data from non-cancer patients with impaired kidney function.
Here we present a new statistical model for GFR in patients with cancer. We initially collected data
from 2,579 patients managed at two cancer centres. Using regression modelling based on patient de-
mographics and serum creatinine levels, a new model, CamGFR, was developed that is more accurate
than other currently available models for GFR.
Following this, data from a further 7,944 patients were collected across nine cancer centres. These data
enabled the assessment of the impact of different creatinine measurement methods, such as standard-
ising creatinine to isotope dilution mass spectrometry (IDMS). Given that the method for creatinine
measurement affects the reported laboratory value, the CamGFR model was adjusted to allow use for
creatinine, which was or was not IDMS standardised.
Further analyses included the search for clinical correlates with renal function and assessment of
whether such correlates can improve the estimation of GFR; the effect of treatment on GFR and esti-
mated GFR; the examination of the effect of unstable creatinine on GFR estimation using longitudinal
data; and a comparison of renal function between patients with and without cancer.
In summary, this thesis presents results that may help improve the estimation of kidney function and
thereby care for patients with cancer.
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In clinical practice, decisions about patient care are made, in part, through information obtained
from a patient’s medical history but they are also made through medical investigations. These
investigations often deliver biochemical results for individuals which, when aggregated, can be
used to develop statistical models to better inform clinical practice and patient management.
One example is the use of statistical models to estimate organ function; one such function that
has long been modelled is the kidney. Knowledge of kidney function is critical to decision-
making in clinical practice as it influences decisions on treatment regimens, disease diagnosis
and progression, and drug administration. The kidney has a further advantage over other organs
in that it has a measurable quantity which represents its filtration function - glomerular filtration
rate (GFR).
GFR is the rate at which fluid is filtered from the blood to the urine, which is the key role of
the kidney. It has various uses in clinical decision-making and patient-management, one of the
main ones being to diagnose chronic kidney disease (CKD). From a cancer perspective, a key
use case of patient GFR is in dosing certain chemotherapy drugs.
Accurate assessment of a patient’s GFR can be made using methods that measure the decay of
exogenous filtration markers. However, these procedures are typically costly and require time
and expertise. Hence, the overwhelming majority of reported GFR values are estimated from a
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statistical model. These statistical models commonly relate GFR to the patient’s blood serum
creatinine concentration along with other demographic variables, such as age or sex.
There are existing statistical models to estimate GFR, however, there is cause to review them for
the following key reasons. First, an increasing amount of data is being generated by hospitals
during patient treatment, thus enabling improved statistical analysis and thus the potential for
improved models. Secondly, the methods used to measure clinical variables, such as creatinine,
are consistently evolving and improving, and this can affect any model based upon these
variables. Finally, and specifically for patients with cancer, existing models to estimate GFR
have been developed in non-cancer patient populations with limited large-scale validation for
patients with cancer. The broad implications of this are currently unknown.
Considering the aforementioned points, the purpose of this thesis is to develop a model to best
estimate GFR with a particular focus on patients with cancer. For this we collected a large
multicentre dataset of patients with cancer and used this data not only to develop a new model
but also to investigate additional aspects of patient biology that may inform renal function.
1.2 Overview of thesis
1.2.1 Chapter overview
In Chapter 2 we provide an introduction on the physiology of the kidney and approaches that
have been taken to measure and estimate glomerular filtration rate (GFR). The chapter begins
with an overview of renal function and its importance in patient management within clinical
medicine. We then introduce the anatomy and physiology of the kidneys and the measure of
a kidney’s function through GFR. Next, this chapter defines GFR and its determinants, and
provides methods used to both measure and estimate GFR. Chapter 2 concludes with a detailed
discussion providing background on the development of both historical and current models used
to estimate GFR, and critiques of these models. Whereby we establish a need for a multi-centre
comparison of these models, and a new model, for GFR in patients with cancer.
In Chapter 3, we introduce the data for this thesis in addition to relevant clinical and statistical
methodology. The first half of this chapter explains the clinical data: how data were acquired
from cancer treatment hospitals or centres; the clinical methodology used to measure GFR
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and the filtration marker, serum creatinine; the content of individual datasets; and finally
how data were evaluated and quality controlled for the purpose of this thesis. In this initial
section we point out the successive nature of data acquisition, with data acquired both pre- and
post-publication of the initial CamGFR model, which is discussed further in Chapter 4. The
second half of Chapter 3 then provides detail on statistical methodology that is relevant and
will be used in this thesis, including regression modelling, model section methods and statistics
used to compare different models.
The focus of Chapter 4 is on the development of a new serum creatinine-based model for GFR
in patients with cancer, named CamGFR. This chapter is split into three component parts:
the initial CamGFR development, comparison of creatinine values for different measurement
methods and the resultant impact on modelling GFR, and finally, expansion of the CamGFR
model for creatinine that is traceable to an IDMS standard.
In Chapter 5 we conduct an exploratory study of other biochemical and hematological blood
tests aside from serum creatinine. In this study we use the additional blood tests to more
accurately estimate GFR and to discuss the implications of the fitted relationships between
GFR and particular blood tests.
In Chapter 6 we provide further statistical and exploratory studies, discussing additional clinical
considerations for accurately modelling GFR in patients with cancer. We examine the effect of
treatment, in particular chemotherapy, on a patient’s GFR and creatinine, and the implications
of this on estimating GFR. Using longitudinal serum creatinine data we then assess estimated
GFR in patients whose serum creatinine is not stable and discuss future work in relation to this.
Finally, we compare measured GFR in patients with cancer to healthy kidney donor patients.
In the concluding chapter, Chapter 7, we reflect upon the key findings in this thesis, consider
limitations of this work and discuss how the CamGFR model and supporting studies may be
developed in the future.
1.2.2 Original contributions
I have made a number of original contributions in this thesis. Particular contributions include:
• The first multi-centre comparison of models to estimate GFR in patients with cancer
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• Development of a new model to estimate GFR in patients with cancer, for which the
applicability may go further than only for patients with cancer
• An analysis of the relationship between measured GFR and commonly used biochemical
and haematological blood tests
We expect to improve GFR modelling in the future by collecting further types of data. The
initial stages of this work are outlined in Chapter 5 and Chapter 6.
1.2.3 Publications
During my time at Cambridge, I have been a named author of four publications. Two of these
publications are directly related to the work for this thesis, which will be described in depth.
These papers are listed below:
• Janowitz, T.*, Williams, E. H.*, Marshall, A., Ainsworth, N., Thomas, P. B., Sammut, S.
J.,Shepherd, S., White, J., Mark, P. B., Lynch, A. G., Jodrell, D. I., Tavaré, S., and Earl,
H. (2017). New model for estimating glomerular filtration rate in patients with cancer.
Journal of Clinical Oncology, 35:2798–2805.
* These authors contributed equally to the work.
• Williams, E. H., Connell, C. M., Weaver, J. M. J., Beh, I., Potts, H., Whitley, C. T.,
Bird,N., Al-Sayed, T., Monaghan, P., Fehr, M., Cathomas, R., Bertelli, G., Quinton, A.,
Lewis, P., Shamash, J., Wilson, P., Dooley, M., Poole, S., Mark, P. B., Bookman, M.
A., Earl, H., Jodrell, D., Tavaré, S., Lynch, A. G., and Janowitz, T. (2019). Multicentre
validation of the CamGFR model for estimated glomerular filtration rate. JNCI Cancer
Spectrum, 10.1093/jncics/pkz068.
Additionally, I have been involved in several other projects which are not discussed in this
thesis. In particular, I was the statistician on an analysis of trends in T-cell checkpoint-targeted
cancer immunotherapy clinical trials and on the analysis of interim results from the national
Hepatitis Prevention, Control, and Elimination (HPCE) in Mongolia. This work contributed to
the publication of two additional papers and a further paper which is currently under review.
These papers are included in the Appendix and are listed below:
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• Connell, C. M., Raby, S., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D.
I., Janowitz, T. (2017), Cancer immunotherapy trial registrations increase exponentially
but chronic immunosuppressive glucocorticoid therapy may compromise outcomes.
Annals of Oncology, 28:1678–1679.
• Connell, C. M., Raby, S., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell,
D. I., Janowitz, T. (2018). Cancer immunotherapy trials underutilize immune response
monitoring. Oncologist 23:116–117.
• Dashdorj, N., Potts, H., Bungert, A., Bat-Ulzii, P., Dashtseren, B., Baatarsuren1, U.,
Myanganbayar, M., Williams, E. H., Glenn, J. S., Genden, Z., Mordorj, A., Duger, D.,
Unurjarga, T., Yagaanbuyant, D., Janowitz, T., Dashdor N. (2019), Interim results of the




Background to renal function and GFR
The aim of this chapter is to provide background information about glomerular filtration rate
(GFR), including its physiology, definition, determinants, and the methods used to measure
or estimate it. We begin in Section 2.1 by introducing renal function and establishing its
importance for patient management within clinical medicine. In Section 2.2, we provide
background information on the physiology of the kidney, a biological and mathematical
definition of GFR, and normal ranges for GFR and discuss factors which affect these. In
Section 2.3 we discuss measuring GFR using the clearance of an ideal filtration marker and
its challenges. The chapter concludes with Section 2.4, where we discuss the theory behind
estimating GFR using endogenous filtration markers, discuss the commonly used markers, and
provide a background and critique for numerous previous models developed to estimate GFR.
In providing a background to GFR, this chapter uses several sources. Key sources are listed
below and can be consulted for additional detail on the given subject areas:
• Guyton and Hall: Textbook of Medical Physiology, Chapter 26, 27 and 32 provides
further detail on the physiology of the kidney [50]
• Mathematical Physiology II: Systems Physiology, Chapter 17, provides a more mathe-
matical discussion of GFR [68]
• Chronic Kidney Disease, Dialysis, and Transplantation, Chapter 41 provides details on
the methods and theory of measuring or estimating GFR [53]
8 Background to renal function and GFR
2.1 Renal function and its role in patient management
The failure of one or more organ systems often leads to poor clinical outcomes for patients. One
of the key organ systems that affects a patient’s outcome is the renal system, which maintains
many aspects of homeostasis in the body through regulation of electrolytes, water, and pH,
excretion of metabolic waste products, and the production of hormones which control the
production of red blood cells, regulate blood pressure, and regulate calcium levels in the body.
Acute kidney injury or chronic kidney disease can cause dysregulation of electrolyte, water
and pH levels, a build-up of metabolic waste products in the blood, and failure of the hormone
systems regulated by the kidney. These problems are associated with poor clinical outcome for
patients [129]
In healthy individuals and throughout most of our lives, renal function is maintained at a steady
level, excluding changes due to circadian rhythm [69]. This steady level reflects healthy organ
tissues and, upon injury, recovery of organ tissues. However, renal function can be affected
by pathological disease processes, by ageing, and by iatrogenic insults for example surgery,
radiocontrast agents or medications [1, 49]. Epidemiological studies have demonstrated that
chronic kidney disease reduces life expectancy [41]. Loss of renal function is also associated
with poor clinical outcomes in the intensive care unit (ICU) setting [125]. This is irrespective
of the underlying disease process that initiated admission to the ICU. Importantly, a reversal of
loss of renal function has been demonstrated as a successful way to prolong life, giving way to
the common practice of renal replacement therapy, as haemofiltration in the ICU and as dialysis
in outpatient management. A final piece of evidence for the importance of intact renal function
is the survival benefit for patients who have received transplantations of donor kidneys [82].
Considering the fundamental importance of renal function to the wellbeing and survival of
patients, it is unsurprising that clinicians use renal function as a guide for many important
decision-making processes. Examples include, but are not restricted to: decision-making around
nephrotoxic intravenous contrast media administration in radiological imaging techniques, such
as computed tomography (CT) or magnetic resonance imaging (MRI) scans, as seen in the
guidelines from the Royal College of Radiologists [124]; management through intensive care
admission and haemofiltration; administration of dialysis or renal transplantation as mentioned
above; and administration of potentially nephrotoxic drugs or of drugs that are filtered and
preferentially excreted by the renal system and therefore have pharmacokinetics that are
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dependent on renal function, such as carboplatin whose dose in calculated using the Calvert
equation [13].
In conclusion, the assessment of the filtration function of the kidney is a fundamental component
in the assessment of the physiological wellbeing of a patient and informs multiple critical
decision-making processes for the management of patients and the prescription of many
medications. Having established the principal importance of renal function, the next section
will discuss the physiology of renal filtration, followed by a description of the methods by
which renal function can be measured and finally, how renal function is commonly assessed in
the clinical setting.
2.2 Anatomy and physiology of the kidney
The renal system comprises two kidneys located in the lower abdomen. They are well-
vascularised retroperitoneal organs. Functionally, their role can be divided into metabolic
contributions, endocrine functions and filtration functions. Metabolically, they have a role in
the metabolism of carbohydrates, proteins and lipids, and in converting a precursor of vitamin
D to its active form, calcitriol [26]. Endocrinologically, one of their most important functions is
the production of erythropoietin, one of the hormones that regulates production and differentia-
tion of blood precursor cells, in particular erythrocytes [61]. However, physiologically, the main
function of kidneys is filtration, which maintains fluid/water and electrolyte homoeostasis in the
entire organism and allows excretion of waste products [50, Chapter 26 and 32]. Henceforth,
when referring to renal function, only the filtration function of the kidney is being considered.
The functional unit of renal filtration is the nephron, Figure 2.1 A. Each kidney is composed of
millions of nephrons acting in parallel. These, in turn, consist of a glomerulus encased by a
Bowman’s capsule and a renal tubule. The glomerulus is a system of parallel branching and
rejoining capillaries. Blood enters the glomerulus where, due to the hydrostatic and colloid
osmotic forces acting across the capillary membrane [50, Chapter 26], fluid is filtered into the
Bowman’s capsule along with any dissolved substances of small molecular weight to form
primary urine [68, Chapter 17]. A healthy individual produces up to 160 litres of primary urine
per day. This is concentrated in the tubular system through processes of reabsorption coupled
with electrolyte balancing to produce the secondary urine of about 1.5 litres that is collected in
the bladder and ultimately excreted from the body.














































































































Figure 2.1 (A) Cross-section of the kidney and a schematic of a single nephron with the major compo-
nents labelled. (B) Plot of average relative concentrations of various electrolytes and other metabolites
as a function of distance along the renal tubule system. These include amino acids, protein, glucose,
bicarbonate (HCO3), sodium (Na), chlorine (Cl), potassium (K), urea, inulin, creatinine and polycyclic
aromatic hydrocarbons (PAH). A value above 1 indicates that the substance is reabsorbed into the blood
to a lesser extent than the water and/or is secreted into the urine in the tubules [50, Figure 26-3, p. 305
and Figure 27-14 p. 334].
Electrolytes and other metabolites are reabsorbed throughout the infrastructure of the nephron,
with different metabolites reabsorbed at different stages, as shown in Figure 2.1 (B). This
reabsorption is achieved by both passive and active transport. Amino acids, proteins and
glucose, which are essential molecules for energy and tissue metabolism and maintenance of
the body, are fully reabsorbed in the proximal tubule. Electrolytes, mainly potassium, sodium
and chloride, are reabsorbed in the loop of Henle and then become more concentrated as water
is reabsorbed in the distal tubule and collecting tubule, and are excreted in small amounts. The
same applies to bicarbonate, which is the key substance by which the kidney regulates the pH
(acid-base balance). Metabolic breakdown products such as creatinine and urea are increasingly
concentrated throughout the process of water reabsorption and the formation of secondary urine
[50, Chapter 27].
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2.2.1 Definition of glomerular filtration rate
A measurable component of the filtration function of the kidney is the glomerular filtration rate
(GFR). GFR is defined as the total volume of fluid filtered from the glomerular capillaries to
the Bowman’s capsules per unit time. This rate is influenced by hydrostatic and colloid osmotic
pressure differences between the glomerular capillaries and the Bowman’s capsule. Hence, a
mathematical expression for the glomerular filtration rate would be:
GFR = K f × (PG −PB −πG +πB) (2.1)
where K f is the glomerular capillary filtration coefficient, a product of the filtering surface
area and the hydraulic permeability of the capillaries, PG is the glomerular hydrostatic pressure
promoting filtration, PB is the hydrostatic pressure in Bowman’s capsule opposing filtration, πG
is the colloid osmotic pressure of the glomerular capillary plasma proteins opposing filtration
and πB the colloid osmotic pressure of the proteins in Bowman’s capsule promoting filtration
[50, Chapter 26]. However, this is a simplified relationship as the kidneys have mechanisms
for autoregulation of GFR including tubuloglomerular feedback and the myogenic mechanism,
which maintains a stable glomerular filtration rate despite changes in blood pressure.
2.2.2 Normal range and determinants of GFR
Before discussing normal ranges for GFR, we should first discuss the units typically used
for GFR. Although GFR is measured as units of volume per unit time, e.g. millilitres per
minute (mL/min), when assessing a patient’s renal function, in particular with regards to
chronic kidney disease, the effect of body size on GFR is often removed. This is achieved by
normalising the GFR to a body surface area (BSA) of 1.73 m2, where 1.73 m2 is the estimated
body surface area of an adult with a height of 1.7 m and a mass of 63 kg. As a result, GFR
is commonly reported in the units mL/min/1.73m2, rather than mL/min. It is important to
note that BSA cannot be easily measured and is instead estimated using an equation involving
patient height and weight e.g. DuBois & DuBois [33] or Haycock [52]. Some have questioned
the rationale of normalising the GFR to body surface area due to inaccuracies of the estimation
equation and the validity of representing body size using BSA [42]. This has led to suggestions
for the use of extracellular fluid volume (ECFV) as opposed to BSA.
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Numerous studies have been performed to calculate a normal range for GFR in healthy popula-
tions. In an analysis of 3,000 healthy potential kidney donors by The Renal Association they
report an average GFR of 100 mL/min/1.73m2 for men and 98 mL/min/1.73m2 for women
who were younger than 34, with average GFR decreasing by 0.6 mL/min/1.73m2/year for
men and 0.8 mL/min/1.73m2/year for women after that [11]. Other studies have shown simi-
lar rates of decreasing GFR. However, there is not a consensus as to whether this decline is
normal or due to age-related disease processes [53, Chapter 2].
Further to the above study, Delanaye et al. [30] discusses normal ranges from 23 different
publications. These publications often stratified their results by patients’ age and gender and
were sometimes limited to a particular ethnic group or particular GFR measurement method.
In these publications, the normal ranges differed considerably and differences between GFR
adjusted by BSA in men and women were reported in some studies but not in others. When a
difference was observed, this was typically around 8% in men and women of a similar age.
As well as body size and sex there are additional determinants of GFR, such as other patient
demographics, protein intake, pregnancy, diurnal variation and antihypertensive therapy. The
association between GFR and age has been shown in both cross-sectional and longitudinal
studies. As stated above, The Renal Association reported a decline of 8 mL/min/1.73m2
and 6 mL/min/1.73m2 per decade after the age of 34 for men and women respectively [11].
Evaluating differences in ethnicity are complicated by the fact that most studies of normal
GFR values used Caucasian populations. Where there has been evaluation of normal GFR
in different ethnic groups, typically the ethnic populations were homogeneous and hence it
is difficult to evaluate whether any observed differences are due to ethnicity or other study
designs. One study of an Indian population gave an average GFR of 81.4 mL/min/1.73m2 for
potential kidney donors [4] and in a study of a South Asian population, the average GFR was
reported as 94.1 mL/min/1.73m2 [59].
The effects of protein intake on the GFR have been widely studied, especially in the context of
chronic kidney disease. After consuming a protein meal GFR has been shown to rise, with the
type of protein and feeding habits thought to cause varying effects [53]. GFR has also been
observed to increase by up to 50% during pregnancy [18]. This increase is thought to be caused
by a decrease in oncotic pressure, πG, which itself is caused by an expansion of the plasma
volume.
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Diurnal or circadian variations in GFR are well established, with a difference of up to 30%
over the 24 hour mean [138]. The drivers for this fluctuation are not fully understood and
may be partly or wholly driven by diurnal variations in other factors affecting GFR such as
protein intake, mentioned above, or hydration [3]. Daily fluctuations in blood pressure in
normal conditions do not affect the GFR. This is due to renal autoregulation whereby the
kidneys counteract the changes in blood pressure by constriction or dilation of the afferent
arterioles, maintaining PG. However, chronic elevation of blood pressure has been associated
with deterioration in GFR, a phenomenon that is thought to be due to remodelling of the
microvasculature of the kidney. This is true for seemingly isolated hypertension and has been
confirmed for those conditions where hypertension co-exists or as a secondary phenomenon
for a primary disease such as diabetes. However, diabetes in its own right causes injury to the
vasculature presumably due to non-specific protein glycosylation by the hemiacetal form of
glucose, and this in turn will cause hypertension as well as decreasing renal function.
2.3 Measuring GFR
Given the importance of GFR in clinical decision-making, considerable efforts have been
dedicated to the assessment of GFR. GFR cannot be measured directly, so its value is instead
inferred from the clearance of an ideal filtration marker, which ideally has the following four
properties:
1. It is cleared from the blood by urinary excretion alone.
2. It is freely filtered from the glomerular capillaries into the Bowman’s capsule.
3. It is not secreted, reabsorbed, synthesised or metabolised as filtrate flows through the
renal tubules.
4. It does not affect the filtration function of the kidney.
If a substance meets all these requirements, then GFR is equal to the clearance rate Cx of the
filtration marker x. Further, the amount which is eliminated from the plasma (Ax = GFR×Px),
will equal the amount of the substance which is excreted in the urine (Ux ×V ). Hence, we can










where Cx is the clearance of filtration marker x, Ax is the amount eliminated from the plasma
per unit time, Px is the average plasma concentration, Ux is the average urine concentration, and
V is the urine flow rate.
GFR can be measured in two ways using an ideal filtration marker. Traditionally, it would be
measured via the urinary clearance of the filtration marker thus computing GFR using equation
2.2. Alternatively, GFR can be calculated using the plasma clearance of an exogenous filtration
marker following a bolus intravenous injection, using equation 2.3 with Px calculated using
the area under the decay curve and Ax the amount administered. Plasma clearance has a key
advantage over urinary clearance in that it does not require urinary collection. However, it still
requires a relatively long waiting period to determine the decay curve, approximately 5 hours,
which is exacerbated for patients with particularly low GFR values.
Many filtration markers have been proposed and used to measure GFR. Historically, GFR was
measured with urinary clearance of endogenous filtration markers such as creatinine or urea.
However, these markers cannot be truly considered ideal as they do not meet all the properties
stipulated above. In particular, creatinine clearance systematically underestimates GFR due to
creatinine reabsorption in the renal tubules. One of the early exogenous markers proposed was
inulin, which meets all the requirements for an ideal filtration marker [53, Chapter 2]. However,
it has the disadvantages of being difficult to dissolve in water, difficult to measure, in short
supply, and it is required to be administered as a continuous infusion thus only allowing it to be
used for urinary clearance calculations. Hence, other markers have been proposed and are now
more commonly used, such as: 125I-Iothalmate, Iohexol, 51Cr-Ethylenediaminetetraacetic acid
(51Cr-EDTA) or 99mTc-Diethylenetriamine pentaacetate (99mTc-DPTA). A comparison of these
markers can be found in [53, Chapter 2].
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2.4 Estimating GFR
The clearance methods for measuring GFR described above are costly, challenging to perform
and time-consuming, particularly for regular clinical practice. As an alternative, regression-
based models have been developed which regress GFR against the plasma or serum level of a
naturally occurring filtration marker along with other variables known to affect its level, such
as the factors discussed in Section 2.2.2. Most commonly, this filtration marker is chosen to be
serum creatinine. However, urea, cystatin C or a combination of markers have also been used.
2.4.1 Theoretical rationale
Equation 2.2 for GFR was derived from equating the plasma clearance rate of a filtration marker
to the rate at which it is excreted in the urine. If the filtration marker is also at a steady state in
the plasma, then its generation rate Gx must also be equal to:
Gx = GFR×Px (2.4)
However, if the marker x is not a perfect filtration marker and some reabsorption or secretion
occurs in the tubules (which is the case for the naturally occurring filtration markers mentioned
above) this can be added to Equation 2.4 as follows:
Gx = GFR×Px −Rx +Sx (2.5)






Assuming the generation, reabsorption and secretion rates remain the same, we observe that
a change in the plasma concentration implies GFR has also changed. However, we cannot
practically measure the generation, reabsorption and secretion rates in the above equation.
Instead, we use patient demographic variables as surrogates for these rates and use regression
analysis to relate GFR to the plasma concentration of the filtration marker and the demographic
variables.
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2.4.2 Filtration markers
The most commonly used filtration marker for regression-based models for GFR is serum crea-
tinine. Creatinine is formed by a non-enzymatic cyclic reaction of creatine or phosphocreatine
and as such can be understood as a by-product of energy maintenance and metabolism, which
occurs mostly in the muscles [53, Chapter 2]. This means that creatinine is produced at a
reasonably constant rate, which depends mainly on muscle mass but to a lesser extent on diet,
creatine supplements and disorders of skeletal muscle. As creatinine has a small molecular di-
ameter and does not bind to plasma proteins, it is freely filtered from the glomerular capillaries
into the Bowman’s capsule. Creatinine is also secreted by the tubules (see Figure 2.1), thus
creatinine clearance is an overestimate of GFR.
Creatinine can be measured easily in serum, plasma and urine by a variety of different methods.
The most accurate method to measure creatinine uses isotope dilution mass spectrometry
(IDMS), using either gas or liquid chromatography [131]. However, this method is not practical
on a large scale. Instead, one of two groups of methods are usually used, Jaffe or enzymatic.
Jaffe (or alkaline picrate) methods are the more traditional methods used to measure creatinine.
They use the Jaffe reaction where creatinine reacts with picrate ions under alkaline conditions to
form a red-orange complex which can be detected and quantified [57]. However, this reaction is
not entirely specific, as picrate can react with other components, known as pseudo-chromogens.
The assay is also known to have interaction with bilirubin or other specific drugs [28]. This
interference causes conventional Jaffe assays to overestimate the concentration of serum
creatinine in a given sample. The kinetic Jaffe method is an adjustment to the above where
the colour change is measured kinetically. This reduces the interference from other molecules
due to the differential rate of colour development for non-creatinine substances compared
to creatinine. Enzymatic methods were developed to further reduce the interference from
other substances. The two enzymatic methods used in clinical laboratories are the creatinine
iminohydrolase method, and the creatininase, creatinase, and sarcosine oxidase method [53,
Chapter 2].
Both Jaffe and enzymatic methods are known to have inter-laboratory variation, which is
problematic when using creatinine as a marker for kidney function [23]. Hence the National
Kidney Disease Education Program (NKDEP) and the International Federation of Clinical
Chemistry and Laboratory Medicine produced guidelines that recommended standardisation of
all creatinine assays to IDMS-traceable reference values [84]. IDMS-traceable creatinine is the
standard in the US and is now becoming common in the UK.
2.4 Estimating GFR 17
The other commonly used filtration marker is cystatin C, with reports that it should be used
as an alternative, or in addition to, creatinine. Cystatin C is a small, 122 amino acid, 13 kDa
protein that is a member of the family of cysteine proteinase inhibitors [72]. Its primary
biological function is to regulate the activity of cysteine protease enzymes, which degrade
proteins. Cystatin C is thought to be produced by all human nucleated cells at a stable rate and
as such is found in virtually all cells and body fluids. Due to its small size (3nm) it can be freely
filtered by the glomerulus. Once filtered, it is not secreted but is reabsorbed in the tubules and
degraded by the proximal tubular cells, thus not returning to the blood. A study which used
labelled cystatin C in rats showed that the clearance rate was 94% that of 51Cr-EDTA and it
was highly correlated with 51Cr-EDTA as renal function was artificially reduced [122]. The
study also observed extrarenal elimination of cystatin C in the spleen, diaphragm, heart, liver,
and lungs at approximately 15% of total cystatin C elimination.
There are two methods by which commercially available assays measure cystatin C: particle-
enhanced turbidimetric immunoassay (PETIA) or particle-enhanced nephelometric immunoas-
say (PENIA). Considerable differences have been observed between these two methods in
several studies [128, 29], highlighting the need for assay standardisation. In light of this, an In-
ternational Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Working Group
on Standardization of Cystatin C (WG-SCC) was established, and human serum reference
material for cystatin C has been developed [47].
The use of cystatin C as a filtration marker over creatinine has several key benefits. The main
benefit of cystatin C is that it is not as dependent on body composition, in particular muscle
mass has little or no effect on its concentration [127, 115]. This means that models using
cystatin C have less of a need to factor in the patient’s sex or race when modelling GFR.
Furthermore, this lack of dependence on body composition allows the possibility of producing
a model for both adult and paediatric patients. Cystatin C based models have been shown
to better predict the consequences of kidney disease, in particular end-stage renal disease,
cardiovascular manifestation, hospitalisation and death [46].
However, there are also disadvantages of cystatin C. Studies have found that cystatin C may be
affected by a number of pathological conditions, which may be caused by an underlying change
in the patient’s renal function or may be independent of the renal function. Specific examples
include increased cystatin C for patients with HIV infection [87], asthma [20], hyperthyroidism
[39], and corticosteroid treatment [8]. Decreased cystatin C was observed in abdominal aortic
aneurysm [119], neurologic inflammatory disorder [85], and (in particular for this thesis) some
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cancers [70, 130]. Furthermore, another disadvantage of cystatin C is the high cost of measuring
it compared with creatinine. In 2013 the reagent cost per test was $4 for cystatin C, compared
with $1.50 for enzymatic creatinine and $0.20 for Jaffe creatinine [120]. This high cost also
means that cystatin C is not currently routinely measured at hospitals; this is in particular true
for the hospitals where data were acquired for this thesis. Thus for a hospital to change from a
creatinine based model to a cystatin C based model they would need to add cystatin C to the
routine biochemical measurements performed, at further expense.
Another filtration marker which has been used to assess renal function is serum urea nitro-
gen (SUN). SUN concentration in urine was used as an assessment of renal function before
regression-based models for GFR were developed. SUN is a breakdown product in the nitrogen
cycle, which is made in the liver and is mainly excreted through the kidneys. Its concentration
in plasma is affected by numerous factors, in addition to GFR. These factors include dietary
protein intake, corticosteroids, diuretics, or tetracyclines, infection, trauma, congestive heart
failure, and sodium depletion [53, Chapter 2]. However, even given these factors, the concen-
tration of SUN is predictive of a patient’s renal function, with its concentration correlated with
serum creatinine concentration. Compared with creatinine, less effort has been made to study
and resolve any inter-laboratory variability of the measurement of SUN.
2.4.3 Previous models
Numerous models have been developed that model GFR and are used to estimate GFR in
clinical practice. This section will provide details of the more commonly used models both past
and present. We focus on creatinine-based models which are used later in this thesis. However,
some cystatin C models are also briefly described. The variables and units used for each model
are consistent with units provided is Table 2.1. Note that to maintain the consistency for units,
some models may be displayed differently from their original publication.
Cockcroft-Gault
In 1976, Cockcroft and Gault published a model to estimate GFR which is still used to the
present day. The Cockcroft-Gault model used serum creatinine, along with age, sex, weight
and height [22]. This equation was developed to estimate creatinine clearance, which is an
overestimation of GFR, as mentioned in Section 2.4.2. The model was derived using data from
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Key Unit Variable description
GFR mL/min Glomerular filtration rate
GFRBSA mL/min/1.73m2 Body surface area adjusted glomerular filtration rate
CCr mL/min Creatinine clearance
CCrBSA mL/min/1.73m2 Body surface area adjusted creatinine clearance
SCr mg/dL Serum creatinine
SUN mg/dL Serum urea nitrogen
Alb g/dL Serum albumin




BSA m2 Body surface area
SexF Male = 0, Female = 1 Categorical variable specifying gender
Black
Ethnically black = 1
Other = 0
Categorical variable specifying whether the patient
is ethnically black
NSAID Yes = 1, No = 0 Non-steroidal anti-inflammatory drugs
Table 2.1 Model variable notation and units.




Compared with previously published models [34, 62, 63] the Cockcroft-Gault model showed
improved accuracy in estimating creatinine clearance and was accepted as the standard method
to estimate creatinine clearance for many years.
The Cockcroft-Gault equation is still used today in certain clinical contexts due to customary
clinical practice. This is despite the fact that there are now more accurate models available and
many inherent problems associated with the Cockcroft-Gault equation. Cockcroft-Gault was
derived using a dataset of 249 patients who were mostly hospitalised men, all of whom had
chronic kidney disease (CKD). This fact alone would indicate that there would be limitations in
using this equation when the patient does not have CKD because they are more likely to have a
higher GFR. Additionally, it was developed using older methods to measure serum creatinine,
which have since improved in both accuracy and reliability.
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MDRD
The Modification of Diet in Renal Disease (MDRD) study was a multicentre trial to evaluate
the effect of dietary protein restriction and strict blood pressure control on the progression of
renal disease [74]. The study comprised 1,628 CKD patients, with measurements for GFR,
serum creatinine, and several other variables. A secondary purpose of this trial was to develop
an equation to improve the estimation of GFR from serum creatinine.
In the study, the accurate GFR measurement was calculated as the renal clearance of 125-I
Iothalamate. GFR was expressed per 1.73m2 and modelled on the log scale. The study used a
stepwise linear regression to determine a set of variables that jointly predict GFR. The variables
considered were: weight, height, sex, ethnicity, age, diagnosis of diabetes, serum creatinine
concentration, serum urea nitrogen level, serum albumin level, serum phosphorus level, serum
calcium level, mean arterial pressure, urine creatinine level, urine urea nitrogen level, urine
protein level, and urine phosphorus level. The model was developed using a random training
set of 1,070 out of the 1,628 patients.
From the MDRD study, a six-variable equation was developed containing the variables serum




However, due to serum albumin level and serum urea nitrogen level often not being available in
clinical practice, a simpler equation which did not contain these two variables was produced:
GFRBSA = 186Age−0.203SCr−1.154(1−0.268SexF)(1+0.212Black) (2.8)
After the National Kidney Disease Education Programme (NKDEP) published recommen-
dations for the measurement of creatinine in 2006 [84], which resulted in isotope dilution
mass spectrometry traceable (IDMS-traceable) creatinine being adopted, the MDRD equation
was subsequently updated for this creatinine type [76]. In this adjustment, the constant of
proportionality was changed from 186 to 175, resulting in the following equation:
GFRBSA = 175Age−0.203SCr−1.154(1−0.268SexF)(1+0.212Black) (2.9)
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This change improved the performance of the MDRD equation when creatinine was IDMS-
traceable, resulting in less biased estimates [19]. As with the Cockcroft-Gault equation, the
MDRD equation also has the limitation of being developed using a cohort of only CKD patients.
So, once again, this equation is likely to be inaccurate for any patient who does not suffer from
CKD.
CKD-EPI
Currently, the most commonly used creatinine-based model for GFR is the CKD-EPI (Chronic
Kidney Disease Epidemiology Collaboration) published in 2009 [77]. It was developed with
the aim of creating a more accurate equation than the MDRD and to remove the systematic
underestimation of GFR at high values. A pooled multicentre dataset of 8,254 patients from
six research studies and four clinical populations was used in the development of the equation.
It was further validated with an external dataset of 3,896 from six research studies and ten
clinical populations. These patients were a mix of of high-risk populations (defined as GFR
<90 mL/min/1.73m2), such as patients with CKD, and low-risk populations who were po-
tential kidney donors. Of the 8,254 in the development and internal validation dataset, 71%
came from high-risk populations. Of the 3,896 validation samples, 72% came from high-risk
populations. For the development and internal validation datasets, the accurate measurement of
GFR was calculated using the urinary clearance of 125I-Iothalamate. However, for the external
validation dataset, iothalamate and other exogenous markers were used. The original serum
creatinine values were recalibrated to the Roche enzymatic method [77].
















κ is 0.7 for females and 0.9 for males
α is −0.329 for females and −0.411 for males
This equation can be simplified to a linear regression for log(GFRBSA) with the dependent
variables log(SCr) and log(Age), sex and race. The fitted relationship for log(SCr) is continuous
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piecewise linear with one spline point, which is at a different value of log(SCr) for males and
females (Figure 2.2). The CKD-EPI model was compared to the MDRD model and showed
improved accuracy in both the internal and external validation datasets, with results consistent



















Figure 2.2 The fitted relationship between log(GFRBSA) and log(SCr) in the CKD-EPI model. Specific
examples shown are for a 50 years old male and female with no race adjustment.
Other models
Below is a list of other models; this is not an exhaustive list, but includes all models which
were analysed in this thesis, along with more recent cystatin C based models. In addition to
the models listed here, others have been developed or are a reparametrisation for different
subgroups of patients [78, 81, 54, 123]. A comprehensive list of 26 creatinine based models
published prior to 2012 was composed by Shaffi et al. [116], which compared these models for
solid organ transplant patients.
1. Jellife [62, 64, 63] Jellife published several models between 1971 and 1973 concerning
models to estimate GFR based on serum creatinine measurements. The most used model






Similar to the Cockcroft-Gault model mentioned previously, this model has many of the
same issues and so its use has declined over time in favour of newer models.
2. Wright [137]: Wright et al. published a set of models in 2001 which either did, or
did not, include creatine kinase concentration as a variable and used either Jaffe serum
2.4 Estimating GFR 23
creatinine measurements or enzymatic serum creatinine measurements. This is one of
only two models developed using data specifically from patients with cancer and the
only model out of the two to be widely used. The model was developed using a dataset
containing only 62 patients. Below is the model that does not contain creatine kinase and





3. Mayo quadratic [108]: The Mayo quadratic model was developed after the publication
of the MDRD model in an attempt to improve the estimation of GFR in patients with
age-normal GFR. It is the only model to model the relationship between log(GFRBSA)











Additionally, for the above model, if SCr < 0.8mg/dL, use 0.8 for SCr.
4. Lund-Malmo [7]: This is a revised version of the original Lund-Malmo model [6]. It
was developed using a Swedish population of 850 patients and used IDMS-traceable
creatinine. Similar to the CKD-EPI model, the fitted relationship between log(GFRBSA)
and creatinine is piecewise continuous curve. The model has the following form:
GFRBSA = exp(X +2.5+0.06SexF −0.0158Age+0.438log(Age)) (2.14)
where
if female and SCr < 150: X = 0.0121(150−SCr)





if male and SCr < 180: X = 0.00968(180−SCr)





5. Giglio [43]: This model was developed using 641 patients with cancer who were treated
at Sahlgrenska University Hospital, Gothenburg, Sweden. Along with the Wright model
discussed above, this was the only other model developed using patients with cancer and
the only one to use a reasonably large population of patients with cancer. This model is
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rarely discussed in the literature.




6. FAS [102, 101]: The FAS equation was developed to be suitable for estimating GFR in all
age groups. The model takes a slightly different approach by first normalising creatinine
by the median creatinine for matched healthy subjects. The first model (FAScrea) is




SCr/Qcrea for 2 ≤ Age ≤ 40
107.3
SCr/Qcrea ×0.988
Age−40 for Age > 40
(2.16)
where Qcrea is the median serum creatinine in a healthy population with the same age
and sex for the FAScrea model. A table of Qcrea values was provided in the manuscript
[102]. This group added to the FAScrea model by producing two new models which either





for 2 ≤ Age ≤ 40
107.3
CysC/QcysC
×0.988Age−40 for Age > 40
(2.17)





for 2 ≤ Age ≤ 40
107.3
αSCr/Qcrea+(1−α)CysC/QcysC
×0.988Age−40 for Age > 40
(2.18)
where typically α = 0.5 is chosen.
7. CKD-EPI - cystatin C [58]: An extension of the CKD-EPI model which used cystatin
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The version which includes both cystatin C and creatinine takes a similar form and can
be found in the publication [58].
8. CAPA [48]: The CAPA model was developed using the same Swedish patient population
as the Lund-Malmo mentioned previously with the addition of some adults in Japan and
children in Holland and Sweden. It uses cystatin C only as its filtration marker and is
valid for both adults and children.
GFRBSA = 130CysC−1.069Age−0.117 −7 (2.20)
9. Schwartz [112] Originally developed in the 1970 [111, 110], the Schwartz model has
since been revised using IDMS-traceable creatinine [112]. The model is suitable for






A more accurate model which contains the additional variables serum urea nitrogen,














2.4.4 Comparison of models for patients with cancer
Some previous efforts have been made to compare these models in patients with cancer,
particularly looking at patients who are treated with platinum-based chemotherapy drugs such
as cisplatin or carboplatin. We searched for all such comparisons conducted since 2007 where
different models to estimate GFR in an adult population were compared. We only included
studies that compared estimated GFR to GFR measured using a nuclear tracer method. In total
we reviewed eight publications, with the results from each publication summarised below.
• Lindberg et al. [80] compared Cockcroft-Gault and CKD-EPI for 94 patients with head
and neck cancer who were treated with cisplatin. The publication found a bias for GFR
estimated using CKD-EPI but not for Cockroft-Gault
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• Cathomas et al. [15] compared Cockcroft-Gault, CKD-EPI, Jellife, Martin, Mayo,
MDRD, Wright for 426 patients with stage I seminoma treated with adjuvant carboplatin
treated between 1999 and 2012. Wright and Cockcroft-Gault showed the least bias of the
seven models. All models were shown to lead to underdosing of carboplatin compared
with 51Cr-EDTA GFR. The data used in this publication were acquired for analysis in
this thesis.
• Lauritsen et al. [73] compared Cockcroft-Gault, MDRD, Wright and CKD-EPI for 390
patients with disseminated germ cell cancer who received conventional chemotherapy
between 1984 and 2007 at a single centre. For GFR prior to chemotherapy treatment,
Cockcroft-Gault was the most accurate with a mean absolute percentage error (MAPE)
of 10.8% followed by Wright at 11.1%. Wright was the least biased (based on percentage
error). After chemotherapy, measured GFR was seen to decline significantly without a
corresponding increase in creatinine. Thus all models overestimated GFR after receiving
chemotherapy. This publication is discussed further in Section 6.1
• Quinton et al. [106] compared Cockcroft–Gault, Jelliffe and Wright for 68 patients with
stage I testicular seminoma. The Wright model was found to be most accurate with
a MAPE of 12.9%, and also the least biased. The data used in this publication were
acquired for analysis in this thesis.
• Craig et al. [24] compared MDRD, CKD-EPI and Cockcroft-Gault for 288 patients
who were treated with chemotherapy. All three models were found to be biased to
overestimate GFR. Cockroft-Gault was the most accurate based on the proportion of
patients with an absolute percentage error less than 30% (P30).
• Ainsworth et al. [2] compared Cockcroft–Gault, Jelliffe, Wright and MDRD in 660 oncol-
ogy patients from Addenbrookes Hospital, Cambridge and found that Cockcroft–Gault
was the most accurate and least biased. The patient data used in this publication form a
subset of the data analysed acquired from Addenbrookes Hospital, Cambridge for this
thesis.
• Barraclough et al. [5] compared Cockcroft–Gault, MDRD and Wright for 367 patients
with cancer between April 2005 and January 2007. Wright was found to be the most
accurate with a MAPE of 19%. Wright and Cockroft Gault were the least biased.
• Poole et al. [100] compared MDRD, Cockcroft-Gault, Wright, Martin, and Jelliffe in
510 patients with cancer. Wright was the most accurate as measured by the proportion
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of patients with an estimated GFR within 30% of their measured GFR (P30). Wright
and Martin were the only two models which were not biased. Data from this publication
were acquired for analysis in this thesis.
This review demonstrated a need to carry out a large multi-centre validation of models to
estimate GFR in patients with cancer for a number of reasons. First, although the Wright
model was seen to be most accurate in three out of the eight publications, they generally had
inconsistent conclusions in assessing which model is more accurate or least biased. Moreover,
all of these publications used patients from a single centre, with some comprising only of
patients with a particular cancer type. Finally, most publications used creatinine which was not
IDMS-traceable.
A further demonstration of the inconsistent choice of model for patients with cancer can be
shown by examining the methods used to determine GFR in clinical trials involving carboplatin.
In a sample of clinical trials, 51Cr-EDTA [56, 92, 140], the Cockcroft-Gault model [66, 27,
105], the Jelliffe model [32, 67, 95, 103], and 24 hour urine creatinine collections [92] were all
used to calculate GFR. All these calculated the dose for carboplatin for the determined GFR
using the Calvert equation [13].
2.5 Summary
This chapter has introduced GFR, its determinants and methods used to both measure and
estimate it. We have discussed previous regression-based models to estimate GFR and identified
a clinical need to develop a new model especially for patients with cancer. This need arises due
to the fact that none of the available models, with the exception of the Wright model which
was developed using a small sample of 62 patients and the Giglio model which is rarely cited,
have been developed using data from patients with cancer. Despite this, these previous models
are commonly used in day-to-day clinical medicine for patients with cancer, in particular for
dosing carboplatin.
Additionally, there is limited consensus for the best method to estimate GFR when different
models are compared in a population of patients with cancer. This is demonstrated in the
literature review of previous publications. It is also further evidenced by the lack of consensus
in the method used to calculate GFR with respect to carboplatin dosing in clinical trials. This
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limited consensus demonstrates the need for further comparison of previous models, and a new
model, for GFR in patients with cancer.
In Chapter 4 we work to address these areas of clinical need. We will both develop our own
new model and compare previously published models with a large multi-centre validation to
assess the most accurate and least bias method for estimating GFR in patients with cancer.
First, in Chapter 3 we introduce the data we will use and the relevant clinical and statistical
methodology that will guide this work.
Chapter 3
Methodology
This chapter introduces the data, which was collated from multiple cancer treatment centres,
and the clinical methodology used for these data. We then give detail of some of the statistical
methodology used throughout the remainder of this thesis.
3.1 Clinical methodology
This first section focuses on the clinical and data methodology. We start with an explanation of
how data were acquired from cancer treatment hospitals or centres, noting the successive nature
of data acquisition both pre- and post-publication of the initial CamGFR model. The individual
datasets are then described in order to detail the contents and measurement methods used at the
hospitals or centres. We conclude this section by evaluating data inclusion or exclusion criteria.
3.1.1 Data acquisition
The majority of data for this thesis were obtained from patients treated at Addenbrooke’s
Hospital, Cambridge. These patient data were originally acquired from Addenbrooke’s Hospital
by Dr. Nicola Ainsworth under an audit project. This project was later expanded to acquire
more anonymised data, under a quality improvement project. The project was approved by
the audit team (Service Evaluation no. is 907; QSIS reg. no. 6907) and by Dr. Hugo Ford
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(divisional director). Dr. Tobias Janowitz (Honorary Consultant and CRUK Scientist) was the
lead name on the project.
Additional data were obtained from other cancer treatment hospitals or centres. Candidate
centres were identified by literature review and through established clinical collaborations. All
major oncological centres within the UK were approached. The following centres provided
data: University Beatson West of Scotland Cancer Centre, Glasgow; Hospital Southampton
NHS Foundation Trust; a combined South Wales hospital group; Manchester University NHS
Foundation Trust; Western General Hospital, Edinburgh; and Barts Health NHS Trust, London.
Clinicians had oversight over the quality improvement project (QIP), audit or study protocol
at their respective centre. The named contact clinician or clinicians for each of these centres
were: Dr P. Mark; Dr M. Fehr and Dr R. Cathomas; Dr G. Bertelli; Dr J. Weaver and Dr P.
Monaghan; Dr I. Beh; and Dr J. Shamash, respectively. Data from two additional international
centres were acquired: Sahlgrenska University Hospital, Gothenburg; and the Peter MacCallum
Cancer Institute, Melbourne. The named contact clinicians were Dr D. Giglio and Dr M
Dooley, respectively. Data were fully anonymised prior to transfer for analysis. No identifiable
patient information was exchanged in the process of data compilation. Ethical approval for data
acquired at the other cancer centres was overseen by the lead clinician from that centre.
The data described above were acquired in succession, with the content and structure of Chapter
4 reflecting this. Originally, a dataset, hereafter referred to as Cambridge Original, was acquired
from Addenbrooke’s Hospital over 6.5-year period from August 2006 until January 2013. A
subset of these data were previously used in a publication [2]. Additionally, a second previously
published dataset, referred to as Glasgow and composed of male patients only with stage I
seminoma, was obtained from the Beatson West of Scotland Cancer Centre, Glasgow, United
Kingdom [118]. These data informed the analysis in Section 4.1 and the publication of the
CamGFR model [60].
After publication of the CamGFR model eight new datasets were acquired. One of these was
a second dataset from Addenbrooke’s Hospital and is referred to as Cambridge New. This
dataset consisted of patients treated between January 2013 and April 2019. When both datasets
(Cambridge Original and Cambridge New) are combined for analysis, the data are referred
to as Cambridge. The other seven new datasets were of patients treated at different cancer
centres across the UK and internationally: University Hospital Southampton NHS Foundation
Trust [15]; a combined South Wales hospital dataset [106, 90]; Manchester University NHS
Foundation Trust; Western General Hospital, Edinburgh; Sahlgrenska University Hospital,
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Gothenburg [43]; the Peter MacCallum Cancer Institute, Melbourne [100]; and Barts Health
NHS Trust, London, with citations indicating previous publications containing these data.
These datasets shall be referred to as Southampton, South Wales, Manchester, Edinburgh,
Gothenburg, Melbourne, and London-Barts respectively. These data were from a variety of
different sources. Some data were historical and had been used in previous publications, which
are given above, while others were collected specifically for this thesis.
3.1.2 Content and measurement methods for datasets
All datasets contained the following minimum set of variables for each patient: nuclear medicine
measured GFR (mL/min), blood serum creatinine (mg/dL), sex, age (years), height (cm) and
weight (kg). Additionally, a final variable for body surface area (m2) was calculated for all
samples. This variable was not measured but calculated using patient height and weight in the
DeBois equation [33]:
BSA = 0.007184×Height0.725 ×Weight0.425
The typical procedure for calculating nuclear medicine GFR (nmGFR) is by an intravenous
bolus injection of an exogenous filtration marker, with clearance computed from the amount
of the marker administered divided by the area under the curve of plasma concentration over
time. The exogenous filtration markers 51Cr-EDTA or 99Tc-DPTA were used, as indicated
specifically in Table 3.1.
For nmGFR performed at Addenbrooke’s Hospital, Cambridge, a fixed dose of 2 megabecquerel
(MBq) was injected and measured at three time points. The protocol for time points was 1, 2
and 4 hours post-injection by venous extraction and direct blood or plasma scintigraphy. For
measurements performed at Western General, Edinburgh, where 99Tc-DPTA was used, a dose
of 10MBq was administered and measurements were performed 1, 2 and 3 hours post-injection.
Blood serum creatinine (SCr) was measured using either a Jaffe or enzymatic method, both
of which are described in Section 2.4.2, by using clinical analysers from a variety of different
providers. Information on the clinical analysers and the method used for each centre is provided
in Table 3.1.
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Data set Creatinine measurement method Nuclear tracer
Cambridge Original Dimension RXL composted Jaffe, non-IDMS-traceable 51Cr-EDTA
Glasgow An Abbott Architect assay using the Jaffe method, IDMS-traceable 51Cr-EDTA
Southampton
Jaffe method; given the date range, most




Different centres used either Jaffe or enzymatic methods;
IDMS usage not known
51Cr-EDTA
Manchester
Before 08/06/16: Jaffe method, using O’Leary reagent
After 08/06/16: Kinetic Jaffe on Siemens ADVIA
analyser, IDMS-traceable
51Cr-EDTA
London-Barts Unknown method; IDMS usage not known 51Cr-EDTA
Edinburgh
An Abbott Architect assay using the Jaffe method
non-IDMS-traceable
99Tc-DPTA
Gothenburg Roche enzymatic colorimetric test, IDMS-traceable 51Cr-EDTA
Melbourne Jaffe method; non-IDMS-traceable 99Tc-DPTA
Cambridge New
Before 12/12/13: Dimension RXL composite Jaffe,
non-IDMS-traceable
12/12/13 - 01/03/16: Siemens ADCEA 2410 Jaffe, IDMS-traceable
After 01/03/16: Siemens ADCEA 2410 Enzymatic, IDMS-traceable
51Cr-EDTA
Table 3.1 Summary of the creatinine and GFR measurement methods used at each centre which
contributed patient data. IDMS-traceable indicates that the creatinine values were traceable to isotope
dilution mass spectrometry standard reference material.
In addition to the minimum set of variables, some of the datasets had additional variables and
information:
• Disease diagnosis was known for all patients apart from those from Melbourne.
• Specific date differences between GFR and creatinine measurements were known for all,
apart from Southampton, South Wales, and Melbourne.
• Ethnicity was known for the majority of the patients from Cambridge New and Manch-
ester.
• The Gothenburg dataset included the additional variables: previous and current treatment,
diabetes, insulin, metformin and hypertension.
• The Glasgow dataset included the additional variables: serum urea nitrate (mmol/L) and
albumin (g/L) concentrations, information on clinical diagnoses such as type 2 diabetes
mellitus and hypertension, and information on chemotherapeutic treatment in the form of
the area-under-the-curve (AUC) for the administered carboplatin dose.
• The Cambridge New and London-Barts datasets included several routine biochemical
and haematological blood test results. Cambridge New included all blood tests that the
patient received within 30 days of their nmGFR measurement, whilst London-Barts
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included only a subset of these variables. These variables included, but are not limited
to, albumin (g/L), sodium (mmol/L), serum urea nitrate (mmol/L), alkaline phosphates
(U/L), potassium, hemoglobin (g/L), white blood cells count (109/L), mean corpuscular
volume (fL).
Some of the datasets contained patients who had more than one nmGFR measurement. In
particular Edinburgh, Gothenburg, Cambridge Original, and Cambridge New were known to
have some patients with two or more nmGFR measurements, although this was not known
for Cambridge Original when the data were first acquired. Additionally, there is a small
overlap where some patients have nmGFR measurements in both the Cambridge Original and
Cambridge New datasets.
3.1.3 Inclusion and exclusion criteria
After receiving data from different cancer centres, the data were evaluated and quality controlled.
This process involved adjusting units of measurements to be consistent across datasets, cor-
recting obvious data and annotation errors, and excluding data where the reason for suspected
errors could not be identified.
Records with data outside the inclusion criteria were removed prior to analysis. The inclusion
criteria were:
• Serum creatinine value between 18 µmol/L (0.2 mg/dL) and 400 µmol/L (4.5 mg/dL)
• Age of 18 years or older
• Creatinine and GFR measurements performed within 30 days of each other
The creatinine cut-off values were chosen for the following reasons: the lower value is the
typical detection threshold on the measurement assay; the upper value is 3-4 times the upper
limit of the normal range of creatinine defined at most centres, thus corresponding to a value at
which most clinicians would consider kidney function severely impaired. Only adult patients
were included as adolescent physiology can differ considerably from adult physiology. The
choice of 30 days was made to minimise errors caused by changing creatinine. This criterion
is further assessed in Section 4.3.2. Criteria for the inclusion of patients with repeat GFR
measurements changed for the different workflows and these are given in the relevant sections.
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3.2 Statistical methodology
This section provides background to the main regression methods used in this thesis. We begin
by introducing linear models, and their generalisation to generalised linear models, which
themselves can be further generalised to generalised additive models. Then we discuss various
methods used for selecting variables for different regression models and the statistics used to
compare different models.
3.2.1 Background to linear, generalised linear and generalised additive
models
A normal linear regression model assumes that the regression function E(Y |X) for the variable
Y is a linear combination of the covariates X = (X1,X2, . . . ,Xp). The model can be split into
three components:
1. The structure of covariates as a linear predictor
η = β T X
where X represents the covariates and β are the regression coefficients associated with X
2. The relation η = µ between the expectation µ = E(Y |X) and the linear predictor η
3. The probability distribution for Y , which is assumed to be normal
Y ∼ N(µ,σ2)
A generalised linear model (GLM) is a generalisation of a linear model which extends compo-
nents 2 and 3. Specifically,
2. The linear predictor η is mapped to the expectation µ = E(Y |X) by the response function
h such that
µ = E [Y |X ] = h(η) = h(β T X)
Equivalently,
g(µ) = β T X
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where g = h−1 is known as the link function. The link function is used to transform
between the range of the response variable and range of the linear predictor.
3. The probability distribution for Y is from the exponential family of distributions, where







where b and c are fixed real-valued functions, θ is the natural parameter, φ is the disper-
sion parameter of an exponential family of distributions. Most common distributions,
including the normal, Bernoulli, Poisson, and gamma can be written in this form.
A generalised additive model further generalises component 1, allowing a more general rela-
tionship between the linear predictor and the covariates. Specifically
1. Each covariate xi is related to the linear predictor η by a function fi





where the functions fi may be parametric, non-parametric or semi-parametric.
Parameters are most commonly estimated using maximum likelihood. The likelihood equations
are almost always non-linear and cannot be solved analytically. Instead, these equations are
often solved using iterative weighted least squares, which is an example of Fisher scoring
[114]. In this thesis parameters were evaluated using the R package stats [107] for linear and
generalised linear models, while the R package mgcv [134] was used for generalised additive
models.
Box-Cox transformation
Box and Cox produced a method in 1964 that aims to find a power transform for the response
variable y in a linear regression such that all the model assumptions are satisfied [10]. Suppose






log(y) λ = 0
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such that y(λ ) satisfies the standard linear model assumptions (including that y(λ ) has a normal
distribution). The Box-Cox method then chooses λ via a likelihood argument. Omitting the
intermediate steps, the profile log likelihood for λ , dropping any terms that do not depend on
λ , is:









log(RSSλ ) = (λ +1)∑ logyi
where RSSλ is the residual sum of squares for the regression, and β̂λ and σ̂2λ are the usual
maximum likelihood estimates. A plot of Lp(λ ) can then summarise the information concerning
λ , with an approximate 1−α confidence interval given by the λ values satisfying:






The R package MASS [126] was used to calculate these Box-Cox transformations.
3.2.2 Variable selection and regularisation
Variable selection is intended to choose the best subset of predictors which together explain
the variability observed in the response variable. This is carried out for a number of reasons:
to explain the data in the simplest way (the principle of Occam’s Razor states that among
several plausible explanations of a phenomenon, the simplest is the best); to avoid the use of
unnecessary predictors will add noise when using the model for estimation; and cost – if the
model is used for prediction we should avoid including additional predictors which may cost
more to measure.
When considering variables to include in a model it is important to respect the hierarchy. This
means that an interaction term x1x2 between variables x1 and x2 should not be included in a
model unless both x1 and x2 variables are also included. To do so would mean that interpretation
of variables would be scale dependent.
There are many different methods to use for variable selection. Below we will outline the
methods chosen for the regression models considered in this thesis.
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Subset selection
Subset selection aims to choose a set of variables which minimise a given information criterion
(IC). Ideally, a model would be fitted for all possible subsets of the p predictors and the
information criterion calculated for each model. The model which minimises the IC would then
be chosen. However, if we have p predictors, the number of models to be examined is 2p (not
including possible pairwise interactions or different transformations to the predictors), which
increases exponentially as p increases. Hence, for computational reasons stepwise methods
are commonly used [51, Chapter 3]. These methods work by moving through the hierarchical
model space and during each iteration of the algorithm, comparing models using an information
criterion. Forward selection, backwards elimination or bidirectional elimination methods can
be used. This thesis used bidirectional elimination, where the algorithm works by:
1. Beginning at a given model, such as null model, which only contains the coefficient for
the intercept
2. For each iteration, calculating the IC for all possible models that can be reached by
adding or subtracting one model term to the current model (ensuring the model remains
hierarchical)
3. Choosing to move to the model that has the smallest IC value
4. Repeating the process until no more model terms are added or subtracted
Forward selection and backwards elimination work similarly, except that model terms may only
be added during forward selection or removed during backwards elimination.
There are numerous choices for the information criterion used to select the best model, with
common choices including Mallows’s Cp, Akaike’s information criterion (AIC), Bayesian
information criterion (BIC) or adjusted R2. In this thesis we will use BIC, as it tends to select






where L̂ is the maximised value of the log likelihood, n is the number of observations and p is
the number of parameters [113].
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In addition to using BIC as an information criterion we consider two cross-validation based
criteria [51, Chapter 7] [139, 12, 117]. These have the advantage that they provide a direct
estimate of the test error, and help to avoid overfitting, which can be an issue with the above
methods. For cross-validation, observations are randomly divided into a training dataset and
testing dataset. Parameters of the model are then estimated on the training set, and are then used
to estimate the dependent variable in the testing set. The accuracy of these predictions is then
summarised, most commonly using root-mean-square-error (RMSE). In k-fold cross-validation,
the data are split into k groups. Each of these groups is subsequently used as a test set, while
the rest of the groups are combined as a training set. Thus we obtain k estimates of RMSE
which are combined by taking the average. For this thesis two values of k are used, 5-fold cross
validation, and leave-out-1 cross validation (where k = n, the number of observations). When
performing 5-fold cross-validation, the statistic has a random component associated with it due
to the random nature of splitting the dataset into five groups. To mitigate this randomness the
cross-validation is repeated R times, and the cross validation statistics averaged. When using
a five-fold cross validation criterion, where the data are randomly split into five subsets, the
procedure was repeated 2,000 times with the most commonly observed model selected.
Shrinkage methods
As an alternative to the subset selection methods, techniques that shrink coefficient estimates
towards zero can be used. Shrinkage methods have the advantage of subset regression in that
they do not suffer from the high variability caused by having a variable either discarded or
retained [51, Chapter 3]. Here we discuss elastic net regularisation, which is a generalisation of
the lasso and ridge regression methods.
For lasso (least absolute selection and shrinkage operator) regression where the coefficients
β̂ lasso minimise:




|β j|≤ λ (3.2)
where λ ≥ 0 is a penalisation parameter which controls the shrinkage, with smaller values
increasing the shrinkage of coefficients towards zero. This penalty term results in shrinking the
coefficients towards zero by a fixed amount which is dependent on λ . Some coefficients will
be exactly zero with a sufficiently small λ , thus lasso is also performing variable selection. The
coefficients are calculated using the least angle regression algorithm.
3.2 Statistical methodology 39
The other common alternative to lasso regression is ridge regression, which uses an alternative
penalty term. Here the coefficients β̂ ridge minimise:






j ≤ λ (3.3)
With this penalty term the shrinkage of the coefficients is dependent on the value of the
coefficients and hence no coefficients will exactly equal zero. Both these penalty terms are
combined for elastic net regularization where coefficients β̂ elastic minimise:




((1−α)|β j|+αβ 2j )≤ λ (3.4)
where α ∈ [0,1] determines the mix of the two penalties.
To choose the appropriate penalisation parameter λ a cross-validation approach is used, whereby
a model is fitted over a grid of λ values. For each model the mean-squared error is calculated
using 10-fold cross validation. Finally, the model is refitted using all the available observations
and the selected value of the tuning parameter. When choosing the final λ value, it is further
recommended to choose the λ which is one standard deviation larger than the minimum value.
This is recommended so that the simplest model is chosen, whose accuracy is comparable with
the best model [51]. The R package glmnet [40] was used to fit all elastic net models.
Variable selection for GAMs
When considering GAM models we used the R package mgcv [135] to select smoothness
parameters and model variables. We chose to use the semi-parametric P-spline (or penalised
B-spline) for any continuous variable [37]. P-splines combine a B-spline basis, with a penalty
on the basis coefficients. This penalty term is included to impose smoothness and reduce
overfitting.
To estimate the smoothing parameters from the data we used restricted maximum likelihood
(REML), which works by treating the smoothing parameter as a variance and iteratively
updating it by choosing the value which maximises the restricted likelihood function [133].
However, P-splines and smoothness selection using REML can not remove a smoothed variable
from the model entirely. This is due to the P-splines considering some set of non-zero functions
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as completely smooth, with further penalisation not changing the fitted function. To overcome
this an additional penalty is added, which penalises only functions in the null space of the
P-spline penalty [136]. Further detail can be found in the mgcv R package [135] documentation
and in the provided citations.
3.2.3 Statistics for model comparison
When evaluating or comparing the performance of statistical estimation methods we will
discuss three different measures of performance: bias, precision and accuracy. The bias of an
estimator is the difference between the expected value of the estimator and the true value of
the quantity being estimated. When this difference is zero we call the estimator unbiased. The
precision of an estimator is a measure of how similar multiple estimates are to each other, and
not necessarily to the true value. In other words, precision is the reciprocal of the variance of
an estimator. Bias and precision are then two components of accuracy, which is a measure of
closeness of the estimated value and the true value of the quantity.
To assess these three measures four different metrics were used. The median residual was
used to assess bias, the residual interquartile range (IQR) was used to assess precision, and
both root-mean-squared error (RMSE) and the proportion of patients with an absolute error
greater than 20% (P20) were used to assess accuracy. The two measures of accuracy represent
a traditional measure of accuracy (RMSE) and a more clinical robust measure of accuracy
(P20), where 20% reflects a clinically significant error. For Section 4.1 we additionally used
median percentage error (MPE) and absolute percentage error (APE) to assess a models bias
and accuracy respectively.
For each of these statistics, 95% confidence intervals were calculated using the bootstrap
resampling procedure. Specifically, 2,000 resamples with replacement (where the sample size
was the same as the number of data points) were taken from the data. The metric was then
calculated for each of these 2,000 samples and using the normal approximation a confidence
interval was constructed [25].
To calculate p-values for the hypothesis test between two models for a given metric, another
bootstrap procedure was used [36]. This procedure has two samples z and y of lengths n and
m respectively, from the probability distributions F and G. In our case F and G were the
probability distributions of the residuals for the two equations of interest. The null hypothesis
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H0 : F = G was tested against the alternative hypothesis H1 : F ̸= G. Then let x = [z,y], and
choose a test statistic t(x), which has the form t(x) = f (z)− f (y), where the function f (·)
was either RMSE, median, IQR or P20. An approximate p-value is calculated by using the
following procedure:
• For r = 1, ...,R, let x∗r be a sample with replacement of size n+m from the pooled vector








r ) = f (z
∗
r )− f (y∗r ), r = 1,2, ...,R




where tobs = t(x) = f (z)− f (y) is the observed value of the statistic and 1A is the
indicator function which returns 1 if A is true and 0 otherwise. The absolute values of t
are considered so as to perform a two-sided test.
It should be noted that the hypothesis test is strictly testing the null hypothesis H0 : F = G and
not the null hypothesis H0 : f (F) = f (G). When the approximate p-values are calculated with




A new creatinine-based model for GFR
This chapter describes the process of developing a new serum creatinine based model to
estimate GFR. In Section 4.1 we describe the initial development of a new model, CamGFR.
Following this, and after additional data were collected, Section 4.2 validates the CamGFR
model and compares it with previously developed models. This section further examines the
impact of different methodologies to measure serum creatinine on model accuracy. Given these
results, the CamGFR model was redeveloped using a larger dataset in Section 4.3. Finally,
some closing remarks and discussion are provided in Section 4.3.3.
4.1 CamGFR: developing the original model
In this section we describe the original development of the CamGFR model [60]. As described
in Section 3.1, the data used for this analysis consisted of a dataset of patients with cancer from
Addenbrooke’s Hospital, Cambridge Original, along with a small supplementary dataset of
patients all with stage I seminoma from Beatson West of Scotland Cancer Centre, Glasgow.
The model was developed and internally validated using the Cambridge Original dataset with
external validation performed using the Glasgow dataset.
Whilst developing the CamGFR model (which ultimately modelled square-root transformed
GFR as an ordinary linear model), linear, generalised linear and generalised additive models
were all considered, as discussed in Section 3.2.1. The analysis of linear and generalised linear
models will be discussed and compared in the following sections. Generalised additive models
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were considered but ultimately discounted due the complexity in providing a written equation
for a clinician to use and unreliable prediction intervals. However, generalised additive models
are later used in Chapter 5 when we consider including additional variables into a model.
Previous models, such as the CKD-EPI or MDRD, modelled GFR using body surface area
adjusted units. As discussed in Section 2.2.1, this is due to healthy kidney function being
viewed as a function of the patient’s BSA and hence general clinical decisions are made using
these adjusted units. However, when prescribing a renally excreted drug based on the patient’s
renal function, such as carboplatin, GFR in unadjusted units is used, which can also be referred
to as absolute GFR. Furthermore, there is no universal consensus on which equation to use to
calculate a patient’s body surface area, with the DuBois & DuBois [33] and Haycock [52], two
commonly used equations. This lack of consensus and the small differences between alternative
equations for GFR can result in additional errors being introduced. Thus to mitigate for this we
chose to model GFR in its natural units, mL/min, and considered BSA (calculated using the
DuBois & DuBois equation) as a variable for the model.
4.1.1 Data cleaning and description
Before analyses were performed, data were examined and cleaned. This involved first graph-
ically examining the data and editing any obvious mistakes. For example, one patient was
identified as having their height and weight interchanged. If the source of the mistake was
not obvious then those data were excluded. Data were also excluded if they did not meet the
inclusion criteria described in Section 3.1.3; 193 were removed as the time between GFR and
creatinine measurement exceeded 30 days and 19 patients with an age of less than 18 years
at the time of the measured GFR date were removed. Due to early anonymisation of the data
used for the original analysis, no information was available as to whether any nuclear medicine
GFR measurements were from patients who had repeat measurements, hence, data were not
excluded based on this criterion.
After the above patients were excluded, there was a total of 2,471 patients in the Cambridge
Original dataset and 111 in the Glasgow dataset. Table 4.1 summarises the patient characteris-
tics for these two datasets.
The patient population in the Cambridge Original dataset was diverse as evidenced by a
wide range of measured GFR (11–211 mL/min), age (18–92 years), and serum creatinine
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Cambridge original Glasgow
median (IQR) range mean (SD) median (IQR) range mean (SD)
Age [years] 61 (50-69) 18-92 58 (15) 39 (33-46) 21-69 40 (10)
Weight [kg] 73 (62-85) 37-163 75 (17) 86 (76-98) 51-161 87 (18)
Height [cm] 168 (161-176) 125-200 168 (10) 178 (174-182) 131-192 177 (8)
BSA [m2] 1.84 (1.67-2.00) 1.24-2.79 1.84 (0.23) 2.04 (1.92-2.15) 1.48-2.73 2.04 (0.21)
Serum creatinine [mg/dL] 0.91 (0.77-1.07) 0.29-5.62 0.96 (0.34) 0.92 (0.81-1.01) 0.62-1.45 0.92 (0.14)
51Cr-EDTA GFR [mL/min] 81 (63-103) 11-211 84 (29) 113 (101-131) 45-202 116 (26)
51Cr-EDTA GFR [mL/min/1.73m2] 79 (62-94) 10-201 78 (24) 95 (88-105) 35-160 98 (17)
No. (%) No. (%)
51Cr-EDTA GFR
<40 mL/min/1.73m2 131 (5) 1 (1)
[40 , 60)mL/min/1.73m2 430 (17) 1 (1)
[60 , 90)mL/min/1.73m2 1134 (46) 34 (30)
≥90 mL/min/1.73m2 775 (31) 75 (68)
Sex
Female 1398 (57) 0 (0)
Male 1073 (43) 111 (100)
Abbreviations: BSA - body surface area, GFR - glomerular filtration rate, IQR - inter quartile range
[a,b) indicates values ranging from a to b excluding a but including b
Modified from Table 1 in [60]
Table 4.1 Patient characteristics for the Cambridge Original and Glasgow datasets.
(0.29–5.62 mg/dL). Patients had a higher mean measured GFR (78 mL/min/1.73m2) than
previously published studies that were mostly reliant on patients with kidney disease rather
than with cancer, as discussed in Section 2.4.3. In particular, it was significantly higher
than the patient population used to develop CKD-EPI (68 mL/min/1.73m2) and 186-MDRD
(39.8 mL/min/1.73m2) models. Furthermore, the median (79 mL/min/1.73m2) was higher
than the median of the patient population used to develop the Wright model (73 mL/min/1.73m2).
The patient population contained a higher proportion of males (57%) compared with females
(43%). The median age of the patients was 61.1 years, which is older than the UK population
average but was expected given that all of the patients have had cancer. In fact, the average age
of a cancer patient at diagnosis was 68 in the UK between 2014 and 2016 [14]. Male patients in
the dataset were younger on average than female patients (median 56 years compared with 64
years). This difference can be explained by the patients’ type of cancer which is treated using
carboplatin chemotherapy, in particular germ cell tumours and ovarian cancer. Of the 1,250
patients with a categorised diagnosis, 231 males were categorised with a germ cell tumour
and 404 females were categorised with a gynaecological cancer, which were the largest cancer
subgroups for each sex, and these patients had a median age of 35 and 65 respectively.
The patients’ blood serum creatinine (SCr) ranged from 0.29 to 5.62 mg/dL. However, 90%
of the data were distributed between 0.59 and 1.54 mg/dL, with a mean value of 0.96 mg/dL.
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Serum creatinine had a skewed distribution with a long tail to the higher values. Males had
higher values of serum creatinine, mean 1.06 mg/dL compared with 0.883 mg/dL for females.
However, as males tend to have greater muscle mass, and as muscle mass is correlated with
serum creatinine, this was not an unexpected finding. The variables height, weight and surface
area all had approximately normal distributions.
Figure 4.1 shows the bivariate relationship between GFR and the other variables. Height,
weight and BSA have an approximate liner relationship with GFR. For weight and BSA, there
appears to be a difference in the slope of the fitted lines between genders, whilst for height
there appears to be a difference in the intercept. The relationship between GFR and age is
approximately flat before the age of 40 years with a linear decline afterward. This is the same
as the observed relationship between GFR and age in healthy kidney donor patients [38]. Any
small differences between cancer and kidney donor patients are discussed further in Section 6.3
The relationship of GFR with creatinine is non-linear and heteroscedastic, evidenced by the
decreasing variability of GFR with increasing serum creatinine. Furthermore, the plot displayed
in Figure 4.1 suggests that a log transformation of creatinine would be beneficial, both to
mitigate the skewness in the data and to approximate a more linear relationship between GFR
and log(SCr). This is the transformation that most previously developed models have used.
4.1.2 Model development
We used the cleaned and transformed data to develop a new model for GFR in patients with
cancer. For this, the Cambridge Original dataset was divided randomly into a development and
internal validation set at a ratio of 4:1. The new model was subsequently developed using the
development dataset and internally validated against previously published models using the
separate internal validation dataset.
Distribution of GFR
The first step to fit a generalised linear model is to decide on the distribution of the error terms.
By definition, the minimum for GFR is zero in the absence of functional glomeruli and the
values for GFR are thus strictly positive with a skew to the right. Common distributions with
these attributes are the gamma and log-normal distributions, however the normal distribution
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Figure 4.1 Relationship between GFR and the continuous explanatory variable for patients in the
Cambridge Original dataset. (A) Plot of the GFR against each of the other continuous variables (age,
BSA, height, weight, SCr) and the natural logarithm of serum creatinine (log(SCr)) for the Cambridge
Original dataset. Smoothed trend lines are calculated using a generalised additive model with a cubic
spline basis. Points and lines are coloured by sex. (B) Pearson correlation matrix for the continuous
variables in the Cambridge Original dataset. Abbreviations: BSA - body surface area, SCr - serum
creatinine, GFR - glomerular filtration rate.
may also be suitable. We plotted the data to examine the best fit and from Figure 4.2 (A) and
(B) it is evident that the gamma distribution best describes the data distribution, demonstrated
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by the theoretical densities and quantities matching the observed density and quantities in the
histogram and quantile-quantile plot respectively.
For a GLM, not only is there a choice for the distribution of the response variable, but there is
also a choice for the link function. A common option is to choose the natural or canonical link
because it has the small advantage of simplifying some calculations. The canonical link for
the gamma distribution is the inverse function. However, this raises some issues as it would
be possible, though unlikely, for the model to predict negative fitted values for GFR, which
is paradoxical and not desirable. For the gamma distribution, another more common choice

























































Figure 4.2 Fitted distributions for GFR along with the Box-Cox log-likelihood showing square-root
transformation is suitable. (A) Histogram of GFR along with the probability density curve for a gamma,
log-normal and normal distribution. The parameters for each distribution are calculated via maximum
likelihood. (B) Quantile-quantile plot comparing the gamma, log-normal and normal distribution. (C)
Profile log-likelihood for Box-Cox method. Horizontal lines are drawn for the maximum likelihood and
the lower and upper values for the 95% confidence interval. (D) Normal distribution quantile-quantile
plot for square-root transformed GFR.
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An alternative to fitting a GLM would be to transform the GFR to be normally distributed and fit
a linear model. To find the most suitable transformation the Box-Cox method was used, which
calculates the power transformation to apply to the data to produce approximately normally
distributed residuals [10]. This method requires an initial model that includes all key predictor
variables used in previously published creatinine based models for GFR (creatinine, age, sex,
body surface area, height, and weight).
GFR = β0 +β1SCr+β2Age+β3Wt+β4Ht+β5BSA+β6SexM + ε (4.1)
where ε is normally distributed with mean 0 and a given variance. In this equation and following
equations variable units and definition are as defined in Table 2.1 and additionally SexM equals 1
for males and 0 for females. The Box-Cox method produced the maximum likelihood estimate
for the power transformation of λ = 0.473 (95% CI 0.400 - 0.547), Figure 4.2 (C). This
confidence interval contained 0.5, corresponding to the square root transformation. A quantile-
quantile plot (Figure 4.2 D) confirms that square-root transformed GFR is approximately
normally distributed. Furthermore, this transformation guarantees that predicted GFR values
cannot be negative. Most previous models have used a log-transformation for GFR, however,
since the Box-Cox confidence interval for λ does not include zero, there is little support for
this being an appropriate transformation.
Variable selection
The next stage in fitting the model was to select the variables that are to be included. As
described in Section 4.1.2, several different approaches were used to determine which variables
should be considered. For this analysis we chose to use a stepwise selection procedure with
three different criteria, five-fold cross validation, leave-one-out cross-validation and Bayesian
information criterion (BIC). These selection criteria were used for both the linear model with
transformed GFR and the generalised linear model.
Linear model with transformed GFR
An assumption for linear modelling is that the relationship between the independent and every
dependent variable is linear. We assessed this graphically using residual against fitted value
plots obtained by fitting the initial model (Equation 4.1) with the response variable now equal
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to square-root transformed GFR. The plots for age, height, weight and body surface area
showed no patterns and hence no transformation was required (Figure 4.3 A-D). In contrast,
the plot for creatinine suggested a non-linear relationship between creatinine and square-root
GFR (Figure 4.3 E). Through a sequence of transformation attempts and reassessments we
determined that natural logarithm transformation as well as inclusion of squared and cubic
terms of this transformation, achieved linearity (Figure 4.3 F-H). These additional polynomial
terms also significantly improved the initial model containing all variables (p-value <0.0001,
F-test).
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Figure 4.3 Model residuals against explanatory variables for the initial model and after including square
and cubic log(SCr) terms. (A-E) Model residuals from the fitted initial model (Equation 4.1) plotted
against each of the explanatory variables in that model: age (A), body surface area (B), height (C), weight
(D), and creatinine (E). (F-H) Model residual against natural logarithm of creatinine after creatinine is
replaced by transformed creatinine in the simple model (F), an additional squared log(SCr) (G) as well
as cubic log(SCr) (H) are added to the initial model. All data smoothing lines are loess curves with the
span parameter set to 0.9. Figure is adapted from Supplemental Figure 3 in [60]
Next, we determined the variables to include in the final model. Initial exploratory analyses
indicated that pairwise interaction terms might lead to improved estimation of GFR. Hence,
models with pairwise interaction terms were considered with the exception of squared and
cubic log(SCr). It was required that the model remained hierarchical, that is, a model with a
pairwise interaction between two variables must also contain both those variables.
4.1 CamGFR: developing the original model 51
After performing stepwise selection with the three different criteria, the same model was
selected using the leave-one-out and BIC criteria. The same model was also the most frequently
returned model at a count of 854 from the 2,000 repetitions of the five-fold cross-validation
criterion, representing a four times more frequent return than the second most frequent model.
This model contained the variables age, BSA, sex, log(SCr) along with its squared and cubic
terms, and the age-sex and BSA-age interaction terms. The coefficients of the model used for
the internal validation (sqrt LM) were calculated using the full validation dataset and the R
package stats.
Gamma generalised linear model
A similar procedure was used to select the variables for the gamma generalised model. As above,
all pairwise interaction terms were considered along with squared and cubic log(SCr) terms.
When applying the stepwise selection procedure for gamma GLM the three different criteria
selected different models. When using BIC as the criterion, the variables selected differed from
the variables selected for the linear model with sqrt-transformed GFR by changing the BSA-age
interaction term to a log(SCr)-sex interaction term. The variables selected using leave-one-out
and leave-out-n additionally included the height and the log(SCr)-age interaction term. The
leave-one-out did not include the cubic log(SCr) term.
The model selected for the leave-out-n criteria is the model that was observed most frequently
in the 2,000 repetitions. For the linear model above, the model was observed almost four times
more often than the next most commonly selected model. However, for the gamma GLM the
top three models were observed 584, 471, and 401 times out of the 2,000 iterations. Given
this, and as simpler models are preferable, we chose the model selected using BIC to compare
against the square-root transformed GFR linear model. As above, the coefficients of the model
used for the internal validation (gamma GLM) were calculated using the full validation dataset
and the R package stats.
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4.1.3 Model validation and assessment
Internal validation
The selected square-root transformed linear model (sqrt LM) and gamma generalised linear
model (gamma GLM) from Section 4.1.2 were compared with each other and previously
published models using the internal validation dataset. This dataset had no role in developing
the models or fitting the parameters. If a previously published model estimated GFR using BSA
adjusted units, the estimated value was first unadjusted before being used in the comparison.
As discussed in Section 3.2.3, five statistics were used to compare models for this publication.
These were median percentage error (MPE), root-mean-squared-error (RMSE), interquartile
range of the residuals (residual IQR), and median absolute percentage error (MAPE). All
statistics were calculated using the original scale of GFR. These statistics assess different
aspects of a model’s fit, namely its accuracy, precision, and bias, with the final statistics
assessing the number of patients who would have a clinically relevant estimation error.
Table 4.2 provides summary statistics to compare the sqrt LM with the gamma GLM along with
other previously published models using the internal validating dataset. The sqrt LM was the
most accurate and precise, evidenced by lower RMSE, residual IQR and median APE values.
No significant bias was observed for either model. Given these results, we chose to use the sqrt
LM model for future work. This was despite the advantage of modelling GFR on the original
scale provided by the gamma model.
The sqrt LM was also the most accurate model when compared with previously developed
models. It had the lowest RMSE at 15.00 mL/min (95% CI 14.12–16.00), compared with
16.30 mL/min (95% CI 15.34–17.38) for the CKD-EPI and 23.75 mL/min (95% CI 22.36–
25.33) for the Cockcroft-Gault.
Most published models were developed from datasets including many patients with impaired
kidney function. To reflect this, we performed a subgroup analysis in patients with eGFR less
than or more than 60 mL/min. The number of patients with an eGFR less than 60 mL/min
varied for each model, ranging from 38 for the Mayo model to 160 for the Jelliffe model, and
the Sqrt LM model had 88 patients. The Wright model had the lowest RMSE of 11.53 mL/min
(95% CI 9.95–13.70) in the subset of patients with an eGFR of less than 60 mL/min, followed
by the new linear model (11.64 mL/min, 95% CI 10.15–13.66). For patients with eGFR more















Sqrt LM 79.63 15.00 0.51 17.66 0.65 11.59
Gamma GLM 80.00 15.17 -0.10 18.58 -0.11 12.01
CKD-EPI 80.63 16.30 -0.03 20.04 -0.03 12.97
MDRD 73.51 17.46 6.99 19.23 8.93 14.60
Cockcroft Gault 79.01 23.75 -0.79 24.47 -1.04 15.55
Jelliffe 71.39 21.39 7.52 21.82 10.90 17.40
Wright 86.14 22.77 -6.12 23.85 -8.55 13.88
Mayo 93.25 23.73 -14.91 22.64 -19.41 20.74
Martin 85.87 25.49 -8.20 24.79 -10.34 16.18
Glasgow
CamGFR 111.82 18.94 1.61 22.92 1.39 11.18
CKD-EPI 120.62 21.33 -5.27 27.52 -4.41 12.95
MDRD 104.44 22.88 10.00 26.96 9.22 12.25
Cockcroft Gault 126.52 32.32 -18.04 31.57 -14.14 16.30
Jelliffe 104.97 24.38 9.11 27.69 7.55 13.65
Wright 126.27 26.49 -12.39 29.09 -9.91 14.80
Mayo 146.21 36.50 -31.52 27.26 -27.43 27.56
Martin 133.37 37.74 -23.87 32.83 -22.34 22.34
Abbreviations: eGFR - estimated, RMSE - root-mean-squared-error, IQR - inter quartile range
PE - percentage error, APE - absolute percentage error
SqrtLM - square root transformed linear model fitted on model development dataset
GammaGLM - gamma distribution generalized linear model fitted on model development dataset
CamGFR - final square root transformed linear model fitted on the full Cambridge original dataset
CKD-EPI - Chronic Kidney Disease Epidemiology model, MDRD - Modification of Diet in Renal Disease model
Table 4.2 Summary statistics for the newly developed and previously published models on the internal
(Cambridge Original) validation and external (Glasgow) validation datasets.
than 60 mL/min, the new model was the most accurate and least biased with a RMSE of
15.63 mL/min (95% CI 14.62–16.79) and a median residual of 0.61ml/min.
There was a noticeable difference in all models’ accuracy between the two subgroups where
patients with a smaller eGFR had more accurate estimated values. This is likely due to the
fact that GFR is modelled on a different scale from the scale at which accuracy is calculated.
Specifically, for the new linear model, it is modelled on the square root scale where the variance
of the residuals is constant. However, when the estimated values are squared, the variability in
the larger estimated values is proportionally higher than that of smaller estimated values.
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Assessing model robustness
After this comparison we also assessed the dependence of the final model on the random
partitioning of the dataset. Hence, the full dataset was partitioned 100 times into different
development and internal validation datasets in a 4:1 split. All three model selection methods
were repeated on each one of these repartitioned datasets, with 100 rather than 2,000 repetitions
for the five-fold cross-validation. Our final model was selected most frequently in the 100
datasets for all three stepwise selection criterion. Using the five-fold cross-validation criterion
it was chosen 22 times and the next most common model, which was chosen 20 times, only
differed from the final model by an additional height variable. The leave-one-out cross-
validation criterion returned the new model 16 times and the second most frequent model was
returned 15 times. Again, the second most frequent model only differed by an additional height
variable from the new model. The BIC selection criterion selected the new model 31 times
with the next most frequently selected 15 times. We found that for 14 random data splits all
three methods returned the final model. The next most frequent model, which contained an
additional height term, was only selected five times by all three methods.
Once the variables selected were confirmed, the final coefficients of the model were calculated
from the full Cambridge Original dataset. This model is referred to as the CamGFR model, or
the original CamGFR model in later sections. Figure 4.4 provides diagnostic plots for the new
model confirming that no single data point was influential in the full dataset (highest Cook’s
distance value: 0.094). The residual against fitted value plot showed an overall good fit to
the data (Figure 4.4 A). Importantly, there was no heteroscedasticity in the final linear model
and we thus confirmed that calculation of confidence intervals (or prediction intervals) for the
estimated GFR values was appropriate (Figure 4.4 B).
The CamGFR model with coefficients rounded to 3 significant figures was the following
√
GFR =1.81+0.0191Age+4.73BSA−3.72log(SCr)−0.914log(SCr)2+
1.063log(SCr)3 +(0.0202+0.0125Age)SexM +0.0297AgeBSA+ ε
(4.2)
where:
• GFR is glomerular filtration rate with units mL/min
• Age has the units years











































































Figure 4.4 Model diagnostic plots for CamGFR fitted on the full Cambridge Original dataset. (A)
Residual against fitted value plot. (B) Scale-location plot. For both these plots the fitted curve is
calculated using loess with a span equal to 0.5. (C) Leverage against standardised residuals where the
dashed red line indicates a Cook’s distance of 0.5. (D) Bar plot of Cook’s distances for all samples used
to fit the final model.
• BSA is body surface area with units m2 calculated using the DuBois & DuBois equation
[33]
• SCr is blood serum creatinine concentration with units mg/dL
• SexM is equal to 1 when the patient is male and 0 when the patient is female
• ε are independent, mean zero normally distributed random variables with a constant
variance
This model had a multiple R2 value equal to 0.726 and the standard error of the residuals was
0.842. The standard errors of the coefficients can be seen in Table 4.5.
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External validation
Finally, we externally validated the model using a dataset from a different cancer centre.
Table 4.2 provides the summary statistics for comparing the CamGFR model with the previously
published model on the Glasgow external validation dataset. As with the internal validation,
the CamGFR model remained the most accurate compared with all other published models or
BSA adjusted published models. The RMSE for the GFR calculated with the new model was
18.93 mL/min compared with 21.33 mL/min for BSA adjusted CKD-EPI, and 32.32 mL/min
for Cockcroft-Gault. Of the 111 patients in the external validation dataset, 105 (94.6%) had the
measured GFR within the 95% confidence interval.
Dosing for carboplatin
We investigated the relevance of our findings to chemotherapy treatment in clinical practice by
assessing the dose accuracy for the chemotherapy drug carboplatin, which is excreted renally.
To calculate the dose for carboplatin the Calvert formula [13] is used:
Dose [mg] = AUC [mg/mL/min] (GFR [mL/min]+25) (4.3)
where AUC is the target area under the curve for the dose concentration time curve. For a given
AUC this is linear in GFR, hence any improvement in the accuracy of GFR estimation will
translate to an improvement in the accuracy of the dose given as confirmed by our calculations.
This improvement is clinically significant because the fraction of patients that receive a dose
inaccuracy of more than 20% is reduced by using eGFR calculated using the CamGFR model.
4.1.4 Discussion
This section has described our work to develop a new model to estimate GFR in patients
with cancer [60]. There are multiple appropriate approaches with differing advantages and
disadvantages that could have been employed. Ultimately, for reasons discussed in this chapter,
we chose to model square root transformation of GFR as a linear combination of explanatory
variables with a cubic polynomial fitted for the log transformation of serum creatinine to capture
the complex relationship between GFR and serum creatinine.
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The CamGFR model is distinguished from previous models by the patient population used to
develop it. With the exception of the Wright model [137] and the Giglio model [43] previous
models to estimate GFR have been developed using data from non-cancer patients. For non-
cancer patients a common reason to measure GFR is to diagnose or monitor chronic kidney
disease. Hence, these patient populations are often particularly enriched for patients with
impaired kidney function compared with both our dataset and the normal population.
One of the primary reasons to measure GFR for patients with cancer is for dose calculations
for carboplatin. However, as discussed in Section 2.5 there is little consensus in the choice of
method to calculate GFR for this purpose. The CamGFR model was developed in an attempt to
rectify this issue. CamGFR reduces the fraction of patients who receive a carboplatin dose that
is more than 20% different from the dose calculated using 51Cr-EDTA GFR, compared with
previous models.
To allow clinicians to utilise the CamGFR model, we developed a web application using the
R package shiny [16], which is a web application framework for R. This application allows a
user to input a patient’s demographics and serum creatinine data, and returns estimated GFR
using the CamGFR and the next best model, CKD-EPI. Importantly, for the CamGFR model
the application provides confidence intervals for the predicted value and an estimate of the
probability that the predicted value is above or below a given threshold. This gives clinicians or
other users a sense of the accuracy of the estimated value, which should be considered when
making patient management decisions such as drug prescriptions. No other currently available
model provides an estimate of the accuracy of its estimated model. Since the publication of
the CamGFR model in July 2017, the application has had an average of 56 uses per week. A
screen shot of the application is provided in Figure 4.5.
Of course, the CamGFR model has some limitations. First, using creatinine as the primary
explanatory variable in predicting GFR has its own limitations. Other predicting variables
such as cystatin C have been proposed as alternative or adjunctive variables. However, cystatin
C measurements are not routinely collected and so were not available. Furthermore, use of
cystatin C has been called into question in patients with cancer because levels may fluctuate in
a cancer-dependent and kidney-function-independent manner [70]. Additionally, we did not
analyse measurements of albumin, muscle mass, information on dietary and fluid intake, or
co-morbidities (such as diabetes mellitus) due to lack of data.
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Figure 4.5 Screen shot of the shiny application for the CamGFR model. The application allows users to
input a patient’s information and it returns an estimate of GFR from the CamGFR model along with a
confidence interval for this predicted value and a probability of the estimated value being above or below
a chosen threshold. Histograms are provided in another tab so that the user can compare the patient’s
data to those used to build the CamGFR model.
Link to the application: tavarelab.cruk.cam.ac.uk/JanowitzWilliamsGFR
This study is also limited by the Caucasian-only population, a fact that is attributable to the
single centre population demographics. Others have shown that adjustment factors improve
GFR prediction for patients who are ethnically black [77, 74]. We were not able to assess
whether such an adjustment factor would be required for the CamGFR model. The final
coefficients reported in our study may be centre-dependent as a result of differing creatinine
results and patient population. As discussed in Section 2.4.2, the issues with centre-dependent
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creatinine values is being addressed by international guidelines to standardise creatinine
reporting. These guidelines were not yet implemented at Addenbrooke’s Hospital at the time
of our initial data collection. It is now recommended that serum creatinine values should be
calibrated to IDMS-traceable reference samples. This issue is further exacerbated by the small
and male-only validation dataset, which does not provide sufficient evidence for generally
applicability of the CamGFR model. Further investigation is required to validate or adjust the
CamGFR model with data from multiple cancer centres.
4.2 Creatinine data analysis and validation of the CamGFR
model
After the publication of the CamGFR model, we sought to collect further data, particularly
from different cancer centres, in order to address some of the limitations raised in the previous
section. Using these data, we addressed two main points. First, we assessed the differences
in the serum creatinine resulting from inter-centre variability, calibration to IDMS reference
material, and different assay methodology. We then validated the CamGFR model using a more
extensive and diverse patient population.
In total, eight new datasets were acquired, consisting of 6,952 patients and 7,944 nmGFR
measurements. The number of nmGFR measurements was greater than the number of patients
because a subgroup of patients had multiple nmGFR measurements taken during their cancer
management (mean 1.14, range 1-18). Of the 7,944 GFR measurements, 3,919 had creatinine
measured that was traceable to an IDMS standard reference material (IDMS-traceable). For a
subset of these patients, additional biochemical results such as albumin and urea were available
along with creatinine. Ethnicity was known for 2,758 of the patients. However, 95% of patients
with known ethnicity were white. Table 4.3 provides a patient population summary for each of
the eight new datasets. The number of patients in each dataset ranged from 108 in London-Barts
to 2,737 in the Cambridge New dataset. Specific disease or cancer site diagnosis information
was known for the majority of patients from all datasets apart from Melbourne. Overall, the
majority of creatinine was measured using a non-IDMS-traceable method.
The methods used to measure GFR and serum creatinine are discussed in Section 3.1.2 and
detailed in Table 3.1. The methodology used to measure creatinine or GFR differed among
the eight new datasets. For Cambridge New and Manchester, the creatinine methodology
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also changed within the date range of the dataset. Specifically, in the Cambridge New dataset
creatinine was first measured using a non-IDMS-traceable Jaffe assay, then an IDMS-traceable
Jaffe assay, and finally an IDMS-traceable enzymatic assay. Similarly, in the Manchester
dataset creatinine was originally measured using a non-IDMS-traceable Jaffe assay which was
changed to an IDMS-traceable Jaffe assay. Overall, the majority of creatinine was measured
using a non-IDMS-traceable method. For GFR, two of the datasets (Edinburgh and Melbourne)











Southampton 01/01/99 - 01/01/12 436 436 436 0 Cancer - Seminoma
Wales 01/01/05 - 01/01/11 157 157 157 0
Cancer - Seminoma
and Ovarian
Manchester 02/04/12 - 07/02/17 2,068 2,068 1,591 282 Cancer general
London-Barts 16/08/10 - 12/12/17 108 108 108 0 Cancer - Seminoma
Edinburgh 01/13/11 - 21/12/17 598 628 585 0 Cancer and nephrology
Gothenburg 01/02/08 - 28/08/12 627 914 627 914
Cancer and two
non-cancer patients
Melbourne 05/01/00 - 28/01/05 311 311 0 0 Cancer general
Cambridge new 01/02/13 - 20/04/19 2,737 3,452 2,548 2,723
Cancer and
non-cancer general
Date range refers to the range of dates within which patients received treatment.
No. of patients refers to the total number of individuals in the respective datasets.
No of nmGFR (or number of rows of the dataset) is the total number of nmGFR measurements in the dataset, where an
individual patient may have more than one measurement.
No. with diagnosis is the number of rows with a known diagnosis.
No. with IDMS is the number of rows for which creatinine was traceable to an IDMS reference.
Table 4.3 Patient population summary for each of the eight new datasets.
4.2.1 Comparing different methodology for serum creatinine measure-
ment
As discussed in Section 2.4.2, there are two distinguishing characteristics for measured creati-
nine. First, the method used to measure serum creatinine can either be a Jaffe reaction or an
enzymatic method. For the ten datasets, six used a Jaffe method to measure creatinine, Gothen-
burg used an enzymatic method, Cambridge New changed from a Jaffe to an enzymatic method,
and we did not know the methodology used for the final two centres. Second, creatinine can
be IDMS-traceable or not. IDMS-traceable creatinine was implemented in three (Gothenburg,
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Cambridge new and Manchester) out of the ten datasets used in this thesis. For Gothenburg,
all of the creatinine data were IDMS-traceable, which is in contrast to Cambridge New and
Manchester where IDMS-traceable creatinine was introduced during the data collection pe-
riod. This combination of different creatinine characteristics in the ten datasets enabled us to
compare the differences in serum creatinine for those measurements which were or were not
IDMS-traceable, and which were measured using a Jaffe or enzymatic method.
Of the ten datasets, three (Glasgow, Southampton and London-Barts) contained only male
patients with germ cell cancer, Wales contained only male patients with germ cell cancer
or female patients with ovarian cancer, with the remaining centres comprising of a general
cancer patient population, some with small subsets of non-cancer patients. Given this, serum
creatinine from different centres and measurement methods were compared separately in three
groups of patients: male patients with germ cell cancers (n = 1,439), female patients with
gynaecological cancers (n = 1,414), and general patients with cancer (n = 7,853). These were
chosen so that all centres could be compared while mitigating the bias caused by differences in
patient demographics with particular cancer diagnoses in the comparison. Germ cell cancer
and gynaecological cancer were also the most common diagnoses for male and female patients
respectively. Creatinine values were compared on the natural logarithm scale.
Figure 4.6 compares the creatinine values from the centres which had a general cancer patient
population. It is evident that the non-IDMS-traceable values are larger than IDMS-traceable
values on average. The mean of log(SCr) across the four centres using non-IDMS-traceable
Jaffe was −0.0571 (s.d. 0.0037), which was considerably higher than the mean for the two
centres with IDMS-traceable enzymatic (mean −0.225, s.d. 0.0070) and IDMS-traceable Jaffe
(mean −0.257, s.d. 0.0097) creatinine values. The differences between all three types of
creatinine values were significant, when compared using a t-test. The variability between
centres of mean log(SCr) measured using a non-IDMS-traceable method was greater than the
IDMS-traceable methods. No significant difference was observed between the two centres with
IDMS-traceable enzymatic or IDMS-traceable Jaffe creatinine values, p-value 0.45 and 0.16
respectively. For non-IDMS-traceable, log(SCr) was significantly different when comparing
Cambridge with the other three centres, p-value < 0.0001 for all.
Examining the centres which changed their methodology during the data collection period,
namely Cambridge and Manchester, enables a direct comparison of the differing methodologies.
Figure 4.6 shows the timelines of creatinine values for both of these centres. For Cambridge,
multiple creatinine values per patient are included. However, the data were thinned so that there




























































Figure 4.6 Comparison of creatinine methods in patients with cancer. (A) Boxplots for creatinine
measurements split by centre and measurement methodology. The numbers in the box correspond to
the number of values contained in the given boxplot. The different methodologies were compared with
a t-test with ** : p < 0.01, **** : p < 0.0001. (B) density plot for different creatinine methodologies
with the data combined from the different centres in (A). (C) Timeline of creatinine measurements from
Cambridge. Creatinine is log transformed and data have been thinned so that for any given patient
there is a minimum of 30 days between creatinine measurements. The two vertical lines correspond to
dates when creatinine measurement methodology changed from non-IDMS-traceable Jaffe to IDMS-
traceable Jaffe to IDMS-traceable enzymatic. (D) Timeline of creatinine measurements from Manchester.
Creatinine is log-transformed and one point corresponds to one patient. The vertical line corresponds
to the date when creatinine measurement methodology changed from non-IDMS-traceable Jaffe to
IDMS-traceable Jaffe. Smoothed lines are calculated a using generalised additive model with a cubic
spline basis.
were at least 30 days between consecutive measurements from any given patient. This was to
mitigate the effect of patients having many creatinine measurements in a short period of time
when monitoring particularly high creatinine. There is a clear difference in the distribution of
log(SCr) when either centres moved from an non-IDMS-traceable Jaffe to an IDMS-traceable
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Jaffe method. Moreover, there is a significant difference in the mean log(SCr) value for the
non-IDMS-traceable creatinine (p-value < 0.0001) between the two centres but no difference in
the mean log(SCr) when both centres were using a IDMS-traceable Jaffe method. Comparing
the IDMS-traceable Jaffe with the IDMS-traceable enzymatic creatinine in the Cambridge
dataset is more difficult. Although overall there is a significant difference in the mean values
(p-value 0.002), the mean value appears to fluctuate during the observation period. During
the IDMS-traceable Jaffe period there is an increase in the mean value, while during the
IDMS-traceable enzymatic period there appears to be an increase in the mean at the end of the































































Figure 4.7 Comparison of creatinine methods for patients with gynaecological or germ cell cancers.
Boxplots for creatinine measurements split by centre and measurement methodology for male patients
with germ cell cancer (A) or female patients with gynaecological cancer (B). The numbers in the box
correspond to the number of values contained in the given boxplot. Differences in the mean value
between the different methodologies were compared with a t-test (top), differences between centre using
a given method were compared using a linear model followed by one-way ANOVA. ns : p < 0.05, * : p
< 0.05, *** : p < 0.001, **** : p < 0.0001.
Similar differences between the creatinine methods were observed when the analysis was
repeated for male patients with germ cell tumours or female patients with gynaecological
cancers. For both, the mean non-IDMS-traceable Jaffe log(SCr) was significantly higher than
the IDMS-traceable methods, with inter-centre variability considerably higher when the method
was not IDMS-traceable. Additionally, as before, the mean IDMS-traceable Jaffe creatinine was
slightly lower than the mean IDMS-traceable enzymatic. A final interesting observation, when
comparing non-IDMS-traceable log(SCr) for patients with germ cell cancers in the Edinburgh
dataset with patients in the Cambridge or Manchester dataset, the mean is substantially lower.
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However, for patients with gynaecological cancer the mean value is substantially higher. The
reason for this is not known, however, it may be driven by the observation that the measured
GFR values were significantly lower for gynaecological patients in the Edinburgh dataset
compared with those from Cambridge or Manchester.
To summarise, from the data there is a clear difference between the mean creatinine value
between IDMS-traceable and non-IDMS-traceable values, with IDMS-traceable creatinine
being significantly lower on average. There appears to be a small difference between IDMS-
traceable Jaffe and IDMS-traceable enzymatic creatinine, with the Jaffe method producing
slightly lower values. However, the evidence for this is driven by the Cambridge dataset, where
the mean log(SCr) appears to fluctuate after the introduction of the IDMS-traceable method.
The differences observed between the IDMS-traceable and the non-IDMS-traceable (or con-
ventional) assays are supported by previous literature. As discussed in Chapter 2 Section 2.4,
conventional Jaffe assays were known to overestimate creatinine as a result of picrate reaction
with other molecules. Hence, it is not surprising that calibration of these methods reduces
the measured creatinine. This reduction was widely acknowledged and discussed, particularly
when the National Kidney Disease Education Program first started to recommend that all
creatinine should be IDMS-traceable [84, 97, 75]. This difference led to Ortho Clinical Diag-
nostics producing an equation to convert IDMS-traceable creatinine to "conventional units"
[93], which has subsequently been recommended to allow the use of older GFR estimation
models developed using conventional creatinine assays.
Previous literature does not fully support the differences observed between the enzymatic and
Jaffe methods. A study by the French Society of Clinical Biochemistry compared creatinine
determined by use of compensated Jaffe and enzymatic methods from four different assay
manufacturers which were all IDMS-traceable [9]. The study found that the Jaffe method was
biased to overestimate the true value in the assays from three out of the four manufacturers.
Two of these manufacturers were Roche and Siemens, who produced the assays used to
measure creatinine in our data (see Table 3.1). The enzymatic assays produced smaller and
less biased results than the corresponding Jaffe assay from the same manufacturer. This result
is the opposite of what we see from our data, where the Jaffe values were smaller on average
compared with enzymatic values. Another study performed in China found similar results,
where Jaffe methods were observed to overestimate true creatinine values, whereas enzymatic
methods had a tendency to underestimate creatinine but were less biased [94]. Another study
which analysed the results from 26 different instruments at five different target serum creatinine
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concentrations gave a more complicated picture [55]. Although IDMS-traceable Jaffe methods
were biased to overestimate creatinine for low concentrations, for higher concentrations the
different methods were more comparable.
Given these findings, in particular the observed differences in serum creatinine between assays
which are IDMS-traceable and conventional non-IDMS-traceable assays, it is clear that the
published CamGFR model [60] developed in Section 4.1 needs to be adjusted before it is
suitable for use with creatinine that is traceable to IDMS reference material. However, given
that conventional assays are still routinely used, both in the UK and abroad, it was first important
to validate the CamGFR using conventional creatinine that is not IDMS-traceable. The next
section compares the CamGFR model with other models using the large multi-centre non-
IDMS-traceable creatinine data. Following this, Section 4.3 further develops the CamGFR
model to be suitable for serum creatinine traceable to an IDMS-traceable standard.
4.2.2 Validation of CamGFR for non-IDMS-traceable creatinine data
The work in this section is based on our publication, in which the CamGFR model was compared
with other previously published models in a large multi-centre dataset [132]. This dataset
includes all patients acquired after the publication of CamGFR who had serum creatinine
measured using conventional non-IDMS-traceable assays. For some patients, no specific
information was known on the methodology used to measure creatinine, however it was
suspected that the methods were non-IDMS-traceable and hence these patients were included.
In total there were 3,786 patients from seven different centres, of which 3,484 patients had
solid cancer, 136 had haematological cancer, and 166 had a non-cancer diagnosis.
As discussed previously, all these patients had creatinine and GFR measured within 30 days
of each other. In fact, for 27% of the patients the measurements were performed on the same
day and 89% within a week. The median GFR was 85 mL/min ((IQR 61–109 mg/dL) and the
median serum creatinine was 0.95 mg/dL (IQR 0.83–1.11 mg/dL). The median age, height,
weight and BSA were 59 years, 169 cm, 74 kg and 1.85 m2 respectively (Table 4.4). These
are broadly comparable with the Cambridge Original dataset (Table 4.1); the main difference
being a higher proportion of male patients (55% compared with 43%) which resulted in a
higher median measured GFR, higher median serum creatinine. Of the 3,786 patients, 22 were
classified as ethnically black.
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Median (IQR) Range Mean (SD)
Age [years] 59 (45-70) 18-91 57 (16)
Weight [kg] 74 (63-86) 33-200 76 (19)
Height [cm] 169 (160-177) 137-204 169 (11)
BSA [m2] 1.85 (1.68-2.02) 1.17-3.17 1.85 (0.25)
Serum creatinine [mg/dL] 0.95 (0.83-1.11) 0.43-4.45 0.99 (0.28)
GFR [mL/min] 85 (61-109) 9-209 86 (32)
Dataset Total Solid tumour Haematology Non-cancer Female Race - black
Cambridge 404 227 114 63 198 6
Edinburgh 597 472 22 103 245 0
London-Barts 108 108 0 0 0 0
Manchester 1777 1777 0 0 1066 16
Melbourne 308 308 0 0 111 0
Southampton 436 436 0 0 0 0
Wales 156 156 0 0 89 0
Total 3786 3484 136 166 1709 22
GFR was measured using either 99mTc-DTPA (Edinburgh and Melbourne) or 51Cr-EDTA (all others).
GFR - Glomerular filtration rate, BSA - Body surface area (calculated using DuBois-DuBois [33]), IQR - interquartile range
Modified from Table 1 in [132]
Table 4.4 Patient characteristics for CamGFR validation data. Continuous data are summarised for all
centres together (top) and categorical data are split by dataset (bottom).
Figure 4.8 compares the distributions of the continuous variables for the patients from the seven
different centres. Patients from Southampton and London-Barts have a higher GFR, height and
weight and a lower age than patients from other centres. This is due to them comprising male
patients with germ cell tumours. Patients from Manchester and Melbourne were typically older
compared with other centres. Patients from Manchester were shorter, weighed less and had
lower measured GFR too. This is may be driven by the higher proportion of female patients
(60% compared with 44% for the other mixed centres, Table 4.4). Inter-centre comparisons of
log(SCr) were discussed in the previous section.
The same published models compared in Section 4.1 were again compared. As discussed in
Chapter 3, Section 3.2.3 the statistics used to compare models were changed slightly between
the two publications. Here, models were compared using RMSE, residual IQR and median
residual, which assessed the models’ accuracy, precision and bias respectively. A final statistic,
denoted P20, which is the proportion of patients with an absolute percentage error more
than 20%, was used as a measure of the clinical robust measurement of accuracy. Bootstrap
resampling methods were used to calculate approximate 95% confidence intervals [25] and
to calculate p-values [36] for comparing statistics from different models, further detailed in
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Height [cm] log(SCr) Weight [kg]
Age [years] BSA [m²] GFR [ml/min]
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Figure 4.8 Boxplot of the continuous variables (age, BSA, GFR, height, weight, log(SCr)) for each
centre used to validate the CamGFR model.
Section 3.2.3. Models were compared on the whole patient population as well as in relevant
sub-populations, such as for each centre separately.
Overall, CamGFR was significantly more accurate in estimating GFR than all other models,
both by RMSE or P20, followed by the CKD-EPI model (Figure 4.9). The RMSE for the
CamGFR model was 17.3 mL/min (CI 16.7 to 17.8 mL/min) compared with 18.1 mL/min
(CI 17.6 to 18.7 mL/min) for the CKD-EPI model (p-value = 0.03). For P20, the value for
CamGFR was 0.295 (CI 0.281 to 0.310), or in other words 29.5% of patients’ estimated GFR
differed by more than 20% of their true GFR. This compares with 0.318 (CI 0.304 to 0.333 for
CKD-EPI), which was significantly higher than the CamGFR (p-value = 0.03).
The residual median was 1.30 mL/min (CI 0.74 to 1.8 mL/min) for CamGFR and 0.60 mL/min
(CI 0.08 to 1.11 mL/min) for CKD-EPI, indicating a small but significant bias to overall under-
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estimation of GFR in both models. For the MDRD and Cockcroft-Gault, the residual median
was not significantly different from zero. For the other four models (Wright, Jelliffe, Martin and
Mayo) large biases were observed, with the residual median equal to −4.86, 9.37, −7.89 and
−16.77 respectively. Since the RMSE of Jelliffe, Martin and Mayo is larger than 22 mL/min,
these models were not compared further.
When comparing models in individual centres, the CamGFR was most accurate in six of the
seven centres. The exception was Melbourne, where the Wright model was the most accurate.
The accuracy of all models fluctuated between models, with the RMSE for the CamGFR
ranging from 15.7 mL/min for patients from Cambridge to 23.5 mL/min for patients from
Cambridge. This accuracy was partially driven by centre-dependent bias for serum creatinine.
All models were generally biased to overestimate GFR for patients from Edinburgh, Wales and
London-Barts, and to underestimate GFR for patients from Southampton and Melbourne. This
is evidenced by the sign of the median and the confidence interval not overlapping zero, with a
positive median residual indicating underestimation. The CamGFR, CKD-EPI and MDRD had
no significant bias for patients from Cambridge New. This centre-specific bias can be correlated
to a degree with previous observations of centre-specific differences in serum creatinine, see
Figures 4.6 and 4.7. More specifically, the creatinine for patients from Southampton and
Melbourne was higher compared with centres with a similar patient population. In particular
compared with creatinine from Cambridge which was used to develop the CamGFR and
showed no bias. Thus, given that a higher creatinine would result in a lower estimated GFR,
these centres would have lower estimated GFR values. The observed underestimation in the
Edinburgh, Wales and London-Barts is harder to explain given the data. Given the previous
observation, we might expect these centres to have lower creatinine compared with the unbiased
centres. However, this is not the case for patients from Edinburgh overall, patients from London-
Barts or germ cell patients from Wales. It is the case for germ cell patients from Edinburgh and
gynaecological patients from Wales.
In further subgroup analysis, we examined the performance of models for patients with solid
cancer, with haematological cancer, and without cancer. CamGFR was the most accurate for
each of these groups, RMSE was 17.3, 18.7 and 14.1 mL/min for CamGFR compared with
18.1, 21.3 and 15.8 mL/min respectively for the CKD-EPI model. The accuracy of CamGFR
in patients without cancer is of particular interest as it was developed using a cancer patient
population yet it accurately predicts GFR in non-cancer patients.
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Figure 4.9 Summary statistics comparing CamGFR with commonly used and well performing models.
Results for the five best-performing models (CamGFR, CKD-EPI, Wright, MDRD-186 and Cockcroft-
Gault) for the 3,268 patients from the non-IDMS-traceable creatinine validation dataset are displayed.
Statistics are shown for all centres and for the individual centres separately. The residual (measured
GFR - estimated GFR) median (first row), residual interquartile range (second row), root-mean-squared
error (third row) and the proportion of patients who have an absolute percentage error more than 20%
(P20) (fourth row) are displayed. All error bars are 95% confidence intervals calculated using bootstrap
resampling with 2,000 repetitions and a normal distribution approximation. Figure is adapted from
Figure 1 in [132]
Differences in accuracy were observed between subgroups split by estimated GFR, age, creati-
nine, or BSA. However, these are likely a result of calculating residuals using untransformed
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GFR and not the transformed scale on which it was modelled. For the CamGFR a square-root
transformation was used, for the other models typically a log transformation is used. This
results in trends for larger absolute residuals for larger GFR values. Figures for all subgroup
analyses are available in [132].
One of the strengths of the CamGFR model is the possibility to calculate the prediction intervals
for the estimated GFR value, which can be set at any predefined level. The statistical consensus
and therefore the clinical consensus is to define a 95% confidence interval. To assess the
reliability of the prediction intervals across the different centres the 95% interval was calculated
for all the patients in the validation dataset. Out of the 3,786 patients, 3,510 (92.7%) had
measured GFR values within their prediction interval, which is slightly lower than the expected
95% value. Figure 4.10 depicts the prediction intervals for the patients from each centre
separately, and provides the percentage of measured GFR values within the 95% prediction
interval for each cancer centre. The previous bias (observed in Figure 4.9) is once again
observable in this plot. In particular, patients from Southampton and Melbourne tend to have
higher measured values than estimated values. However, 95.4% of patients from Southampton
have their measured GFR within the 95% prediction interval whereas for Melbourne it is only
85.7%.
The work up to this point has demonstrated that using non-IDMS-traceable creatinine in the
CamGFR model can reduce the RSME and therefore improve the accuracy of estimated GFR
compared with previously published models. This was observed in the multi-centre analysis
but significant biases for individual centres were also observed. These biases may in part be
explained by the different methods used to measure creatinine, discussed in Section 4.2.1. We
further observed that the average creatinine value was reduced when it was IDMS-traceable
compared with when it was not. This led to the conclusion that the CamGFR would not be
suitable if IDMS-traceable creatinine was used as an input. In the next chapter, we will expand
the CamGFR to be suitable for IDMS-traceable creatinine and in doing so explore whether a
more accurate model can be developed using the additional data collected.
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Figure 4.10 Confidence interval for estimated GFR of each patient used for the CamGFR model
validation. The measured GFR (blue points) and the estimated GFR (black points) for each patient are
displayed. Each horizontal line represents a 95% prediction confidence interval for the patient, with
patients grouped by their cancer centre and ordered in accession by their estimated GFR. For each centre
the percentage of patients whose measured GFR is within the 95% confidence interval is given.
4.3 Refitted CamGFR: Expanding CamGFR for IDMS-traceable
creatinine data
In Section 4.2.1, we observed a significant difference in the average value of serum creatinine
that was or was not traceable isotope dilution mass spectrometry (IDMS) standardised. Given
this difference, if IDMS-traceable creatinine were used with the CamGFR model, the estimated
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GFR would be biased compared with measured GFR. Hence, further refinement was required
for the CamGFR model to be suitable for IDMS-traceable creatinine. This section describes
the redevelopment of the CamGFR model to be suitable for both IDMS-traceable and non-
IDMS-traceable creatinine. Furthermore, the currently available datasets contains more patients
from multiple centres, so that redeveloping the model should produce more accurate and less
centre-dependent coefficients.
Several approaches were considered to redevelop the CamGFR model. First, IDMS-traceable
creatinine values could be normalised to have the same distribution as the non-IDMS-traceable
creatinine. These normalised creatinine values could then used as the input for the CamGFR.
This adjustment approach was suggested by Ortho Clinical Diagnostics [93], who produced the
equation:
non-IDMS-traceable creatinine (mg/dL)= IDMS-traceable creatinine (mg/dL)×1.065+0.067
(4.4)
to convert between IDMS-traceable and non-IDMS-traceable creatinine when using their
analysers. This equation or a similar equation could be used to transform the new IDMS-
traceable creatinine to have the same distribution as the non-IDMS-traceable creatinine for
our data. Then these data could be used with the CamGFR model developed in Section 4.1,
thus mitigating the need to adjust the model. However, this approach has some issues: it does
not utilise the additional data we now have, we cannot be sure that the adjustment equation
we use will be accurate for unseen data from other cancer centres, and it does not resolve the
possible centre-dependence of the CamGFR model. Given these limitations, this solution was
not pursued.
Our first approach to adjusting the CamGFR was to include an additional variable "creatinine-
type", which indicated whether the creatinine was IDMS-traceable or non-IDMS-traceable,
along with interaction terms between this variable and the cubic creatinine variable. The result-
ing model would have the same variables as the original CamGFR, but different coefficients.
Additionally, the coefficients for the creatinine terms would differ based on creatinine-type.
This would allow some consistency with the original CamGFR. However, it relied on the
assumption that the same variables are informative in predicting GFR when using multi-centre
data.
To address the above concerns, we also redeveloped the model from the beginning using the
multi-centre dataset. For this and the previous approach, data were used from the centres which
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had at least some IDMS-traceable creatinine data (Cambridge, Manchester and Gothenburg);
this included the original Cambridge data used to develop CamGFR. These three centres
contained 8,243 GFR measurements from 7,239 patients. In addition to the exclusion criteria
in Section 3.1.3 we further excluded samples if they were a repeat GFR for the same patients
within a year of the last measurement (n = 448). This was to mitigate for any adverse effect
of treatment and loss of independence of the samples. After these samples were removed,
there were 7,795 GFR measurements from 7,238 patients, of which 3,182 had IDMS-traceable
creatinine. The data from these centres were subsequently randomly split into development and
validation datasets at the ratio 4:1.
4.3.1 Refitting the CamGFR model
As discussed above, our first approach was to adjust the CamGFR model with an interaction




GFR = β0 + β1Age + β2BSA + β3SexM + β4ScrIDMS
+ β5 log(Scr)ScrIDMS + β6 log(Scr)2ScrIDMS + β7 log(Scr)3ScrIDMS
+ β8 log(Scr)Scrnon-IDMS + β9 log(Scr)2Scrnon-IDMS
+ β10 log(Scr)3Scrnon-IDMS + β11AgeBSA + β12AgeSexM+ε
where
• βi for i = 0, . . . ,12 are the coefficients estimated via least squares
• BSA is the patient’s body surface area
• SexM is a dummy variable equalling 1 if the patient’s sex is male and 0 if female
• ScrIDMS is a dummy variable equalling 1 if the creatinine measurement is IDMS-traceable
and 0 if it is not
• ScrNon-IDMS is a dummy variable equalling 1 if the creatinine measurement is non-IDMS-
traceable and 0 if it is not
• Scr is the patient’s serum creatinine measurement
• ε are mean zero and constant variance residual
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This model will be referred to as the refitted CamGFR model. The coefficients estimated
from fitting the model using the development dataset are given in Table 4.5. Some coeffi-
cients (β0,β1,β2,β3,β8,β9,β10,β11,β12) are directly comparable with the coefficients from the
original CamGFR model, where the variable ScrNon-IDMS was equal to 1. Hence, Table 4.5
additionally displays the original coefficients, their standard error, and a p-value resulting
from a Z-test for the difference between the two sets of coefficients. Of the nine compara-
ble coefficients, only log(Scr)ScrIDMS had a significantly different coefficient in the refitted
CamGFR model. This suggests that both models are reliable and have not over-fitted the data.
All coefficients in the refitted CamGFR model were significantly different from zero, indicating
that all coefficients are necessary.
Variable Coefficient New New SE Original Original SE p-value*
(Intercept) β0 1.662 0.374 1.814 0.626 0.781
Age β1 0.018 0.006 0.019 0.010 0.793
BSA β2 4.772 0.213 4.733 0.355 0.794
SexM β3 0.302 0.102 0.020 0.174 0.301
ScrIDMS β4 -0.508 0.029
log(Scr) ScrIDMS β5 -3.499 0.084
log(Scr)2 ScrIDMS β6 -0.738 0.092
log(Scr)3 ScrIDMS β7 0.699 0.112
log(Scr) ScrNon-IDMS β8 -4.049 0.077 -3.716 0.086 0.012
log(Scr)2 ScrNon-IDMS β9 -1.162 0.115 -0.914 0.117 0.253
log(Scr)3 ScrNon-IDMS β10 1.532 0.160 1.063 0.132 0.062
Age BSA β11 -0.028 0.004 -0.030 0.006 0.765
Age SexM β12 0.006 0.002 0.012 0.003 0.125
*p-value calculated for the null hypothesis that the coefficients for the two different regression fits are equal [21]
Table 4.5 Comparison of coefficients form the original CamGFR and refitted CamGFR models.
Alternatively, the fit of a regression model can be assessed with the help of summary plots,
as seen in previous sections. Figure 4.11 plots the residuals of the model (on the square root
scale) against the three main continuous variables along with the fitted values. Any trends in
these plots indicate that the model may not be fully explaining the relationship in the data.
In Figure 4.11, no major patterns are seen. However, there does appear to be a small bias to
overestimate GFR for patients who are young, indicated by the deviation of the fitted line from
a residual of 0. The other observed deviations appear to be driven by relatively few samples
and hence are less interesting.
We used the validation dataset to compare estimated GFR from the original and refitted
CamGFR models, Table 4.6. Patients with IDMS-traceable or non-IDMS-traceable creatinine
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Figure 4.11 Model residuals against fitted values and three explanatory variables (age, log(SCr) and
BSA) for the refitted CamGFR model. Residuals and fitted values are shown on the square-root scale.
For each patient the colour indicated creatinine-type (IDMS or non-IDMS) and the shape indicated the
cancer centre. All data smoothing lines are loess curves with the span parameter set to 0.9.
were analysed separately. For non-IDMS-traceable creatinine the refitted and original CamGFR
were broadly comparable in terms of accuracy, precision and bias. The refitted CamGFR
produced slightly higher values for estimated GFR and was more precise and accurate for data
from both centres. However, it was more biased for patients from Cambridge, with a tendency
to overestimate GFR. This is likely due to it being fitted using data from multiple centres and the
inter-centre variability of non-IDMS-traceable creatinine. Overall, the refitted CamGFR was
slightly more accurate although the difference is insignificant. As expected, for IDMS-traceable
creatinine the original model is biased to overestimate GFR. This bias was prevalent for patients
from all centres but was particularly high for patients from Cambridge where on average a
patient GFR would be overestimated by 9.07 mL/min. Overall, the refitted CamGFR was
not biased; however, for patients from Gothenburg there was a bias to underestimate GFR
on average. This is an unexpected result particularly as there was no difference in creatinine
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model Centre n median value RMSE median residual IQR
IDMS creatinine
Original All 618 91.05 17.02 (15.86, 18.20) -8.2 (-9.8, -6.96) 18.23 (16.89, 20.30)
Refitted All 618 81.79 14.97 (13.84, 16.13) 0.73 (-0.68, 2.20) 17.79 (15.78, 19.07)
Original Cambridge 426 92.95 17.58 (16.17, 19.05) -9.07 (-10.22, -7.75) 17.32 (15.43, 19.41)
Refitted Cambridge 426 82.94 14.90 (13.44, 16.40) -0.37 (-1.85, 1.45) 18.26 (16.60, 20.70)
Original Gothenburg 130 87.23 15.78 (13.23, 18.27) -3.8 (-7.72, -0.17) 18.05 (14.81, 21.32)
Refitted Gothenburg 130 78.79 15.36 (13.13, 17.55) 5.21 (2.40, 8.68) 17.77 (14.37, 20.13)
Original Manchester 62 86.54 15.54 (12.11, 19.22) -5.84 (-9.55, -2.23) 15.47 (11.02, 20.33)
Refitted Manchester 62 77.74 14.61 (11.73, 17.70) 1.92 (-2.45, 5.27) 17.00 (13.40, 22.70)
Non-IDMS creatinine
Original All 921 78.63 15.83 (14.95, 16.72) -0.09 (-1.25, 0.92) 19.10 (17.63, 20.95)
Refitted All 921 79.01 15.74 (14.86, 16.63) -0.43 (-1.48, 0.91) 18.55 (17.17, 19.93)
Original Cambridge 577 80.45 15.28 (14.16, 16.38) -0.38 (-1.84, 1.14) 18.95 (16.99, 21.14)
Refitted Cambridge 577 81.36 15.41 (14.29, 16.52) -1.50 (-3.08, -0.18) 18.47 (16.37, 20.43)
Original Manchester 344 76.50 16.72 (15.25, 18.23) 0.48 (-1.12, 2.05) 19.36 (16.49, 22.17)
Refitted Manchester 344 75.77 16.28 (14.84, 17.76) 0.33 (-1.84, 1.95) 18.66 (15.99, 20.94)
Table 4.6 Comparison of the refitted and original CamGFR models for the validation dataset. Patients
with IDMS-traceable and non-IDMS-traceable creatinine are compared separately.
between Cambridge and Gothenburg, Figure 4.6. The refitted CamGFR also had the smallest
RMSE and residual IQR.
To conclude, the refitted CamGFR model fits the data well. It is comparable with the original
CamGFR model for non-IDMS-traceable data and far more accurate for IDMS-traceable
creatinine. The next section will investigate whether further improvements can be achieved by
adjusting the model.
4.3.2 Adjusting the CamGFR model
This section will present the analysis for redeveloping a model to estimate GFR. The analysis
will follow a similar structure to the original development of the CamGFR model discussed in
Section 4.1. Specifically, we first investigate refitting a linear model, with a transformation ap-
plied to the response variable, GFR. Following this we consider whether there is any additional
benefit in modeling the GFR-creatinine and GFR-age relationships with a piecewise linear fit.
Generalised linear models were not considered due to complexities in producing confidence
intervals for the predicted values.
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Assessing relationships in the data
As in Section 4.1, we calculated the Box-Cox transformation. Using the initial model, given in
Equation 4.1, with the addition of the previously discussed interaction term between creatinine
and creatinine-type, the power transformation calculated was 0.578 (95% CI 0.538–0.619).
Although the confidence interval does not contain 0.5 (or the square root transformation), it is
reasonably close. Hence, as with the original CamGFR, this transformation will be used.
Analysis of the relationship between square-root-transformed GFR and the explanatory vari-
ables gave similar observations to those in Figure 4.1. As before, creatinine was log-transformed
to improve linearity and reduce the skewness. A deviation from linearity in the relationship
between age and sqrt(GFR), where the slope of the relationship decreases for young patients,
was more prominent in this dataset compared with Figure 4.1. No difference was observed
between the IDMS-traceable and non-IDMS-traceable patient groups for the non-creatinine
variables. For a subset of the data, ethnicity was annotated with the majority of patients anno-
tated as being ethnically white (2,093 out of 2,205 for the development dataset). There was an
observable difference in the GFR-creatinine relationship between the 21 ethnically black and
the ethnically white patients, where ethnically black patients had a higher GFR for the same
creatinine value. However, due to the small number of ethnically black patients, this variable
was not considered for the model due to difficulty in estimating accurate coefficients.
Stepwise model selection
Stepwise selection, using the three different criteria of five-fold cross validation, leave-one-out
cross validation, and Bayesian information criterion, were again used. The set of models
searched contained all the combinations of the variables for age, sex, height, weight, BSA,
log(SCr), creatinine-type along with the pairwise interaction between these variables.
A few small changes were made to the procedure for the five-fold cross validation criteria.
The model selection algorithm was altered to start from the null model once in every 100
repetitions. For the remaining repetitions the algorithm starts from the previously selected
model. This reduced the computation time to run the algorithm. The number of repetitions was
also increased from 2,000 to 5,000.
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Unlike for the original CamGFR model the three criteria selected slightly different models.
Figure 4.12 summarises the variables included for each selection methods and compares fitted
coefficients with the coefficients for the refitted CamGFR model. All three models included
several new variables that were not included in the refitted CamGFR model. These included
weight and height variables along with the BSA-sex and BSA-height interaction terms, with the
leave-out-n model also including an age-height interaction term. The BIC model was the only
one to retain the age-sex interaction term included in the CamGFR model. All the coefficients
for the additional interaction term were significantly different from zero. Only one of these
models was taken forward for further consideration, and as the leave-one-out model was the
simplest (contained the fewest terms) of the three, it was chosen.
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Figure 4.12 Comparison of the fitted coefficients for the BIC, leave-one-out, leave-out-n and refitted
CamGFR. For each term included in any of the models the point estimate along with a 95% confidence
intervals is shown. Coefficients are split into three groups based on their size and standard error to allow
comparison. If the error bar crosses 0 then this indicates that the coefficient is not significantly different
from 0.
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Segmented regression model
In addition to the above analysis, we examined whether a continuous piecewise linear relation-
ship might be more appropriate for the age and creatinine variables, also known as segmented
regression model. This was driven by previous observations, where the relationship between
age and GFR appear to be piecewise linear with a break point around 40 years. A piecewise
linear curve may also fit the GFR and creatinine relationship with two break points. In addition,
the CKD-EPI models the creatinine-GFR relationship with a piecewise linear fit.
To assess whether using a piecewise linear relationship would improve the model, a new model
was produced which included a piecewise linear relationship for age and creatinine. Models
that only added a piecewise linear relationship for age or creatinine were also considered
but were less accurate and thus will not be discussed here. The model was fitted using the
segmented R package [83], which, given a linear model and the explanatory variables for
which a piecewise relationship is desired, estimates the break points and slope of each piece by
minimising the log-likelihood. For this, initial values need to be supplied for the break points;
these were chosen to be 40 years for age and -0.1 and 0.5 for log(SCr). Figure 4.13 displays
the fitted effect curves for log(SCr) and age and compares it with the corresponding effect
curves for the refitted CamGFR model. For the age, the estimated break point was 36.9 years,
while for log(SCr) the break points were estimated to be -0.137 and 0.504 for IDMS-traceable
creatinine and -0.164 and 0.542 for non-IDMS-traceable creatinine. Interestingly, there was not
a large shift between the piecewise linear curves for IDMS-traceable and non-IDMS-traceable
creatinine, particularly compared with that observed for the cubic fit in the refitted CamGFR
model.
When examining diagnostic plots for the newly fitted model, the small overestimate of GFR in
younger patients, seen in Figure 4.11, was removed. The plot of residual against log(SCr) also
showed some improvements. With these three models, along with the BIC and leave-out-n and
refitted CamGFR model, we move forward and compare them with the published model using
our validation dataset.
Model comparison
The models fitted in the previous sections, namely the refitted CamGFR, the leave-one-out
and the piecewise linear model, were then compared with each other using the validation













































































Figure 4.13 Fitted effect curves for log(SCr) and age for the refitted CamGFR (C and D) and the model
fitted with piecewise linear relationships for both log(SCr) and age (A and B). The curve for log(SCr) is
plotted for IDMS-traceable and non-IDMS-traceable separately. As age has an interaction term with
BSA, the curve for age is plotted for the minimum, 1st quartile, median, 3rd quartile and maximum
values of BSA in the dataset. The values of the variables for the patients used in the model development
dataset can be seen on the x-axis.
dataset. Both IDMS-traceable and non-IDMS-traceable creatinine data were used for this
comparison. Table 4.7 provides the summary statistics for the refitted CamGFR, leave-one-out,
and piecewise linear models for patients in the validation dataset. All models have similar
results for the four statistics used to compare the models. For RMSE, the piecewise linear
model was slightly more accurate than the leave-one-out model which itself was slightly more
accurate than the refitted CamGFR. However, these differences and the differences between
any statistics were not significant, as calculated using the bootstrap procedure described in
Section 3.2.3. All three models were unbiased. These small improvements of the piecewise
linear and leave-one-out models were not deemed sufficient to warrant changing the form of
the CamGFR model, thus we chose the refitted CamGFR as our final model and subsequently
compared this model with previously published models.
The previously published models that we compared with the refitted CamGFR were the CKD-
EPI [77] and MDRD-186 [76] which were compared during the original development of
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model median value RMSE median residual IQR P20
Piecewise linear model 80.67 15.28 (14.58, 15.98) -0.16 (-1.09, 0.76) 18.14 (16.92, 19.21) 0.25 (0.23, 0.27)
Leave-one-out model 80.29 15.31 (14.62, 16.02) -0.05 (-0.88, 0.81) 18.31 (17.44, 19.19) 0.25 (0.23, 0.27)
Refitted CamGFR 80.03 15.44 (14.74, 16.15) -0.07 (-0.89, 0.73) 18.54 (17.61, 19.60) 0.25 (0.23, 0.27)
Table 4.7 Refitted CamGFR, leave-one-out and piecewise linear models comparison on the IDMS-
traceable and non-IDMS-traceable combined data in the validation dataset.
CamGFR (Section 4.1), along with the Lund-Malmo [7] and FAS [102] models. For this
comparison, patients with IDMS-traceable or non-IDMS-traceable were compared separately
as all four previously published models were developed using IDMS-traceable creatinine and
hence may be biased for non-IDMS-traceable creatinine. Figure 4.14 displays the four statistics
used to compare models for each of the models.
The refitted CamGFR was the most accurate and precise for both IDMS-traceable and non-
IDMS-traceable creatinine. For IDMS-traceable creatinine the refitted CamGFR had signifi-
cantly better RMSE than all models (p-value < 0.005) apart from the Lund-Malmo (p-value
0.26). For non-IDMS-traceable data, it was significantly better than all models (p-value <
0.005) apart from the CKD-EPI (p-value 0.06).
The refitted CamGFR was the only model that was unbiased for both IDMS-traceable and
non-IDMS-traceable creatinine. This was not surprising given that it is the only model to
contain a factor differentiating the two creatinine types. What is more surprising, but perhaps
not unexpected given that it was unbiased in validation of the original CamGFR, was the high
bias and poor accuracy of the CKD-EPI model on IDMS-traceable creatinine. The CKD-EPI is
widely recommended as the best model to estimate GFR when creatinine is IDMS-traceable
[11, 86]. However, these results suggest that this could lead to an overall bias to overestimate
GFR by 11.3 mL/min when using the CKD-EPI model. There is a clear difference in accuracy
and bias between the refitted CamGFR and Lund-Malmo compared with the CKD-EPI and the
other two models. There are numerous possible reasons for this discrepancy, the most likely of
which is that the IDMS-traceable data used to develop the CKD-EPI (and MDRD) are different
(or biased) from the IDMS-traceable creatinine data used in this study.
Analysing CamGFR as date difference increases
Throughout this chapter we have only included patients if they have a serum creatinine mea-
surement within 30 days of their nmGFR measurement. This cut-off was originally chosen

































































Figure 4.14 Summary statistics comparing the Refitted CamGFR, Lund-Malmo, CKD-EPI, FAS and
MDRD models. Statistics calculated for the 618 patients with IDMS-traceable creatinine and 921
patients with non-IDMS-traceable creatinine separately. The residual (measured GFR - estimated GFR)
median (first row), residual interquartile range (second row), root-mean-squared error (third row) and
the proportion of patients who have an absolute percentage error more than 20% (P20) (fourth row) are
displayed. All error bars are 95% confidence intervals calculated using bootstrap resampling with 2,000
repetitions and a normal distribution approximation.
quite arbitrarily but with the intention of minimising the errors caused by creatinine or GFR
changing in the intervening time between the two measurements. The 30 days was suggested
by clinical colleagues as reasonable. However, this should be checked as it is conceivable that
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a patient’s serum creatinine may change in the 30 days and thus affect the accuracy or bias
of GFR estimated by any given model. Here we compare estimated GFR from the CamGFR
model by the time between the nmGFR and serum creatinine measurements.
For the three datasets used in this section, the date difference between creatinine and GFR
was not known for any of the patients in Gothenburg and a subset of patients in Cambridge.
Figure 4.15 (A) shows the histogram of the difference in time between the GFR and creatinine
measurement days. All patients within the Manchester dataset had their creatinine measurement
on or in the week after their nmGFR. For patients from Cambridge the time difference was
more variable. The mode for the time difference was zero days and the time difference was
within a week for 81.4% of patients.
To compare the estimated GFR we then grouped patients by the time difference between their
measurements. The groups for the time difference between serum creatinine and nmGFR
measurements were as follows: more than one week before (n = 612), 3-7 days before (n =
714), 1-2 days before (n = 714), on the same day (n = 1,204), 1-2 days after (n = 822), 3-7 days
after (n = 1,819) and more than one week after(n = 549). Patients for whom the time difference
was not known formed another group called "NA" (n = 1,444). The accuracy (RMSE) and bias
(residual median) of the refitted CamGFR for each of these groups is displayed in Figure 4.15
(B) and (C). We did not observe a decrease in accuracy as the time difference lengthened;
if anything, we observed the opposite trend. Likewise, the patients whose creatinine was
measured more than a week after their nmGFR, or more than a week before their nmGFR,
were less biased compared with patients whose creatinine and nmGFR were measured closer
together. The patients where the time difference was not known, had the highest RMSE and
residual median. However, this is confounded by the dataset, as all patients from Gothenburg
are included in this group. Other confounding variables might be involved in this analysis. In
particular, patients who have a creatinine measurement close to their nmGFR may be more
likely to be in-hospital patients which may affect the accuracy of estimated GFR. This is
discussed in further detail in Section 6.1.
4.3.3 Discussion
In Section 4.2.1 we explained that the introduction of blood serum creatinine that is traceable
to an IDMS reference material (IDMS-traceable) has improved the compatibility of creatinine
across different centres but has also led to a decrease in the average creatinine value. This
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Figure 4.15 Comparison of CamGFR accuracy and bias as the time between serum creatinine (SCr) and
GFR measurements increases. (A) Histogram of the SCr and GFR time difference, with bars coloured
by the patients cancer centre. RMSE (B) and residual median (C) for the refitted CamGFR model when
patients are grouped based on the SCr and GFR time difference. Negative time differences indicating
that the serum creatinine was measured before the GFR. All patients from the Cambridge, Manchester
and Gothenburg are included. Where the specific date was not known, these patients were included in
the NA group. The number of patients in each group from left to right are: 612, 714, 531, 1204, 822,
1819, 549, and 1444.
decrease is probably attributable to the historical overestimation of creatinine when measured
by the Jaffe method due to interference from other substances, in particular albumin. The
CamGFR model was developed using data that were not IDMS-traceable and thus an adjustment
was required for the CamGFR model to be suitable for use with IDMS-traceable creatinine.
Hence, in this section, we refitted the previously published [60] and validated [132] CamGFR
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model to be suitable for IDMS-traceable creatinine. This was achieved by adding an additional
interaction term between the creatinine terms in the model and creatinine-type (IDMS or
non-IDMS). We also explored alternative models (e.g. the piecewise linear and leave-one-out
models) and these showed slight improvement in model accuracy. However this improvement
was ultimately deemed not substantial enough to warrant changing the model form, which
has the additional benefit in allowing clinical continuity. We thus now present the refitted
CamGFR, which can be used to make a prediction for GFR based on either non-IDMS-traceable
or IDMS-traceable creatinine data.
Using the multi-centre validation dataset we showed that the refitted CamGFR was the most
accurate and least biased for both IDMS-traceable and non-IDMS-traceable creatinine data
compared with previously published models. The improved accuracy of the CamGFR model
in GFR estimation directly translates into an improved dosing accuracy for carboplatin dose
calculations via the Calvert equation [13]. We further compared the CamGFR with other
models for patients who did not have cancer where the model was equally as accurate.
Of the previously published model (excluding refitted CamGFR), Lund-Malmo was observed
to be the most accurate model for IDMS-traceable data and CKD-EPI was the most accurate
for non-IDMS-traceable data. This second observation is surprising given that CKD-EPI
was developed using IDMS-traceable creatinine, yet using IDMS-traceable creatinine data
in this thesis the model is less accurate and highly biased (with an overestimation of 10.58
ml/min) compared with non-IDMS-traceable creatinine data. Although we have insufficient
information to provide a conclusive explanation for this result, one possible explanation could
be that there are substantial differences in IDMS-traceable creatinine between institutes in
different continents. Although this seems unlikely given the very purpose of IDMS-traceable
creatinine is to reduce inter-centre differences, the CKD-EPI model was developed using a
USA patient population while CamGFR and the Lund-Malmo were developed using European
data. To provide a more conclusive explanation, additional data need to be collected from
North American centres so as to compare the creatinine values and further generalise a model
applicability.
The inclusion of interaction variables as candidate terms for the model enables the identification
of more complex relationships between GFR and the explanatory variables. One particular
example which was observed to be consistently significant in the modelling process was the
BSA-age interaction term, implying that the effects of age and BSA on GFR are not merely
additive. The fitted coefficient for this interaction term is negative, whilst the fitted coefficients
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for age and BSA are positive and negative, respectively. Thus, one interpretation of the BSA-
age interaction term is that as a patient’s BSA increases, the negative association between GFR
and age increases, as seen in Figure 4.13 D. Considering this interaction term from a biological
perspective, and given that BSA is correlated with obesity, we note that this may reflect the
contribution of microvascular disease to the loss of renal function [35]. Microvascular disease
that, in turn, can worsen with age, hypertension and poorly controlled hyperglycaemia.
Despite improved accuracy, the refitted CamGFR model is still limited by a few important
factors. First, although we had a few non-Caucasian patients in our study (n = 22), these were
not enough to add an adjustment to the model. Previous models [77, 76] with a population of
patients with different ethnicities have shown that an adjustment for certain ethnicities improves
the model fit.
Second, although standardisation of serum creatinine assays has reduced the inter-centre
variability, there are still underlying issues in using it as the primary renal filtration marker in
a model for GFR. The primary issue is its dependence on non-kidney factors such as muscle
mass, diet and supplements, as discussed in Section 2.4.2. Furthermore, disease processes or
therapeutics may affect serum creatinine in an unknown and unpredictable manner which could
lead to erroneous estimations for GFR. This has led to the suggestion of alternative filtration
markers to serum creatinine, in particular cystatin C.
Recent literature has shown the potential benefit of using cystatin C as opposed to, or in addition
to, creatinine [58, 89, 48, 101]. Cystatin C has an advantage over creatinine in that it is not
as affected by muscle mass and diet, as a result models which use cystatin C do not typically
require a race adjustment. However, cystatin C is not routinely measured, which is in itself a
disadvantage of including cystatin C in a model. This was something evidenced in this thesis
as the data were collected retrospectively and cystatin C had not been measured in standard
patient blood tests and thus it was not measured for any of the patients in our study. A further
disadvantage is that cystatin C has been shown to have similar issues to creatinine with regards
to inter-centre variability. There is also some evidence for involvement of cystatin C in cancer
progression, which might impact on its validity to be used as a filtration marker for patients
with cancer [70]. Cystatin C is not the only other filtration marker to have been considered
as an alternative to creatinine, other filtration markers have been included in previous models,
namely urea and albumin. We explore these and other haematological and biological blood
results in Chapter 5. These too have issues with inter-centre variation which impacts on their
usefulness for estimation of GFR.
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4.4 Conclusion
Having analysed data from 9,233 patients, we have developed a new model to estimate GFR.
This work has primarily been focused on patients with cancer, for whom GFR is commonly
estimated, but no recent model exists. This is important given that patients with cancer were
typically seen to have normal GFR for their age, this is in contrast to chronic kidney disease
patients who have often been used to develop previous models. We have shown that the refitted
CamGFR model generally performs better than other published models, and, given further
validation, should be considered as a useful estimate of GFR, particularly in patients with
cancer.
It should always be remembered that any estimated GFR from a model has an associated
variability, and thus there may be a large difference between the true GFR and estimated GFR
for any particular patient. As such, clinicians should give careful consideration to the variability
of any estimated GFR. In particular, when reporting an point estimate for GFR a confidence
interval should also be provided. This is available for the CamGFR model via the online
application published alongside the original manuscript [60]. However, wherever possible and
particularly when a high level of confidence is required, GFR should be measured using nuclear
medicine.
There are a number of questions and considerations that have arisen at the culmination of this
chapter. Some of this we will investigate in the next chapters and also within future work,
including:
• Whether for additional haematological and biochemical measurements, any correlation
exists between these measurements and GFR, and the potential implication of this
• Whether inclusion of additional haematological and biochemical measurements will
reduce the risk of inaccurate estimation and hence further improve the accuracy of a
model to estimate GFR
• The possible adverse effects of chemotherapy treatment on a patient’s GFR and serum
creatinine, and the implications of this
• The issues with and implications of estimating a patient’s GFR when their creatinine is
not stable
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• How renal function in patients with cancer compares with renal function for healthy
kidney donor patients, and the effect of this on a model to estimate GFR
Chapter 5
Exploratory analysis of non-creatinine
variables as predictors of GFR
The development of a model to estimate GFR in Chapter 4 focused on using creatinine as
the only clinical measurement. However, in clinical practice many routine measurements are
performed to assess a patient’s general state of health, check for infection, or monitor organ
function. In this chapter we assess whether these other routine clinical measurements may be
predictive of GFR. We begin with exploratory analysis of these data, specifically examining
association of these measurements with GFR. We then consider whether GFR can be more
accurately estimated if these additional variables are included in a regression model. Finally,
using the results of these models, we discuss the particular biochemical or haematological
variables that are predictive of renal function.
5.1 Data description
The data that inform this analysis consist of a subset of Cambridge and London-Barts datasets
used and described in the previous chapter. For patients from Cambridge, the data were
collected by extracting all biochemical and haematological blood tests that were performed
within 30 days of the given patient’s nuclear medicine GFR measurement. This dataset
consisted of 3,000 nuclear medicine GFR measurements (nmGFR) from 2,576 patients. For
these patients, there were 39 biochemical and haematological blood test results, which included
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serum creatinine, observed in 200 or more patients, with a total of 822,171 observations.
Henceforth, the biochemical and haematological blood tests will be referred to more simply as
blood tests.
To reduce the longitudinal data to single time point data, each of the blood tests was filtered,
leaving only those closest in time to the nmGFR measurement. Results were further required
to have been made within 30 days of the nmGFR measurement to be considered valid. This
procedure meant that for a given patient, the different blood tests might not have been performed
on the same day. In fact, only 44.9% of patients had all tests performed on the same day.
Not all blood tests were available for any given patient. The most commonly available
blood tests were for creatinine, sodium, albumin, urea, potassium, alkaline phosphates (ALP),
bilirubin, alanine aminotransferase (ALT), each of which was available for more than 1,900
patients. If the measurement units of the blood tests changed during the collection period, units
were corrected where possible. However, this was not possible for Platelet Distribution Width
(PDW) due to rounding errors, thus it was excluded.
5.2 Correlation of routine biochemical, haematological and
demographic variables
We first examined the correlation between the continuous variables in the extended Cambridge
dataset to study the strength of the relationships between variables. To do this, we used the
Spearman correlation coefficient, as it captures monotonic relationships and not just linear
relationships. Figure 5.1 displays the correlation matrix, in which variables are ordered by
hierarchical clustering of the absolute value of the correlation coefficient.
Groups of correlated variables are observable in the correlation matrix and dendrogram. For
example, white blood cell count and the immune cells eosinophils, basophils, neutrophils
and monocytes are intercorrelated. Lymphocytes, platelets (PLT) and procalcitonin (PCT) are
another intercorrelated group, which was also correlated with the previous group of variables.
Similarly, measures associated with red blood cells were intercorrelated; this included red cell
distribution width (RDW), red blood cell count (RBC), haematocrit and haemoglobin. As ex-
pected, height, weight and BSA, which is a function of height and weight, were intercorrelated.























































































































































































































































































































Figure 5.1 Correlation matrix of GFR along with the demographic , biochemical and haematological
variables. (A) Spearman correlation matrix for the 42 continuous variables. Correlation was calculated
for all complete pairs. With the exception of GFR, variables are ordered by hierarchical clustering
with the distance between two variables x and y set to be (1− |cor(x,y)|). The dendrogram for the
hierarchical clustering is shown in (B).
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When examining the correlation between GFR and all other variables, age, BSA, height and
weight were the variables with the strongest correlation. All four had an absolute correlation
higher than 0.4. Urea had a higher correlation with GFR than creatinine, -0.38 compared with
0.30 respectively. The other variables with an absolute correlation higher than 0.2 in order of
magnitude were albumin, haemoglobin, haematocrit, RBC and ALT.
5.3 Regression modelling for non-creatinine variables
After examining the correlation between GFR and the covariates, we performed a regression
analysis using the extended Cambridge dataset. This had two main aims, the first to examine
whether GFR could be more accurately estimated by including additional blood test rests
available in the extended Cambridge dataset. The second aim was to find variables which are
associated with renal function after accounting for any confounding variables.
For the regression analysis we needed a complete dataset, which was not the case in the
correlation analysis, to model the relationship between GFR and the predictive variables.
Different imputation methods were considered but ultimately not used. Instead, a complete
dataset was produced by excluding either patients or variables from the dataset. For this, we
assessed the trade-off between preserving the number of different variables and preserving
the sample size by examining the missing value pattern. Using this strategy, we excluded 13
variables with more than 1,468 (or 48.9%) missing values. Following this, the 1,490 samples
with missing observations were excluded. The resulting dataset contained 1,510 samples from
1,361 patients and 29 variables including creatinine, age, sex, height, weight and BSA. Similar
to the regression analysis in Chapter 4, this dataset was split into a model fitting (n = 1,208)
and a model validation (n = 302) dataset at a ratio of 4:1.
For the subsequent analysis to be valid, we need to assume that the data are missing completely
at random (MCAR). This assumes that the event that leads to a particular observation being
missing is independent of both observed and missing data [51]. In reality, this is unlikely to be
true for our data for several reasons. Blood test results are often measured together thus the
absence of one is associated with the absence of another. Blood tests are more likely being
obtained in periods of increased health care need due to acute illness or intense therapy. The
value of one measurement may result in the other measurements being performed. For example,















Table 5.1 Non-zero coefficients and their estimated value from the lasso model. Variables are standard-
ised before performing lasso regression.
increased markers of inflammation may lead a clinician to check more carefully for adequate
liver function. Given the above caution should be observed in interpreting any findings.
The distribution of each continuous variable was then examined. As most of the variables
were either counts or concentrations, many were positively skewed. This could have meant
that the GFR variable relationship was not approximately linear. To help resolve this, we log-
transformed all predictive variables whose skewness was greater than 1. A small adjustment of
0.1 was added to each variable, except for creatinine, before log transformation to resolve issues
of log-transforming zero values. The variables which were transformed, by order of skewness,
were APTT, bilirubin, PT, basophils, ALP, neutrophils, WBC, eosinophils, lymphocytes,
creatinine, ALT, monocytes, CRP, urea, PLT, PCT, RDW, and MPV.
Compared with the regression analysis from Chapter 4, this analysis required us to choose a set
of predictive variables from a more extensive list of candidate variables, many of which were
likely to be uninformative. For this, along with the stepwise procedures described and used in
Chapter 4, we also considered elastic net regression methods. Specifically, we used lasso, as
this performs both regularisation and variable selection. Incidentally, it was also more accurate
than other elastic net models. We did not consider pairwise interaction terms as they increased
the number of variables to 781, the square and cubic log(SCr) terms were included.
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Finally, we considered linear additive models (AM) to model the relationship between square-
root transformed GFR and its predictive variables. This allowed us to model non-linear
relationships between GFR and the predictive variables in a more general fashion. All con-
tinuous variables were modelled using P-splines [37]. Variable selection was performed for
the additive model by including an additional penalty to a smooth term, allowing terms to
be removed from the model. Once variables were removed, the model was refitted with the
remaining coefficients. Further details on variable selection for additive models can be found
in Section 4.1.2.
When performing stepwise selection with BIC as the selection criterion, the selected model
contained the variables BSA and log(SCr), along with the squared and cubic terms, age, sex,
haemoglobin, log(SUN), log(ALP), log(ALT), MCV, and albumin. All fitted coefficients were
significantly different from zero.
Lasso regression was performed using 10-fold cross-validation to find the value of the pe-
nalisation parameter λ ; see Section 3.2.2 for further details. The value which minimised the
mean-squared error was λmin = 0.011, and the value which was one standard deviation larger
than this was λ1se = 0.057. Using λ1se the non-zero coefficients are provided in Table 5.1,
along with their estimated value.
When fitting the additive model with our variable selection procedure, the non-zero variables
were log(SCr), BSA, age, height, weight, albumin, log(SUN), potassium, log(ALP), log(ALT),
RBC, log(RDW), log(monocytes), log(neutrophils), and log(lymphocytes). After removing the
zero variables the model coefficients were re-estimated. All remaining coefficients significantly
improved the fit of the model, with p-values calculated using an F-test for each variable.
Figure 5.2 displays the fitted smoothed curves for each of the continuous variables in the model.
Interestingly, the fitted curves for height and weight seem to indicate that as either variable
increases, the predicted value of GFR decreases. This is contrary to the previously seen positive
correlation between GFR and either variable (Figure 5.1). However, the plot is misleading in
this instance; since BSA is calculated from height and weight, positive correlation between
height or weight and GFR are absorbed into the effect of BSA on GFR. Hence, a given increase
in height or weight would result in an increase in BSA, and subsequently an overall increase in
estimated GFR. This case highlights the complexities of examining the individual effects of the
variables, particularly for highly intercorrelated variables.
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Figure 5.2 Fitted smooth functions for all variables in the additive model. Blue curves are the fitted
smoothed functions for each continuous variable in the additive model. The functions are calculated
conditionally on all other variables being equal to their mean and displayed on the square root scale.
Background points are the partial residuals, which are equal to the sum of model residual and the fitted
smoothed function for the given variable.
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Three modelling approaches were considered in this section: stepwise selection with linear
regression, lasso, and additive models. All of these models selected common variables, and all
included the variables that were used for the refitted CamGFR model, specifically BSA, age,
log(Scr) and sex. Variables for log(SUN), log(ALT), log(ALP) and albumin were also included
in all three models. Finally, at least one variable associated with red blood cells was included
in all of the models: haemoglobin for the stepwise model; haemoglobin, RBC and log(RDW)
for the lasso model; and RBC and log(RDW) for the additive model.
5.3.1 Internal validation
To assess the performance of the new models, all three were compared with each other and with
refitted CamGFR, CKD-EPI and Lund-Malmo on the separate validation dataset. Similarly to
the approach in Chapter 4, models were compared using RMSE, residual median and residual
IQR, which aim to assess model accuracy, bias and precision respectively. The more robust
measure of accuracy P20 (the proportion of patients with an absolute error greater than 20%)
was also used. All statistics were calculated using an estimated and observed GFR value on its
ordinary scale to resolve the issue of different transformations used for the published models.
Table 5.2 provides the summary statistics for the six different models using the internal
validation dataset. All three new models were more accurate than refitted CamGFR, which
itself was the most accurate of the creatinine-based models. Of the three new models, the
additive model was slightly more accurate than the other two, both as measured by RMSE and
by P20. None of the new models, along with refitted CamGFR, had a residual median that was
significantly different from zero. The patients that were included in these data overlap with
the Cambridge dataset from Chapter 4 and all had their creatinine measured using an IDMS-
traceable method. Hence, as previously seen, the CKD-EPI was very biased to overestimate
GFR for these patients. In fact, over twice the number of patients had an absolute error greater
than 20% when GFR was estimated using the CKD-EPI model, as compared with any of the
three new models.
Overall, it appears that including the additional variables modestly improves the model. There
is no evidence that any of the models are over-fitting the data. However, over-fitting may
still be an issue given that the models have been trained and validated on patients from a
single centre. Furthermore, similar to issues with inter-centre comparison of serum creatinine
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model RMSE median residual IQR P20
AM 12.96 (11.70, 14.27) -0.91 (-2.72, 0.79) 14.94 (12.36, 17.51) 0.175 (0.133, 0.218)
LASSO 13.23 (11.92, 14.58) -0.56 (-1.85, 0.80) 16.36 (14.06, 19.13) 0.205 (0.161, 0.250)
Stepwise-BIC 13.23 (11.88, 14.63) -0.70 (-2.22, 0.77) 15.19 (13.30, 17.23) 0.192 (0.148, 0.237)
CamGFR 14.02 (12.71, 15.37) -0.70 (-2.02, 0.91) 17.24 (14.44, 20.38) 0.235 (0.188, 0.282)
Lund-Malmo 15.88 (14.40, 17.42) -4.07 (-5.89, -2.05) 17.92 (15.26, 20.29) 0.295 (0.245, 0.344)
CKD-EPI 21.61 (19.72, 23.56) -13.61 (-15.98, -10.75) 18.93 (16.48, 21.53) 0.464 (0.408, 0.520)
Table 5.2 Comparison of the additive (AM), LASSO, Stepwise-BIC with additional non-creatinine
variables, with the creatinine-based refitted CamGFR, Lund-Malmo and CKD-EPI models. Models
were compared by root-mean-squared error (RMSE), median residual, residual interquatile range (IQR)
and proportion of samples with an absolute error greater than 20% (P20). All statistics were calculated
using the 302 patients from the Cambridge internal validation data set containing the additional blood
test results.
measurements, many of the new blood test results may be centre-dependent. The effects of any
such dependence is currently unknown.
5.3.2 External validation
To try to resolve some of the issues raised in the internal validation we aimed to externally
validate the model. In a similar situation to the development of the original CamGFR model,
a small dataset composed of 108 male patients with germ cell cancer treated at Barts Health
NHS Trust, London were used for this external validation. These patients had previously been
used during the validation of the original CamGFR model for non-IDMS-traceable creatinine,
Section 4.2.2.
There were some challenges in using these data for external validation, as some blood test
variables that were available in the Cambridge dataset were absent from London-Barts. Im-
portantly, the variables RDW, RBC, and monocytes were unavailable (these were included in
the lasso or additive models). As a result, we were not able to validate directly the lasso and
additive models but instead re-ran the model selection process using only the variables that
were available in both datasets.
Rather than using external validation in order simply to validate previously developed models,
here we use the London-Barts dataset to assess the impact of using a model developed at one
centre on patients, or blood tests, measured at a different centre. It is particularly important to
undertake this assessment because, unlike for creatinine, there is no international standardisation
98 Exploratory analysis of non-creatinine variables as predictors of GFR
for many of these blood test measurements. Hence, many of these measurements are likely to
exhibit inter-centre variability [98], leading to possible bias and inaccuracy.
Before redeveloping the lasso and additive model, we first compared data from the two centres
to assess differences in the variables. As all the patients from London-Barts were male and
had a germ cell tumour, the same type of patients were extracted from the Cambridge dataset
(n = 149). The difference in creatinine between these two centres was previously compared
in Figure 4.7. Figure 5.3 shows the histogram for each continuous variable available in both
datasets, with colour-coding to differentiate the two datasets. Both albumin and sodium
immediately stand out as having differing distributions between the two centres, with higher
values observed in London-Barts compared with Cambridge. This was also true to a lesser
extent for log(ALP). The distributions of haemoglobin, log(lymphocytes), log(neutrophils)
also all appear slightly different between the two centres. The values for eosinophils were
more heavily rounded in London-Barts, leading to the observed differences in the histogram of
log(eosinophils).
Some of these observed differences could be due to differences in the groups of patients at
the two centres. Patients from the centres were matched by disease, however Addenbrooke’s
Hospital in Cambridge is a tertiary referral centre for germ cell tumours. Therefore, some of
the patients in the Cambridge dataset may have had a more advanced tumour and may have
been generally more unwell. Typically, we would expect a more unwell patient to have lower
albumin, which is what we observe in the Cambridge dataset.
We did not know whether the creatinine values in London-Barts were IDMS-traceable or
not. However, given that its distribution more closely resembled centres that had non-IDMS-
traceable creatinine (Figure 4.7), we suspected that it was non-IDMS-traceable. The compara-
tive creatinine data from the Cambridge dataset used in this chapter were all IDMS-traceable.
The resulting difference in the distribution between the two centres can be observed in Fig-
ure 5.3, with the mode of the London-Barts to the right of Cambridge. However, the magnitude
of this difference is far smaller than for the variables discussed above.
We then redeveloped the lasso and additive models using the Cambridge model development
dataset, but considered only the variables that were available in both Cambridge and London-
Barts. This reduced the number of variables for the development of the models from 29 to
19. For the lasso model this resulted in the variables RBC, log(RDW) being replaced by the
variables log(lymphocytes) and MCV. In addition, the cubic log(SCr) term was now included.
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MCV Potassium Sodium Weight
log_Neutrophils log_PLT log_Urea log_WBC
log_Bilirubin log_Creatinine log_Eosinophils log_Lymphocytes
Height Hemoglobin log_ALP log_ALT
Age Albumin BSA GFR
70 80 90 100 3.0 3.5 4.0 4.5 5.0 130 135 140 145 80 120 160
1 2 3 5 6 7 1.0 1.5 2.0 2.5 1 2 3
1 2 3 −0.8 −0.4 0.0 0.4 −2.0 −1.0 0.0 −1 0 1 2
160 170 180 190 200 10.0 12.5 15.0 17.5 4 5 6 7 2 3 4 5



































Figure 5.3 Histograms of all continuous variables included in both the Cambridge and London-Barts
datasets. Patients were matched by diagnosis, with only the male germ cell patients (n = 149) included
from the Cambridge dataset which was the only type of patient in the London-Barts dataset (n = 108).
Variables are displayed on the scale used for modelling.
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model RMSE median residual IQR P20
LASSO* 17.00 (14.45, 19.62) 1.98 (-1.08, 5.07) 22.82 (18.58, 29.22) 0.172 (0.095, 0.248)
AM* 17.28 (14.68, 19.94) 1.08 (-2.57, 5.59) 22.37 (18.88, 26.63) 0.172 (0.095, 0.247)
Stepwise-BIC 17.92 (15.11, 20.81) -1.19 (-5.78, 3.46) 24.00 (20.28, 29.72) 0.182 (0.104, 0.259)
Lund-Malmo 17.98 (15.61, 20.43) 3.14 (-2.52, 7.88) 23.61 (19.56, 28.43) 0.202 (0.123, 0.280)
CamGFR-IDMS 19.14 (16.40, 21.96) 5.43 (0.89, 9.86) 22.29 (17.69, 27.11) 0.263 (0.174, 0.352)
CamGFR 19.94 (16.50, 23.55) -5.92 (-11.49, -0.64) 22.23 (16.07, 26.09) 0.222 (0.141, 0.304)
CKD-EPI 20.81 (17.72, 24.07) -11.06 (-16.62, -5.89) 24.72 (21.03, 30.73) 0.273 (0.184, 0.363)
* indicated that the model has changed from the model used for the internal validation
Table 5.3 Comparison of the additive (AM), lasso, stepwise-BIC (which contained additional non-
creatinine variables), refitted CamGFR, Lund-Malmo and CKD-EPI models. Models were compared by
root-mean-squared error (RMSE), median residual, residual interquatile range (IQR) and proportion
of samples with an absolute error greater than 20% (P20). All statistics were calculated using the 99
patients from the London-Barts external validation dataset containing the additional blood test results.
Creatinine data was annotated as being non-IDMS-traceable.
For the additive model the variables RBC, log(RDW), log(monocytes), height, and weight were
replaced with log(eosinophils) and MCV. These changes did not result in the accuracy of the
model changing when assessed using the internal validation dataset, with the lasso slightly
more accurate than in its previous development. The RMSE (and confidence interval) was
13.19 (12.21 - 14.33) and 13.20 (12.22 - 14.34) for lasso and additive models respectively.
These two models were then compared with the BIC model, which did not need redevelopment,
and with the creatinine based models (refitted CamGFR, LM and CKD-EPI) on the London-
Barts dataset. Given that it was not known for sure whether the London-Barts creatinine values
were IDMS-traceable or not, the GFR was estimated using the refitted CamGFR for both
possibilities. Nine patients were excluded from the analysis as they had missing values for
MCV, lymphocytes, eosinophils and SUN. This left a dataset that consisted of 99 patients
to compare the models. Table 5.3 provides the four summary statistics used to compare the
models using these patients. Examining the results we see that all three models that use the
additional variables are more accurate than the creatinine-based models. All three new models
along with the Lund-Malmo were unbiased, as evidenced by the confidence interval for the
median residual containing zero. This was surprising given the observed difference in the
distributions of the variables seen in Figure 5.3. Of the three models, the lasso was the most
accurate, although the difference in accuracy between lasso and Lund-Malmo, which was the
best of the creatinine-based models, was small.
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5.4 Biological context of non-creatinine predictive variables
of GFR
Thus far we have shown that including additional blood tests in models for GFR improves
the accuracy of the prediction. Throughout the analysis, some blood tests were consistently
observed to be predictive of GFR. In particular, SUN, albumin, ALP, ALT, and at least one
red blood cell measurement (such as haemoglobin, RBC or RDW) were chosen in each of
the models previously fitted in this section. Here, we will analyse the observed relationships
between GFR and these four blood tests in more detail and discuss whether there may be
biological causes for these relationships.
SUN [mmol/L]
1.0 2.5 7.5 20.0
Albumin [g/L]
10 20 30 40 50
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Figure 5.4 Serum urea nitrogen (SUN), albumin and red blood cell count (RBC) against either GFR
(top row) or the residual when estimating GFR using the refitted CamGFR model (bottom row). SUN is
shown on the log scale. The normal ranges for each variable are displayed as a solid vertical line. For
RBC, the normal range depended on gender, and thus the maximum and minimum over both genders is
shown. Smoothed lines are calculated using a generalised additive model with a cubic spline basis.
Figure 5.4 and 5.5 shows the relationship between both GFR and the residual of the refitted
CamGFR model from Chapter 4 for SUN, albumin, one of the highly intercorrelated red blood
cell measurements (RBC), ALP and ALT. In order to display the relationship between GFR and
each blood test after the effects of creatinine and demographic data (used in refitted CamGFR)
are removed, we have included plots of each blood test against the residual of the refitted
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CamGFR. Additionally, to see the fitted effect of each variable in the additive model, Figure 5.2
can be examined.
First, we discuss serum urea nitrogen (SUN) and albumin, which are blood tests that have been
used in previous models for GFR, specifically the six-variable MDRD [74]. As discussed in
Section 2.4.2, SUN is a breakdown product in the nitrogen cycle and, similar to creatinine, it
has been considered as an endogenous filtration marker and is functional-homologous to serum
creatinine. In Figure 5.4, we see that the relationship between SUN and GFR is approximated
by a piecewise continuous linear function with a spline point at approximately 4.0 mg/dl. For
values below this point, as log(SUN) increases, GFR decreases. This is similar to the previously
observed relationship between creatinine and GFR. Furthermore, SUN is the variable which
has the highest correlation with creatinine (ρ = 0.64). It is therefore not surprising that, when
examining the relationship with the residuals of the refitted CamGFR model, the observed
association is reduced. In the additive model, the fitted function for SUN takes a similar shape
to its raw relationship with GFR (Figure 5.2), indicating that SUN is still predictive even when
both creatinine and SUN are included in a single model. In summary, SUN is acting as another
measure of filtration function along with creatinine.
Serum albumin is a globular protein and is the main protein of human plasma. Its primary
function is to regulate the oncotic pressure of blood. Albumin is produced in the liver, and
medically is often used as a marker of liver function, with low concentrations a marker for liver
disease. Additionally, reduction in serum albumin concentration may be caused by factors such
as reduction in dietary protein intake, major surgery, systemic inflammatory disease, malignant
conditions, or severe cases of the nephrotic syndrome [74]. Figure 5.4 shows the relationship
between albumin and GFR. As with SUN, the relationship appears to be piecewise linear with
a spline point at the the lower value of the normal range 35 g/L. Above this value, and for
the normal range 35–50 g/L, there is a strong positive association between GFR and albumin.
The positive association remains but is greatly reduced when examining the plot of albumin
against the refitted CamGFR residual or in the fitted function for the additive model. This can
be partly explained by examining its correlation with other variables included in the models,
in particular: ρ = 0.49 with haemoglobin, ρ = −0.25 with ALP, ρ = −0.24 with age, and
ρ = 0.21 with BSA.
Next we examine the relationship between GFR and red blood cell measurements: red blood
count (RBC), haematocrit, haemoglobin, and red blood cell distribution width (RDW). RBC is
the measure of the number of red blood cells per volume of blood, haematocrit is the percentage
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of blood comprising red blood cells, and haemoglobin is an oxygen-transport metalloprotein
found in red blood cells. RDW is a measure of the range of variation of red blood cells,
which is negatively correlated with the previous three measures. Each of our models contained
at least one of these measures and often more than one. Figure 5.4 shows the relationship
between GFR and RBC. The plot would change little if haematocrit or haemoglobin were
shown instead, given there is a strong positive correlation between RBC, haematocrit and
haemoglobin (Figure 5.1). Examining this plot, for measured GFR, we observe that increased
RBC is associated with lower GFR (Figure 5.4). Similarly to albumin and SUN discussed
previously, the relationship appears to be piecewise linear with spline point near the lower
normal range value 3.9×1012/L. Above this point, and in the normal range 3.6–5.75×1012/L,
there is strong positive association between GFR and RBC and below this point there is little
association. The association remains after other covariates are accounted for, with a linear
function fitted in the additive model (Figure 5.2). The additive model also fits a negative
association for log(RDW), which itself appears piecewise linear.
There is a plausible biological interpretation for this observed relationship. Specifically, atrophy
of the kidney may affect both its filtration function and other functions. One other function of
the kidney is to produce a hormone erythropoietin which drives haematopoiesis, the production
of the cellular components of the blood. Thus a reduction of erythropoietin may lead to a
decline in red blood cell production, which would lead to a lower red blood cell count. So
overall it is understandable that lower RBC is associated with lower GFR.
Finally, we examine alkaline phosphatase (ALP) and alanine transaminase (ALT), whose main
use is as diagnostic tools in determining liver abnormalities. ALP is a homodimeric protein
enzyme, which is involved in dephosphorylating compounds. It is present in all tissues, but is
particularly concentrated in the liver, bile duct, kidney, bone, intestinal mucosa and placenta.
ALP is used as a diagnostic tool in determining liver or bone abnormalities, in particular
hepatitis, with very elevated levels being an indicator of tissue breakdown in the ducts of the
liver. ALT is a transaminase enzyme involved in the alanine cycle, and is found in various body
tissues but in particular the liver; significantly elevated levels of ALT are also known to be
associated with liver issues [88, 79].
Both these blood tests are markers for liver abnormalities when elevated, however, the direction
of the association with GFR for ALT and ALP is opposing. In the raw relationship (Figure 5.5
A, top), in the relationship with the residuals of refitted CamGFR (Figure 5.5 A, bottom) and
in the additive model (Figure 5.2) we see increased ALP associated with decreased GFR, and
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Figure 5.5 The relationship between Alkaline phosphatase (ALP) or alanine transaminase (ALT) and:
GFR, the residual when estimating GFR using the refitted CamGFR model, age, BSA or sex. (A) ALP
and ALT plotted against either GFR (top row) or the residual when estimating GFR using the refitted
CamGFR model (bottom row). The normal ranges for each variable are displayed as a solid vertical
line. (B) Relationship between ALT or ALP with age, BSA or sex, ALT and ALT ore shown on the log
scale. For both plots ALP and ALT are shown on the log scale and smoothed lines are calculated a using
generalised additive model with a cubic spline basis.
increased ALT associated with increased GFR. For ALP, the decrease in GFR is particularly
seen for patients in the normal range of the measurement (30–130 U/L). Patients with an
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ALP higher than the upper range of normal show less association, but have an average GFR
of around 60 ml/min. When other covariates are accounted for, the decrease in GFR as ALP
increases is seen more clearly throughout the range of ALP values and is more apparent than
the relationship seen with ALT (Figure 5.5 A and Figure 5.2). For ALT, the increase in GFR is
particularly apparent for patients within the normal range (7–40 U/L), with values higher than
the upper limit showing less association. When other covariates are accounted for this positive
association between ALT and GFR remains but is reduced (Figure 5.5 and 5.2).
Elevated levels of both ALP and ALT are associated with poor liver function, which may be
associated with poor kidney function. It is accepted that at the extreme ends of the physiological
spectrum such as cardiorenal and hepatorenal syndrome, as organ failure progresses, multiple
organ failure may occur [91]. This relationship at the extreme of liver and kidney function may
be a continuum of change and not a rapid absolute change. Indeed, in the above, we find that
aspects that seem related to hepatic function become relevant when predicting renal function.
Given this, the opposite direction of the ALT and ALP association with GFR appears to be
contradictory. Both are markers for liver function when elevated, thus we would expect higher
ALP or ALT levels to be associated with lower GFR yet this was only observed for ALP.
To explore ALP and ALT further, we looked at the relationship of both ALP and ALT, not just
with GFR but also, with age, BSA and sex. This is because there are a number of generalisations
that can be made based upon these demographics. In general, men have larger livers with
greater liver function than women, people with a larger surface area have larger livers, and
young people have better liver function than older people. Examining Figure 5.5 B, we see that
ALT decreases as age increases, ALT increases as BSA increases, and there are higher values
of ALT in men compared with women. For ALP, there is no association between ALP and age,
no difference in ALP between men and women, and ALP slightly decreases as BSA increases.
These findings suggest that ALT within its normal range is a positive predictor of liver function.
Although this is contrary to the usual interpretation of high ALT (multiples of the upper limit of
normal) being associated with liver damage [79, 45], it is plausible for this to be the case if the
liver tissue during normal turnover produces, in a mass-dependent manner, subtle leakage of
ALT into the plasma. We could not find any literature to support or contradict this finding either
way. Previous literature has recommended a higher normal range for men than women for ALT
[44, 71], although the laboratory from which the data were obtained did not implement this.
Furthermore, our dataset was not suitable for further examination as most patients in the dataset
were early on in their cancer diagnosis and thus less likely to exhibit severe liver failure.
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The negative association of ALP with renal function suggests that the tissue structure changes
which lead to the release of the ALP molecule may always indicate early or progressing organ
impairment. Again, though very high levels of ALP are known to be a marker for liver damage
[79, 45], we did not have appropriate data to fully investigate this and could not find supporting
or refuting literature for this subtle difference between ALT and ALP.
As a result of these inconclusive findings, we advocate caution in interpreting the possible
relationships between liver function and GFR. Given the observed positive correlation between
ALT and the demographics associated with higher GFR, the positive association between ALT
and GFR may in part be driven by this. However, the positive association between ALT and
GFR remains after these demographics are accounted for and is seen in the refitted CamGFR
residual against ALT plot, in the fitted additive plot, and in the sign of the fitted coefficient for
all models which included ALT. Therefore, even after the effects of these three demographics
are accounted for there is still positive association between GFR and thus kidney function and
ALT. Our findings justify follow up assessments for patients who are likely to have a wide
spectrum of liver function.
5.5 Discussion and conclusion
In this exploratory study we have examined additional haematological and biochemical mea-
surements and their association with GFR. In doing so, we have shown two key findings. First,
that GFR may be more accurately estimated with addition of these variables and second, that in
doing so, the observed relationships may lead to interesting biological observations.
We used three different regression methods to produce three different models, with little
difference between them in accuracy. The three models were a linear model using stepwise
selection to select the variables, a linear model with lasso penalisation, and a additive model
(AM). There was a set of common variables in each of the models (age, SCr, sex, BSA, urea,
albumin, ALP, ALT) and also variables that were unique to one or two of the three models.
Dissimilar variable selection despite similar accuracy across the models could be interpreted in a
number of different ways. It could be that variables specific to each model are not contributing
significantly to model performance. Alternatively, given the inter-correlation between the
additional variables, one individual variable from a group of intercorrelated variables may
adequately explain the relationship with GFR. This later explanation is likely to be the case
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for the intercorrelated set of variables that are associated with RBC, RDW, heamoglobin and
haematocrit.
When comparing the models in the internal validation, the additive model was more accurate
than the other two models and all three models were more accurate than previous creatinine-
based models including the refitted CamGFR model developed in Chapter 4. In the external
validation, the lasso model was more accurate than the other two and, again, all three models
were more accurate than previous models, though the difference in accuracy between these
three models and the Lund-Malmo model was small. The external validation provided further
evidence that a model can be used to estimate GFR for a different centre from where it was
developed without providing highly biased estimates, even when there are known systematic
differences in the input variables.
If at this exploratory stage we were to suggest one of the three models to be used in order
to estimate unobserved data, the lasso model would be preferred. In addition to being less
complicated than the additive model, it is also likely to be the least over-fitted to the development
dataset, as evidenced in the external validation.
Our next step in this analysis would be to collect these additional haematological and biochemi-
cal measurements from several different cancer centres and use them to compare measurements
from different centres to assess their inter-centre variability. We would then seek to develop
a model using data from across these centres that could be further internally and externally
validated. Ideally, this model would be developed to be flexible enough not to need observations
for all variables to estimate GFR.
A second key finding in this exploratory study was to show that a model developed using these
additional variables can lead to interesting observations and hypotheses about the underlying
biology. The resulting relationship between markers of liver function and GFR indicates possi-
ble links between a patient’s liver function and kidney function. One could consider building
models for integrated organ function using very large datasets based on these observations,
however, this likely to be challenging in the case of other organs, which lack specific and
measurable quantification of their function.

Chapter 6
Biological and clinical contexts of GFR
estimation and measurements
In order to accurately estimate a patient’s GFR, there are additional clinical considerations to
be taken into account. In this chapter we discuss some of these in the context of the newly
developed, refitted CamGFR model. First, Section 6.1 takes into account the potential adverse
effects of chemotherapy on a patient’s GFR and serum creatinine, and the subsequent impact
on using models to estimate GFR for these patients. In Section 6.2 we examine the implication
of using a creatinine-based model for patients with creatinine that is not stable by assessing the
performance of the refitted CamGFR model using longitudinal data. Finally, in Section 6.3 we
compare the similarities and difference between patients with and without cancer, with specific
consideration of the impact of these scenarios on modelling GFR depending on the age of the
patient. These further exploratory and statistical studies will draw into question the accuracy
and validity of using refitted CamGFR to estimate GFR in particular clinical circumstances and
given the availability of clinical data. It will moreover provide an insight into the direction of
future work that will build upon the work in this thesis.
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6.1 Estimating GFR in patients under active oncological man-
agement
This section aims to assess the effect of receiving chemotherapy on a patient’s GFR and the
subsequent implications this may have on using models to estimate GFR for these patients.
To do so we would ideally like to have data that are annotated as to whether or not a patient
was receiving treatment at the time of their nuclear medicine GFR measurement (nmGFR).
We would then be able to compare these patients with those who received their nmGFR
measurement prior to treatment commencing and assess the effect treatment has on GFR or
creatinine. Unfortunately, these data were unavailable for patients within our datasets so,
instead, two surrogate methods were used to categorise patients according to whether they were
pre-chemotherapy, currently receiving chemotherapy or had received chemotherapy.
For the first surrogate method, patients who had multiple GFR measurements were compared.
For these patients we assumed that the patients who had repeat measurements within a short
period of time were likely to have had their second measurement whilst under active oncological
management, and those who had a repeat measurement after a long period of time were likely
to have had chemotherapy in the intervening time. For these patients, we assessed the change
in GFR, creatinine and the residual of refitted CamGFR for the repeat GFR measurements.
For the second surrogate method, we compared patients who had numerous creatinine mea-
surements in temporal proximity to their nmGFR with those who had fewer. Here, the main
assumption was that patients who had more creatinine measurements were more likely to be
unwell, more likely to be in-hospital patients, and more likely to be under active oncological
management. Between these two groups of patients the bias and accuracy were compared for
several models to estimate GFR, in particular the refitted CamGFR model which was developed
in Chapter 4.
6.1.1 Patients with multiple GFR measurements
When developing the refitted CamGFR model in Section 4.3, repeat GFR measurements that
were within a year of a patient’s previous measurement were excluded. This exclusion criterion
aimed to remove any nmGFR measurements that were measured while a patient was receiving
treatment and also aimed to reduce the statistical complexities caused by repeat nmGFR
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measurements not being independent. In this section, we further analyse data for patients who
have repeat nmGFR measurements and explore any issues arising from using creatinine-based
estimation models for patients who are receiving treatment.
In total, our dataset consisted of 696 patients with two or more nmGFR measurements. Patients
who did not have cancer or whose diagnosis was not known (n = 36) were excluded, leaving
661 patients for this analysis. These patients were from three centers: Cambridge (n = 537),
Gothenburg (n = 109) and Edinburgh (n = 15). Patients from Cambridge and Edinburgh
had up to five repeat nmGFR measurements, while the patients for Gothenburg had up to
18. Sarcoma was the most common cancer type for patients from Edinburgh (n = 15) and
Gothenburg (n = 41). These sarcoma patients, and patients from Gothenburg generally, had
short periods separating their repeat nmGFR, with the median time between a patient’s first and
second measurement being 83 and 93.5 days for Edinburgh and Gothenburg respectively. This
contrasts with Cambridge where patients with gynecological cancer (n = 205) were the most
common, and for whom the median time between first and second nmGFR was 602.5 days.
Overall, the median period between the first and second nmGFR measurement for patients
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Figure 6.1 Histogram of the period between the first and second nmGFR. Each bar is 25 days wide and
coloured by the centre. A dashed vertical line is displayed at 200 days. Patients with a period larger than
five years are excluded for display purposes (n = 13).
These differences likely reflect the two common reasons for a patient with cancer to have
repeated nmGFR measurements. The patient could have further measurements under active
oncological management to assess whether the dosage should be adjusted; thus, there are
short periods between nmGFR. Alternatively, the patient has one nmGFR at the beginning of
platinum-based chemotherapy, with repeat nmGFR performed if the patient has relapsed before
112 Biological and clinical contexts of GFR estimation and measurements
beginning another chemotherapy regimen. These two groups of patients can be distinguished
by examining the histogram of the period between the first and second nmGFR, Figure 6.1.
The histogram is bimodal with a trough around 200 days where no patients were observed with
a time period between 185 to 205 days. Henceforth, subsequent nmGFR with a period less than
200 from the first nmGFR will be referred to as short-period, and nmGFR with a period greater
than 200 days will be referred to as long-period.
We first examined the changes in GFR for repeat nmGFR. Between the first and second nmGFR
measurement, GFR significantly decreased by an average of 6.35 mL/min (median 5 mL/min).
This decrease can be seen when the change in GFR is plotted against the difference in time
between the first and all subsequent nmGFR, Figure 6.2 (A). In the figure, we observe the
change in GFR is small when the time between nmGFR is short, with an average decrease
of 0.526 mL/min for nmGFR within 50 days of the first nmGFR. However, the decrease is
significant for both the short-period and long-period nmGFR, with a mean reduction of 4.44
and 7.40 mL/min respectively.
The observed reduction in GFR is not matched by an increase in log(SCr), the main variable
likely to change in any creatinine-based model for GFR in the short term, Figure 6.2 (B). While
there is a significant increase in creatinine for the long-period nmGFR measurements (mean
increase 0.054), there was no significant increase in creatinine for the short-period nmGFR
(mean increase 0.002). The other variable that may fluctuate in this period of time is weight. In
the short time-period, no significant change in weight was observed (mean change −0.05 kg,
p-value 0.067), which is in contrast to the significant increase in weight seen in the long-period
(mean change 1.8 kg, p-value <0.0001).
Given that GFR decreased with a corresponding increase in log(SCr) and with only a slight
decrease in weight, it is likely that the bias of creatinine-based models will be affected. Given
that the data contain both IDMS-traceable and non-IDMS-traceable creatinine, only the refitted
CamGFR model was examined as this should be unbiased for both. When GFR is estimated
using the refitted CamGFR model there is a significant bias to underestimate GFR, particularly
for the short-period nmGFR, Figure 6.2 (C). The first nmGFR measurement for each patient
was unbiased with a median residual 0.427 mL/min (95% CI -0.547 to 1.26). The median
residual subsequently reduces to −4.33 mL/min (95% CI -6.54 to -1.62) for short-period
nmGFR, which is a significant bias to overestimate GFR; this bias is then reduced but and
insignificant for the long-period nmGFR with a median residual −1.45 mL/min (95% CI -2.92
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to 0.879). Consequently, the accuracy of the model is affected, with a RMSE of 15.4, 16.6 and
13.7, for the first nmGFR, short-period nmGFR, and long-period respectively.
Further examining Figure 6.2 (A), although overall GFR decreases in the short-term, for
a few patients a large increase in GFR is observed. There were five patients who had a
repeat measurement within two months and for whom their GFR increased by more than
40 mL/min in the second measurement. For these patients it is possible that they originally
had an obstruction to the renal system, caused by or in conjunction with the cancer diagnosis,
which was subsequently cleared before starting treatment. Alternatively, the clinician may have
requested a repeat measurement as they did not trust the accuracy of the original measurement.
For example, if a patient was dehydrated for the original measurement and thus it was necessary
to repeat the nmGFR measurement [121]. Examining the residuals of the refitted CamGFR for
these patients, they all have an estimated GFR which was at least 18 mL/min larger that the
measured GFR, which suggests that indeed the measured GFR was inaccurate for the original
measurement.
This observed reduction in GFR without an increase in creatinine is particularly apparent for
the patients from Edinburgh. All these patients were diagnosed with a sarcoma, in particular
either osteosarcoma, Ewing’s sarcoma or desmoplastic small-round-cell tumor, and were aged
under 50 (median 28 years). Figure 6.3 shows the measured and estimated GFR for the eight
patients from Edinburgh who had at least three nmGFR measurements. Along with displaying
the refitted CamGFR, the CKD-EPI model is also provided as this has been shown to be the
most accurate and is unbiased for non-IDMS-traceable creatinine data (Figure 4.14). For seven
of these eight patients, the nmGFR decreased at least once without a matching decrease in the
estimated GFR. For the one other patient (patient ID: Edinburgh 341), their nmGFR increased
in the two subsequent measurements with the estimated GFR increasing and then slightly
decreasing.
In summary, it appears that patients who have repeated nmGFR measurements within a short
period of time have a decreased GFR without a matching increase in creatinine. This leads
to overestimation of GFR using creatinine-based models. The most likely explanation for
repeat nmGFR measurements in a relatively short period of time is for the first measurement
having been performed before starting treatment and for subsequent measurements performed
whilst under active oncological management. Other possibilities for repeat nmGFR, such as
obstruction to the renal system, are possible but would result in an increase to GFR. Patients



































































Figure 6.2 The difference in GFR (A), the difference in log(SCr) (B), or the residual of the refitted
CamGFR model (C) is plotted against the time difference between the first and subsequent nuclear
medicine GFR measurements for patients with at least two measurements within three years. Points
are coloured by the number of previous measurements for the given patient. All data smoothing lines
are loess curves. Repeat measurements with a gap of more than three years are excluded. A boxplot is
displayed for the refitted CamGFR model residual for the first nmGFR for each patient (C).
with a repeat nmGFR measurement over a longer period of time also have a decreased GFR,
however, these patients also have a matching increased creatinine.
These findings are corroborated by a previous study examining the post-chemotherapy effect
on patient GFR and serum creatinine. Lauritsen et al. studied 390 germ cell patients who were
treated at a Department of Oncology, Rigshospitalet, Copenhagen, Denmark between 1984
and 2007 [73]. They compared a patient’s measured GFR, serum creatinine and estimated
GFR before, after 1 year, after 3 years and after 5 years of receiving chemotherapy (bleomycin,
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Figure 6.3 Measured GFR and estimated GFR, using either the refitted CamGFR model or CKD-EPI
model, for eight patients diagnosed with a sarcoma from Edinburgh. Patients were included if they had
at least three nuclear medicine GFR measurements (nmGFR). Time difference is the time between a
patient’s first nmGFR and subsequent nmGFR. Patients are named via an anonymous patient ID.
etoposide and cisplatin). In this publication, both measured GFR and creatinine were observed
to significantly decrease compared with pre-chemotherapy levels. This led to the examined
models for GFR (CKD-EPI, Wright, MDRD, Cockroft-Gault) generally becoming more biased
to overestimate measured GFR, the exception being MDRD which was biased to underestimate
GFR prior to chemotherapy. Furthermore, GFR that was measured one, three or five years after
receiving chemotherapy were observed to have recovered, although not to the pre-chemotherapy
level.
One weakness of the Lauritsen study is that it presents the change in GFR and creatinine on a
group level and not at an individual level. This is further compounded by the fact that not all
patients who had an initial GFR measurement before treatment began, had subsequent follow
up measurements. This means that a confounding effect cannot be ruled out. For example, the
observed decrease in GFR could be explained if there were patients who had measurements
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taken before treatment but did not have a subsequent measurement, where their original GFR
measurement was high compared with the group overall.
6.1.2 Patients with multiple creatinine measurements
As mentioned in the introduction of this chapter, the second method used to categorise patients
was by the number of creatinine measurements in temporal proximity to their nmGFR. For a
subset of patients from Cambridge, in addition to having the serum creatinine measurement that
was taken closest to the nmGFR measurement, all serum creatinine measurements performed
in the temporal vicinity of their nmGFR measurement were also obtained. Typically, the
serum creatinine measurements were within 30 days either side of the nmGFR measurement.
Using these data we aimed to further corroborate some of the findings in the previous section.
Specifically, we assumed that if a given patient had numerous creatinine measurements prior to
their nmGFR measurement this meant the patient was likely to be an in-hospital patient or a
patient currently receiving chemotherapy treatment. Thus we were examining more than the
effect of chemotherapy, and were looking more generally at the effect of unwellness on model
performance. To assess the performance of creatinine-based models, patients were grouped by
the number of creatinine measurements in the two weeks prior to their nmGFR, the accuracy
and bias of GFR estimated using either Lund-Malmo, refitted CamGFR or lasso (developed in
Chapter 5) was then compared for these groups.
For this comparison we used the same patients that were used to develop and validate the lasso
model. These were chosen to allow the lasso model to be compared with refitted CamGFR
and Lund-Malmo. The Lund-Malmo model was chosen as it was the most accurate for IDMS-
traceable creatinine data (Figure 4.14), which all these patients had apart from for refitted
CamGFR. Again, as in Section 6.1.1, non-cancer or patients with unknown diagnosis were
excluded (n = 119). The remaining 1,391 patients were split into three groups based on how
many creatinine measurements they had in the two weeks before their nmGFR (nSCr). The
groups were as follows: patients who had nSCr between 0 and 3 (n = 1,213), 4 and 7 (n = 111),
and 8 and 22 (n = 67). These cutoff values were chosen to discriminate between patients who
were likely to be out-patients and not currently receiving treatment, out-patients who were
receiving treatment, and in-patients. These groupings were not expected to be entirely accurate
but to provide a gauge as to where there was an effect on the accuracy of the creatinine-based
models. Indeed, when we examined the composition of the two groups with nSCr equal to four
6.1 Estimating GFR in patients under active oncological management 117
or more, we saw that these groups were enriched for patients with a haematological cancer.
In the three groups 452 (37%), 80 (72%) and 52 (78%) patients had a haematological cancer
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Figure 6.4 Boxplot and scatter plot of residuals for the Lund-Malmo, refitted CamGFR and lasso models
against the number of creatinine measurements in the two weeks prior to the nmGFR measurement
(nSCr). (A) Boxplot of each model for patients groups by whether nSCr was between 1 and 3 (n = 1,320),
or 4 and 7 (n = 117), or 8 and 22 (n = 73). Notches are drawn at ±1.58IQR/
√
n, and provide an
indication of whether the medians differ. (B) Model residual against nSCr. The line drawn was calculated
using linear regression. The gradient of the line is significantly below zero for the Lund-Malmo, refitted
CamGFR models, (p-value <0.0001 for both), but not for lasso model (p-value 0.095)
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nSCr n RMSE median residual IQR P20
Lund-Malmo
0-3 1213 14.73 (14.01, 15.45) -3.09 (-4.00, -2.21) 17.28 (16.16, 18.38) 0.261 (0.236, 0.286)
4-7 111 18.38 (15.72, 21.15) -8.31 (-11.58, -4.80) 17.86 (13.63, 22.10) 0.324 (0.237, 0.410)
8-21 67 26.34 (21.41, 31.32) -12.24 (-17.07, -6.26) 26.91 (17.07, 35.29) 0.448 (0.329, 0.564)
refitted CamGFR
0-3 1213 13.73 (13.03, 14.43) 0.20 (-0.68, 1.01) 15.97 (14.65, 17.35) 0.202 (0.179, 0.224)
4-7 111 16.54 (13.95, 19.25) -5.27 (-10.41, -1.69) 19.40 (16.16, 23.28) 0.342 (0.255, 0.428)
8-21 67 18.11 (15.99, 20.33) -7.34 (-11.54, -3.59) 24.08 (15.93, 32.35) 0.388 (0.275, 0.503)
Lasso model
0-3 1213 13.32 (12.66, 14.00) 0.28 (-0.73, 1.12) 15.72 (14.54, 16.75) 0.186 (0.164, 0.208)
4-7 111 15.62 (13.05, 18.33) -0.45 (-3.24, 2.58) 18.98 (15.68, 22.34) 0.225 (0.151, 0.301)
8-21 67 18.82 (15.85, 21.92) -1.91 (-6.52, 3.42) 23.33 (15.47, 31.61) 0.388 (0.275, 0.502)
Table 6.1 Comparison of GFR estimated using either the refitted CamGFR, lasso or Lund-Malmo for
patients split by the number of creatinine measurements in the two weeks prior to their nmGFR (nSCr).
The root-mean-squared error (RMSE), median residual and residual interquartile range (IQR) are given
along with 95% confidence intervals.
Figure 6.4 shows the trend of the residuals for each patient group for the Lund-Malmo model,
refitted CamGFR model, and lasso model as nScr increases. From this figure we observe the
median residual reduces as nScr increases for all three models. If a linear regression is fitted for
the residual against nSCr the fitted slope of this regression is significant below zero for the Lund-
Malmo, refitted CamGFR models, (p-value <0.0001 for both), but not for lasso model (p-value
0.095). When comparing the residuals between the three defined groups we observe that the
refitted CamGFR is unbiased for patients who have nScr between 0 and 3 but has a significant
bias to overestimate GFR for nScr more than 3, with a residual median of −8.41 mm/min for
nScr between 8 and 22. The Lund-Malmo model is biased to overestimate GFR in all three
groups. Finally, the lasso model was the only model to not have a significant slope for the model
residuals as nScr increased. In addition, the residual median was not significantly different from
zero for any of the three groups for the lasso model.
The observed increase in bias for each model as nSCr increased was accompanied by a decrease
in model precision and accuracy, as displayed in Table 6.1. The RMSE, the residual IQR and
proportion of patients with an absolute error of more than 20% (P20) all increase as the nSCr
increase for all models. In particular, P20 was almost double for the patients with nSCr between
8 and 22 compared with nSCr between 0 and 3. These differences between the groups for all
statistics were significant, as evidenced by the non-overlapping confidence intervals.
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Overall, as with Section 6.1.1, there is a link between patients who are more likely to be unwell
and overestimation of creatinine-based models for GFR. This overestimation is both significant
and is associated with less accurate GFR estimations using any of the tested models. Of the
three models tested, the lasso model was least biased for patients who had a high nSCr. This
is an indication that a model which includes other blood test measurements may negate the
overestimation of serum creatinine only models.
There are several limitations that need to be considered when discussing these results. First, our
assumption that patients who had a higher nSCr were more unwell is not completely specific.
There may be several other reasons why a patient would received numerous serum creatinine
measurements. One such example is the potential inter-departmental bias for the number of
serum creatinine blood tests performed, where some departments perform more blood tests
than others. This effect is observed in the data with the high proportion of haematological
patients in the group with the highest nSCr.
6.1.3 Discussion
In Section 6.1.1 we showed that patients who are assumed to be under active oncological
management, in particular whilst receiving or having received platinum-based chemotherapy,
have their GFR underestimated when using a creatinine-based model. This underestimate is the
result of a reduction in GFR, likely caused by the treatment, without a corresponding increase
in serum creatinine. An implication of this is that any model that uses creatinine as its only
filtration marker will not pick up loss of renal function. After a long time period has elapsed
since the start of treatment, GFR remains stable and serum creatinine increases, models to
estimate GFR, in particular refitted CamGFR, are then no longer biased to overestimate GFR.
This finding is particularly relevant to clinical medicine where estimated GFR is used in order
to adjust the dose of carboplatin whilst a patient is undergoing treatment: a large overestimate
of GFR could lead to patient harm in the form of increased and preventable toxicity [65].
As previously discussed, it would appear that serum creatinine remains stable independent
of changes to GFR both during and after chemotherapy treatment. There are a few possible
reasons for this. The value of serum creatinine is known to be dependent upon factors such as
muscle mass, physical activity and, to a lesser extent, it is also dependent upon dietary intake
of protein and other nutrients. Many chemotherapy drugs are thought to cause sarcopenia
[104, 109], which a decrease in serum creatinine is a marker for [96]. Indeed, we observe a
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small decrease in weight between subsequent measurements of GFR within our dataset. The
other influencing factors might too cause a reduction in serum creatinine, and so any increase
that would correspond with reduced GFR could be negated.
Findings from Section 6.1.2 compliment the above, though in this second section patients were
categorised slightly differently dependent on the number of serum creatinine measurements in
the two weeks prior to the nmGFR measurement (nSCr). Thus patients were not necessarily
receiving, or had just received, chemotherapy treatment but were likely to be unwell with
something that was related to their cancer diagnosis. Similar to the previous section, patients
who had a high nSCr, and thus were assumed to be unwell, were overestimated by the three
creatinine-based models assessed. It is likely that, as we observed in Section 6.1.1, these
patients had a reduced GFR without a corresponding increase in serum creatinine, thus leading
to the overestimation.
The model that shows the least amount of overestimation, and thus is most suitable for these
unwell patients, was the lasso model developed in Chapter 5. This is particularly interesting as
it was the only model to include other biological and haematological measurements in addition
to serum creatinine. Thus the inclusion of these other measurements may have negated the lack
of change in serum creatinine observed in Section 6.1.1.
Overall, this work shows that GFR estimated using a creatinine-based equation should not be
recommended for a patient who is under active oncological management, in particular platinum-
based chemotherapy. Models which include additional biological or haematological variables
may produce unbiased estimated values for these patients. However, more analysis is needed to
prove or disprove this claim. Ideally, nuclear tracer measured GFR should be performed if an
accurate measurement of GFR is required. When this is not possible, caution should be taken
when interpreting any estimated GFR values for patients after receiving chemotherapy as any
true loss of renal function may not be observed in estimated GFR.
6.2 Examining unstable creatinine using longitudinal data
In this section, preliminary analysis carried out for patients with longitudinal creatinine data
is discussed. The patients examined here were previously used in Section 6.1.2, where the
total number of measurements rather than the value of the measurements were considered.
Here, we examine in more detail the value of these repeat creatinine measurements and
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their impact on estimating GFR. The majority of the work that is outlined in this section is
exploratory and to be developed in the future, where ultimately we aim to assess whether
multiple creatinine measurements provide further information about a patient’s GFR compared
with single measurements.
In this exploratory analysis the performance of the refitted CamGFR model using longitudinal
data is assessed. This is carried out, first by categorising patients as to whether they have
increasing, decreasing or stable creatinine at the time of their nmGFR measurement. The
performance of the refitted CamGFR model between these categorisations is then assessed. The
model is then further assessed, using different input creatinine values based upon the timing of
their measurement compared with the timing of the nmGFR measurement, for the different
categorisations. These values are also compared against a previously published model, which
adjusts creatinine based upon two subsequent creatinine measurements. Finally, possible future
analyses using both these findings and our data is discussed.
6.2.1 Previous publications examining GFR when creatinine is unstable
Despite the availability of longitudinal creatinine data, estimating GFR using longitudinal
data does not appear to have been extensively researched. Indeed, we only identified a
few publications which explored the issues of estimating GFR when a patient’s creatinine
is changing between two subsequent measurements. In this section we examine two such
publications, the first by Jelliffe et al. [64] who developed a model to estimate GFR using two
creatinine measurements, the second by Chen [17] who suggested an adjustment based on two
subsequent creatinine measurements for any creatinine-based equation. These papers were
published in 1972 and 2013, respectively.
In addition to producing a model for creatinine clearance when a patient’s creatinine is stable
[62, 63], which was discussed in Section 2.4.3. Jelliffe et al. also produced a model that can
be applied when a patient’s creatinine is unstable [64]. This model requires two consecutive
creatinine measurements, and uses the average and difference of these measurements along
with the patient’s sex, age and weight in a model for creatinine clearance. As is the case for
the Jelliffe model for stable creatinine (see Section 2.4.3), this model is likely to be out of date
given changes to the clinical methodology for measuring serum creatinine.
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More recently, Chen [17] derived a theoretical equation, referred to as Kinetic eGFR (KeGFR),
that adjusts the estimated GFR or creatinine clearance value based upon two subsequent creati-
nine measurements and steady state creatinine. This derivation was based on the relationship
between the serum concentration of creatinine and its clearance rate in a dynamic system.
Rather than directly estimating GFR, the equation provides an adjustment for an estimated GFR
value produced by another model. Although this publication was well received with a number
of citations in the literature, little validation could be found. The exception being Pianta et al.
[99] and Dewitte et al. [31] which showed its advantage in predicting delayed graft function
after kidney transplantation and predicting recovery from acute kidney injury respectively. The










• SSCr is the serum creatinine steady state value
• eGFR is the estimated GFR from a creatinine-based model
• SCrmean is the mean of the two creatinine values
• ∆SCr is the change in the creatinine values
• ∆T is the time difference in days between the creatinine measurements
• Max∆SCr is the theoretical maximum change in serum creatinine possible for the patients,
which is typically set to be 1.5 mg/dL.
6.2.2 Exploratory analysis
For the purpose of this exploratory analysis, patients were examined who had at least one
creatinine measurement in the 14 days leading up to, and after, their nmGFR measurement.
Within our data, there were a total of 1,805 patients and 2,041 nmGFR measurements that
met this criterion. First, patients were categorised as to whether their closest creatinine value
before nmGFR was increasing, decreasing or not changing. For a patient to be categorised
as having increasing creatinine we required their creatinine to increase by an average of 5%
per day between the two closest measurements either side of their nmGFR (this is the same
as log(SCr) increasing by log(1.05) = 0.049), and that the difference in the median value of
up to three measurements either side of their nmGFR was increasing by at least 5%. For a
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‘decreasing’ categorization, the same criteria were applied with obvious changes. Of the 2,041
nmGFR measurements in our data, 37 measurements were classified as increasing, 65 were
classified as decreasing, and the remaining data were classified as not changing or stable.
Accuracy and bias of the refitted CamGFR model between increasing, decreasing and not
changing creatinine was then examined. Table 6.2 provides the values of the four statistics
used to compare models along with the median eGFR value and the number of patients in each
category. The estimated GFR value for patients who were increasing was lower on average
compared with patients with stable creatinine with the opposite true for patients with decreasing
creatinine. We found that patients who had increasing creatinine were biased to have their
GFR overestimated, with a median residual of -7.96 (95% CI -15.5 to -0.06). Patients with
decreasing creatinine showed no significant bias. Overall, accuracy was far worse for both
increasing and decreasing creatinine compared with not changing creatinine, with the RMSE
(20.42 and 20.96 compared with 15.16 mL/min) and P20 (0.459 and 0.4 compared with 0.255)
significantly higher. This initial finding implies that additional caution should be taken when
estimating GFR for a patient with increasing or decreasing creatinine. In the long-term one
may consider incorporating the additional uncertainty of the estimated value into the model.
This comparison of the categorised creatinine values was then extended. For each categorisation,
we compared the input of different creatinine values into refitted CamGFR depending on the
timing of the creatinine measurement in relation to the nmGFR measurement. Overall, the input
of three different creatinine values were compared: the closest measurement preceding nmGFR
(CamGFR before), the closest measurement following (CamGFR after), and the measurement
that was overall closest to (CamGFR closest). Where CamGFR closest is what we have used
so far in this thesis. We also compared using these three inputs for refitted CamGFR to the
KeGFR adjusted value, which adjusts for changing creatinine. For KeGFR, we used the median
of measurements in the 60 day window around nmGFR (30 days before and 30 after) as the
value for steady state creatinine. The statistics for each of these are provided in Table 6.1 and
boxplots of the residuals are provided in Figure 6.5.
For patients who were categorised with stable creatinine, no difference was seen in the accuracy
or bias between CamGFR before, CamGFR after and CamGFR closest. However, for patients
with increasing creatinine the estimated values were lower for CamGFR after and higher for
CamGFR before, which resulted in underestimate and overestimate of GFR respectively. The
opposite was true for decreasing creatinine (Figure 6.5). These results were unsurprising, given
that, by definition, patients with increasing creatinine must have a lower value of creatinine
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equation n median eGFR RMSE median residual IQR P20
Decreasing
CamGFR after 65 89.18 20.73 (17.19, 24.46) -8.77 (-14.21, -4.08) 20.98 (12.45, 27.96) 0.462 (0.341, 0.583)
CamGFR closest 65 83.00 20.96 (17.40, 24.80) 1.07 (-2.71, 6.44) 23.75 (15.47, 31.32) 0.400 (0.282, 0.519)
CamGFR before 65 77.33 21.44 (18.01, 25.09) 4.47 (-0.95, 8.95) 22.48 (13.09, 29.84) 0.400 (0.280, 0.522)
CamGFR KeGFR 65 80.95 27.41 (22.77, 32.20) 0.70 (-5.02, 5.60) 31.58 (20.75, 43.60) 0.492 (0.369, 0.615)
Increasing
CamGFR closest 37 76.08 20.42 (14.96, 26.49) -7.96 (-15.46, -0.06) 22.02 (15.76, 31.68) 0.459 (0.301, 0.621)
CamGFR after 37 62.85 22.40 (16.47, 29.01) 6.11 (0.12, 14.86) 17.88 (-1.63, 29.87) 0.405 (0.252, 0.560)
CamGFR KeGFR 37 64.93 23.57 (17.33, 30.58) 4.12 (-5.67, 12.25) 28.23 (19.74, 40.65) 0.514 (0.359, 0.669)
CamGFR before 37 88.50 24.53 (18.93, 30.56) -14.43 (-18.09, -10.67) 15.83 (4.68, 25.07) 0.541 (0.385, 0.699)
Not changing
CamGFR after 1939 81.10 15.11 (14.48, 15.75) -0.96 (-1.75, -0.24) 18.13 (17.04, 19.14) 0.259 (0.239, 0.278)
CamGFR closest 1939 80.76 15.16 (14.53, 15.81) -0.66 (-1.49, 0.10) 17.78 (16.80, 18.87) 0.255 (0.236, 0.275)
CamGFR before 1939 80.96 15.29 (14.60, 15.99) -0.14 (-0.82, 0.67) 17.56 (16.53, 18.57) 0.258 (0.239, 0.277)
CamGFR KeGFR 1939 78.70 18.00 (17.15, 18.87) 0.46 (-0.29, 1.32) 19.83 (18.83, 21.15) 0.317 (0.297, 0.338)
Table 6.2 Comparison of refitted CamGFR for three different creatinine values: closest measurement
preceding (CamGFR before), the closest measurement following (CamGFR after), and the measurement
that was overall closest to (CamGFR closest) the patient’s nmGFR, along with the KeGFR adjusted
estimated value (CamGFR KeGFR). Patients were compared in three separate groups, those with
increasing, decreasing or stable creatinine. Details on the number of patients in each group (n), the
median estimated GFR value (median eGFR), the root-mean-squared error (RMSE), the median residual,
the residual interquartile range (IQR) and the proportion of samples with an absolute error greater than
20% (P20) are provided. 95% confidence intervals are provided in parentheses.
before the nmGFR compared with after. Further comparing the KeGFR adjusted CamGFR
with the three different input values we found that although the estimated GFR is unbiased,
accuracy of the estimation is decreased for the all three categorisations. The RMSE increases
from 15.16, 20.42 and 20.96 to 18.00, 23.47 and 27.41 for stable, increasing and decreasing
creatinine respectively.
Overall, this analysis has shown that when patients have increasing or decreasing creatinine the
accuracy of the refitted CamGFR model is impaired. One may consider introducing additional
uncertainty of the estimated value but otherwise care should be taken. We have also seen
that using a KeGFR adjustment does lead to less biased estimated values for GFR, however
this is at the expense of reduced accuracy, particularly for patients who do not have changing
creatinine. This analysis has been performed using the refitted CamGFR model. This was
chosen as it is unbiased for IDMS-traceable and non-IDMS-traceable creatinine, which were
both present in this dataset. However, similar results were seen for other models which were
overall unbiased in either IDMS-traceable or non-IDMS-traceable creatinine, in particular,
CKD-EPI for non-IMDS creatinine and Lund-Malmo for IDMS-traceable creatinine.
Of course there are a number of considerations that we should take into account when evaluating
these results. One of these considerations is to question the accuracy of the methodology used



















Figure 6.5 Boxplot of residuals for refitted CamGFR and the KeGFR adjusted CamGFR. Patients are
grouped by whether there creatinine was categorised as increasing, decreasing or not changing at the time
of the nmGFR measurements. Four different options are displayed for which input to use in the refitted
CamGFR: the temporally closest measurements to the nmGFR, the temporally closest measurement
which is prior to the nmGFR, the temporally closest measurement which is subsequent to the nmGFR,
and the KeGFR adjusted to refitted CamGFR.
to categorise patients as having increasing, decreasing or stable creatinine. We reviewed the
plots for individual patients who were categorised as having increasing GFR, Figure 6.6. In
these plots some clear evidence of increasing creatinine is observed, whereby the plots exhibit
several low values for creatinine which then steadily increase during the time period when
the nmGFR was measured. Examples of such plots are seen for patients 1, 2, 6, 8 and 13.
Conversely, for some plots the categorisation of increasing creatinine is less clear-cut. One
example of this is observed in the plot for patient 34, where the creatinine values vary during
the time-period without a consistent trend. Further examples where the trend for creatinine
is less clear-cut can be seen in plots for patients 29, 30, 32 and 35. Additionally, comparing
the residuals of the patients who show a clearer increase in creatinine to those who do not, we
see that those with a clearer increase tend to be overestimated (large negative residuals). Thus
the overestimate of refitted CamGFR when a patient has increasing creatinine may be more
significant if patients were more accurately categorised.
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The plot, and associated results, for patient 37 also raise an interesting consideration. The
patient’s creatinine increases from a value of 0.5 mg/dL, eight days before their nmGFR,
to 2 mg/dL, 8 days after. The creatinine value after nmGFR was measured in closest time
proximity, where the value of this patient’s nmGFR was 90 mL/dL. The residual shown
in the plot corresponds to using the creatinine value after nmGFR, which estimated GFR
to be 26 mL/dL. This is in contrast to the result observed when using the creatinine value
measure prior to nmGFR with refitted CamGFR, which produced an estimated value for GFR
of 93.2 mL/dL. What is likely to have occurred is that the patient’s GFR decreased (for reason
such as an acute kidney injury) in the eight days after their nmGFR, causing their creatinine to
increase. Unfortunately our data does not have creatinine measurements for these eight days
that would confirm this hypothesis.
Another consideration is the method used to calculate the steady state of each patient’s serum
creatinine. As described above, for this calculation the median creatinine value measured in
the 30 days before and after nmGFR was used. However, this may be an inaccurate estimation
for many of the patients. Again examining the plots in Figure 6.6, the line for the median
value can be some distance from where the steady state for some individual patients would
be observed. Patient 6, for example, appears to have a steady state creatinine value near their
minimum observed value, however the median value line is positioned for a higher value than
this. Moreover, for some other patients who have few serum creatinine measurements, there is
not enough data to be able to estimate what their steady state creatinine value would be and so
again the median value could be some distance for their steady state creatinine.
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Patient 25: Resid = 0.2 Patient 26: Resid = 1.9 Patient 27: Resid = 4.3 Patient 28: Resid = 6.8
Patient 21: Resid = −6.2 Patient 22: Resid = −3.8 Patient 23: Resid = −1.4 Patient 24: Resid = −1.2
Patient 17: Resid = −11.6 Patient 18: Resid = −11 Patient 19: Resid = −8 Patient 20: Resid = −7.1
Patient 13: Resid = −13.4 Patient 14: Resid = −13 Patient 15: Resid = −12.3 Patient 16: Resid = −12.2
Patient 9: Resid = −16.2 Patient 10: Resid = −15.2 Patient 11: Resid = −14.4 Patient 12: Resid = −14.3
Patient 5: Resid = −19.6 Patient 6: Resid = −18.6 Patient 7: Resid = −16.9 Patient 8: Resid = −16.8
Patient 1: Resid = −39.6 Patient 2: Resid = −35.7 Patient 3: Resid = −26.4 Patient 4: Resid = −20.5






























































































































Figure 6.6 Serum creatinine time series of individuals who were categorised as having increasing serum
creatinine at the time of their nmGFR measurement. All creatinine values measured within 14 days
either side of the nmGFR are included. Patients are ordered by the residual form the refitted CamGFR
model (displayed above each time series) when using the closest creatinine measurement to the nmGFR.
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Patient 37: Resid = 64
Patient 33: Resid = 15 Patient 34: Resid = 30.9 Patient 35: Resid = 32.3 Patient 36: Resid = 38.6
Patient 29: Resid = 6.9 Patient 30: Resid = 7.5 Patient 31: Resid = 9.9 Patient 32: Resid = 10.4
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Figure 6.6 Serum creatinine time series of individuals who were categorised as having increasing serum
creatinine at the time of their nmGFR measurement. All creatinine values measured within 14 days
either side of the nmGFR are included. Patients are ordered by the residual form the refitted CamGFR
model (displayed above each time series) when using the closest creatinine measurement to the nmGFR.
6.2.3 Direction of future work
This section has introduced exploratory analysis of longitudinal creatinine data, which we
intend to develop in the future to examine whether multiple creatinine measurements provide
further information about a patient’s GFR compared with single measurements. One way in
which this may be done is to explore the incorporation of several creatinine values directly in
the refitted CamGFR model to better estimate GFR and the variability of this estimated value.
If a patient’s creatinine is stable but fluctuating then additional measurements of creatinine
may be used to model the variably of the measurement which could then be translated to the
variability in the estimated GFR. We may then also explore the incorporation of these additional
creatinine values alongside the additional biochemical and haematological blood tests that
were investigated in Chapter 5, as this may further improve the accuracy and bias of the model.
This work may also by further extended through examining its application to liver function
where we would model the relationship between the kidney and the liver using longitudinal
measurements that are associated with both kidney and liver function. To carry this out, we
would ideally like patient data that are regularly and routinely collected with multiple nmGFR
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measurements. This would provide some mitigation of the considerations we have raised in
this section. However, data collation of this nature is not often the case in clinical medicine and
so this would need to be taken into account in any future work.
6.3 Comparison of measured GFR between patients with
and without cancer
A final question that has arisen through the work in the thesis is addressed in this section: do
patients with cancer have normal GFR for their age compared with patients who are healthy?
In Section 4.1, we alluded to the fact that the average GFR values in our dataset are higher than
in other datasets used to develop previous models. This was often the case as other datasets
were enriched with chronic kidney disease patients who would typically have values for GFR
that are lower than would be expected for healthy patients of their age. It is therefore unclear
from these data whether patients with cancer have the same normal GFR as healthy patients of
the same age. It is challenging to acquire the data necessary to examine this question because
healthy patients do not usually have their nmGFR measured unless they are candidates to
donate a kidney. In our dataset, we had a small subset of such patients (n = 188), though to
compare these patients with patients with cancer (n = 7,849) we needed more data. Efforts
were therefore made to supplement this data consisting of seemingly healthy patients who are
candidates for kidney transplant surgery. The relationship between GFR and age for patients
with and without cancer was then compared to examine whether patients with cancer have
normal GFR for their age. This was particularly important to assess when considering use of
the refitted CamGFR model to estimate GFR for patients who are healthy.
The supplementary data were acquired from Fenton et al. [38] whose publication focused
on assessing the current GFR threshold values for kidney donations. Multiple attempts were
made to contact the author and acquire data directly, however this proved unsuccessful. The
relevant data (GFR and age) from Figure 1 in the publication was therefore manually extracted.
This led us to acquire additional data from 3,105 prospective liver kidney donors. There were
actually data from 2,974 patients in Fenton et al. however the resolution of Figure 1 led to
some duplication when the plot was extracted. The resulting final dataset consisted of 7,849
and 3,293 patients with and without cancer respectively.
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Using these additional data, the relationship between GFR and age for patients with and without
cancer was compared. Both of these patient types showed a relatively flat relationship between
GFR and age for the age range of 18 to 40 years, with a steady decline in GFR after the age of
40. Using the segmented R package a piecewise linear model was fitted for all of the data to
estimate where the break point was. The estimated break point was calculated as 40.1 years.
With this break point separate piecewise linear models were then fitted for the patients with and
without cancer, which allowed for an estimation of the difference in slope between these two



















Figure 6.7 GFR against age for patients with and without cancer. The majority of the non-cancer
patients were extracted from [38, Figure 1]. The fitted curves are piecewise linear with a break point at
40.5 years.
The difference in the slope of the relationship before the break point was estimated to be
0.048 (cancer: -0.326; non-cancer: -0.278; p-value: 0.056), whereas the difference after the
break point was 0.253 (cancer: -1.014; non-cancer: -0.761; p-value: <0.0001). The plot
of GFR against age for patients with and without cancer, along with these fitted piecewise
linear relationships are shown in Figure 6.7. It appears that for patients under the age of 40,
there is little difference in GFR between patients with and without cancer, whilst after the
age of 40 the difference in GFR increases with age. For patients aged over 70 the mean GFR
was 60.8 mL/min/1.73m2 for patients with cancer compared with 70.0 mL/min/1.73m2 for
patients without cancer (t.test p-value < 0.0001).
For the majority of the age spectrum the differences in GFR between patients with cancer and
healthy patients are minor, however, as age progresses the disparity between measured GFR is
increasingly noticeable. Another way to interpret this finding is that patients with cancer, even
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early in their diagnosis as the majority of the patients in our dataset are, have a kidney function
that corresponds to an older person who does not have cancer. An associative study like this
does not allow us to distinguish as to whether ageing and cancer cause loss of renal function
by the same or different mechanisms, or even the direction of causality. For example, patients
with impaired renal function may be more likely to develop cancer or there may be a latent
variable which predisposes both an increased likelihood of developing cancer and a decline in
renal function. Another possibility is that the observed difference is driven by the small number
of patients who may have already received chemotherapy prior to their nmGFR, which was
observed in Section 6.1, to be associated with declined renal function. Treatment-annotated
data needs to be obtained to rule out this possibility. On the basis of these results we conclude
that there is good evidence for the applicability of refitted CamGFR for patients up to the age




Many aspects of the management of patients with cancer are informed by knowledge of GFR.
The purpose of this thesis was to review previously published models for estimating GFR
and, more importantly, to develop a new regression-based model to best estimate GFR for
patients with cancer. Our work was then further developed, first by considering the inclusion
of additional biochemical and haematological data in a regression-based model for GFR, and
second by critically assessing a model against clinical considerations that should be taken into
account for any estimation of a patient’s GFR. We had a clear rationale for both reviewing
and building upon existing models. Most notably, we identified limited large-scale studies of
existing models and their applicability to patients with cancer. In addition, we identified the
need to consider the increasing availability and volume of routinely measured patient data,
alongside changing methods to measure clinical variables.
We initially developed a model using data from a single centre to estimate GFR for patients with
cancer, the CamGFR model. CamGFR models GFR against a patient’s blood serum creatinine
concentration as well as other demographic data. We showed, both in an internal and in a small
scale external validation, that this model is more accurate than previously published models.
Publication of this initial model enabled us to collate additional datasets from different cancer
centres in order to further develop CamGFR.
Using this large multicentre dataset, we compared different methods to measure serum creati-
nine in order to evaluate whether different methods required adjustments to CamGFR. Overall,
we found a significant difference in serum creatinine values dependent on whether they were
IDMS-traceable or not. Given this result, and the fact that the initial CamGFR model was
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developed in a single centre using only non-IDMS-traceable creatinine, we then sought to rede-
velop the model to be less centre dependant and suitable for both methodologies. The refitted
CamGFR model expanded the initial model by including an interaction term indicating the
creatinine method. The refitted CamGFR model was shown to be more accurate than previously
published models for both IDMS-traceable and non-IDMS-traceable creatinine. Previously
published models were observed to be biased in estimating GFR for one of the two methods. In
particular, the CKD-EPI model (which was developed using IDMS-traceable creatinine) was
highly biased for IDMS-traceable creatinine and unbiased for non-IDMS-traceable creatinine.
We have worked to make this model accessible and usable in day-to-day clinical practice by
developing an online application that enables users to input patient data and receive not only an
estimate of the patient’s GFR but also the user defined confidence interval for this prediction.
Of course, the refitted CamGFR model was not without limitations, which were mainly
concerned with the population demographics and data availability. Serum creatinine was used
as the filtration marker in CamGFR, however, some recent literature has been focused on the
use of cystatin C in conjunction with, or instead of, serum creatinine. Cystatin C was not
measured in any of the cancer centres when the data were collected, and so was not available
for the purpose of this thesis. Our work was also limited by a lack of full annotation with
regards to treatment history and also by a lack of ethnic diversity, as data were predominately
from white Caucasian patients. Future publications may encourage further collaborations and
data sharing so that we may address these limitations and further validate or adjust the model.
We continued our analysis of GFR in patients with cancer by examining whether including
other routine biochemical and hematological variables in the model would further improve
the estimation of GFR. In doing so we found that some variables were consistently observed
to be predictive of GFR, in particular urea, albumin, ALP and ALT. In addition, variables
associated with red blood cells were also predictive of GFR. Including these variables improved
estimations of GFR compared with creatinine only models in both an internal and small
external validation. These fitted relationships further provided interesting observations about
the underlying biology and the correlation between different organ systems, in particular the
liver and kidney. The main limitation for this exploratory study was, once again, that it relied
upon data from a single cancer centre (Cambridge) along with a small number of patients
from a secondary centre. This limitation is particularly important to take into account as we
suspected that many of these routine measurements were likely to have centre dependant biases.
Thus to further develop this study, we will seek to obtain from other centres the same data
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as we had available from Cambridge. If, using additional multicentre data, further validation
corroborates the current finding, we will then aim to develop a final model.
Over the course of our work, through examining literature, conducting analyses, and speaking
with medical and statistical professionals, we came across a number of important clinical
considerations for estimating GFR in patients with cancer. We first considered the effect of
chemotherapy and other treatment on GFR, creatinine and estimated GFR. A key challenge
for this analysis was a lack of data annotation providing detail on a patient’s treatment history.
To resolve this we used two surrogate methods to distinguish patients who had likely received
chemotherapy treatment versus those who had not. Similar to previous studies we found that
after receiving treatment a patient’s GFR was reduced, which was not initially matched by an
increase in serum creatinine. This resulted in an overestimate of GFR for patients under active
oncological management, such as currently receiving, or post chemotherapy. We corroborated
this finding by examining patients who had received numerous serum creatinine blood tests
in the two weeks preceding their nmGFR; these patients also had their GFR overestimated by
creatinine-based models.
Another consideration was the use of creatinine-based models for patients who had unstable
creatinine values. Using longitudinal serum creatinine measurements we categorised patients
as to whether their creatinine was increasing, decreasing or stable at the time of their nmGFR.
We found that patients with increasing creatinine had an overestimated GFR, whereas no bias
was observed for estimated GFR when a patient’s creatinine was decreasing. The limiting
factor with this analysis was the accuracy of the categorisation of patients, which was again
compounded by a lack of consistency in the data available, a factor over which we had no
control.
A final consideration was to assess the applicability of using CamGFR to estimate GFR for
healthy patients. We compared GFR in patients with cancer to healthy kidney donor patients
and observed that for younger patients there was no difference in GFR, however the rate of
decline in GFR with age was seen to be steeper for patients with cancer.
Even though this thesis presents the largest and most extensive dataset collected and analysed
with regards to GFR for patients with cancer, a recurring limiting factor has been a lack of
data availability and data consistency. This is not because such data does not exist, indeed
patient data are regularly used for clinical publications and is routinely collected in hospitals or
treatment centres. This field of research in general would benefit from increasing collaboration
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particularly with regards to the sharing of data. This should be an international effort as the
models produced from work such as that carried out in this thesis may be applied to patient
diagnosis and treatment internationally. Care, of course, needs to be taken to ensure ethical
standards are upheld, with patient anonymity and privacy respected. With the increasing volume,
storage and usage of routine patient data we are entering an exciting time in research. In the
near future, we should be able to use more data driven models to further our understanding of
underlying biology and improve both patient care and outcomes.
To conclude, we have shown that it is feasible to collate retrospective clinical data from multiple
centres which is of sufficient quality to conduct robust statistical modelling. This thesis is the
first multicentre comparison of models to estimate GFR in patients with cancer. In developing a
new statistical model, we address gaps in clinical research that have emerged due to increasing
data availability, the evolution of methods used to measure clinical variables such as creatinine,
and limited research into models that are developed based on patients with cancer. Overall, we
have demonstrated that CamGFR improves the accuracy of existing models for patients with
and without cancer, in turn, this improved accuracy may contribute to improved patient care.
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Appendix A
I have been involved in several other projects for which I have contributed statistical analysis.
While these are not discussed in detail in the body of the thesis, they are included in this
appendix for completeness. I was the statistician on an analysis of trends in T-cell checkpoint-
targeted cancer immunotherapy clinical trials, and on the analysis of interim results from
the national Hepatitis Prevention, Control, and Elimination (HPCE) in Mongolia. This work
contributed to the publication of two additional papers and a further paper which is currently
under review. These papers are presented below.
Regarding these facts, the recently issued guidelines from the
RECIST working group is of major importance to standardize the
i-RECIST. These guidelines (i) define the concept of “unconfirmed
PD ‘/’ confirmed PD” according to the results of the imaging per-
formed after the initial PD, (ii) include clinical stability in the defi-
nition, and (iii) define confirmed PD when a new lesion occurs
[5]. The authors should be applauded for this initiative; the defini-
tion of endpoints do not differ according to the sponsor.
Use of a common and standardized language is critical when
designing and analyzing clinical trials. Current ongoing trials used
widely different definitions of confirmed PD, creating major difficul-
ties when discussing results. The RECIST working group guidelines
should be endorsed to avoid non-reproducibility of trial results.
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Cancer immunotherapy trial registrations
increase exponentially but chronic
immunosuppressive glucocorticoid therapy
may compromise outcomes
T cell checkpoint-targeted immunotherapy is effective in multi-
ple cancers, but only in subsets of patients [1]. Failure of immu-
notherapy may be secondary to tumour intrinsic and/or systemic
factors that impair immune response. Glucocorticoid adminis-
tration has known systemic immunosuppressive effects [2] with
potential to impair immunotherapy outcome [3], and should
therefore be regulated at patient enrolment.
We performed a cross-sectional analysis of T cell checkpoint-
targeted cancer immunotherapy trials in solid malignancies regis-
tered on the U.S. National Institutes of Health (NIH) trial registry
(clinicaltrials.gov) by October 7, 2016. Trials were searched by
study type, condition, and interventions targeting the T cell check-
point proteins CTLA-4, PD-1, PD-L1, PD-L2, LAG3, B7-H3,
CD137, OX40, CD27 and GITR. Trials were reviewed manually
and independently by two clinicians and registered data on gluco-
corticoid administration within enrolment criteria recorded.
We identified 1017 registered T cell checkpoint-targeted cancer
immunotherapy trials. The number of registrations has progres-
sively increased, exponentially between 2010 and 2015 (R2¼ 0.95)
(Figure 1A). For the completed years, 2001–2015, chronic gluco-
corticoid administration was stated as an exclusion criterion in
40% (276/685), permitted in 29% (201/685) and not specified in
30% (208/685) of trial registration details. The proportion of trials
that did not allow glucocorticoid use has decreased significantly
(P< 0.001), while the proportion allowing glucocorticoid use has
increased significantly (P< 0.001) (Figure 1B). Of the trials per-
mitting glucocorticoid use, the maximum permitted dose of pre-
dnisolone equivalent per day was up to 10 mg in 57% of trials
(115/201), over 10 mg in 4% of trials (9/201) and not specified in
14% of trials (28/201); 24% of trials (49/201) permitted chronic
glucocorticoid use for physiological replacement.
These findings are concerning. The immunosuppressive effects
of glucocorticoids are dose dependent, starting at less than 10 mg
of prednisolone per day [2], and may be compounded by hypoal-
buminaemia present in patients with cancer [4]. Moreover, our
pre-clinical work has demonstrated that low dose glucocorticoid
administration is sufficient to suppress response to cancer immu-
notherapy [3]. Therefore, unregulated glucocorticoid adminis-
tration may result in treatment failure independent of the T cell
checkpoint-targeted agent or tumour type.
The use of glucocorticoids as appetite stimulants and anti-
emetics, particularly relevant in combination trials with emeto-
genic chemotherapy or radiotherapy, may also be immunosup-
pressive and will require critical review. While the use of
glucocorticoids for adrenal replacement or chronic immune ill-
ness may be unavoidable, stratification for their use at enrolment
should be considered.
In addition to glucocorticoid administration, endogenous glu-
cocorticoid levels may also impact on response to immunother-
apy. Monitoring and stratification according to baseline
glucocorticoid levels, or clinical surrogates of these such as longi-
tudinal weight measurements [3], may yield predictive and prog-
nostic markers of response.
We note that the chronic use of glucocorticoids should be con-
sidered independently from the use of glucocorticoids in manag-
ing immune-related adverse events during immunotherapy. In
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fact, the positive correlation of autoimmune side effects and
treatment efficacy [5] provides further rationale for considering
the role of systemic immunomodulatory variables in determining
response to immunotherapy.
Our study is limited by the exclusive use of data from the U.S.
NIH trial registry. However, this is the largest clinical trial regis-
try, and the registration of key inclusion and exclusion criteria is
international standard [6] and has been mandatory for consider-
ation of publication by the International Committee of Medical
Journal Editors member journals since 2005.
In summary, we find glucocorticoid administration to be a
neglected immunomodulatory variable in cancer immunother-
apy trials, and suggest striving for greater harmony in the moni-
toring and regulation of systemic glucocorticoids to improve
outcomes in cancer immunotherapy.
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Figure 1. Longitudinal registration count and glucocorticoid administration in T cell checkpoint-targeted cancer immunotherapy trials. (A) Annual registration count of T cell checkpoint-tar-
geted cancer immunotherapy trials. Trials registered by October 7, 2016 on the U.S. National Institutes of Health (NIH) trial registry were categorized according to year of registration and check-
point protein target. T cell checkpoint proteins targeted in fewer than 10 trials are grouped as ‘other’, and include single agent OX40, GITR, CD137, B7-H3, LAG3, PD-L2, CD27 and trials
comparing multiple checkpoint-targeting agents. ‘Combination’ trials include all pre-defined T cell checkpoint-targeted agents used in combination with another agent. (B) Specification of glu-
cocorticoid administration within enrolment criteria of T cell checkpoint-targeted cancer immunotherapy trials. Trials registered on the U.S. NIH trial registry between 2001 and 2015 were cate-
gorized according to the specification of chronic systemic glucocorticoid administration within registered patient enrolment criteria. Univariate analysis for data presented was performed using
the Cochran–Armitage test for trend assuming monotonical change over time and expected frequencies were met (80% of expected frequencies>5). ***P< 0.001; NS¼ not significant.
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ABSTRACT
Immune-related radiological and biomarker monitoring in can-
cer immunotherapy trials permits interrogation of efficacy and
reasons for therapeutic failure. We report the results from a
cross-sectional analysis of response monitoring in 685 T-cell
checkpoint-targeted cancer immunotherapy trials in solid
malignancies, as registered on the U.S. National Institutes of
Health trial registry by October 2016. Immune-related radio-
logical response criteria were registered for only 25% of clinical
trials. Only 38% of trials registered an exploratory immunologi-
cal biomarker, and registration of immunological biomarkers
has decreased over the last 15 years.We suggest that increas-
ing the utilization of immune-related response monitoring
across cancer immunotherapy trials will improve analysis of
outcomes and facilitate translational efforts to extend the ben-
efit of immunotherapy to a greater proportion of patients with
cancer.The Oncologist 2018;23:116–117
T-cell checkpoint-targeted cancer immunotherapies are making
an increasing impact on clinical practice, and their investigation
in clinical trials has risen exponentially [1]. Effective and effi-
cient response evaluation is essential, but presents challenges
due to idiosyncratic radiological responses and lack of early
response biomarkers. Concerted efforts to overcome these
challenges have included the generation of immune-related
response criteria (irRC) [2, 3] to better accommodate
immunotherapy-associated response kinetics, and recommen-
dations for immunological monitoring throughout all phases
of clinical trial design to help identify predictive/prognostic
biomarkers of response and mechanistic insight into patterns
of resistance [3, 4].
We assessed quantitatively the inclusion of irRC and
immunological biomarker primary response monitoring in the
registration details of T-cell checkpoint-targeted cancer immu-
notherapy trials in solid malignancies registered on the NIH
trial registry (clinicaltrials.gov) by October 7, 2016. To over-
come potential limitations from incomplete registrations,
data were analyzed across three consecutive 5-year periods.
During the completed years, 2001–2015, 91% (622/685) of
immunotherapy trials registered use of a radiological endpoint.
Analyzing the trend of utilization, we found a significantly
increasing (p 5 .014) proportion of these trials specified use of
the World Health Organization/Response Evaluation Criteria in
Solid Tumors, reaching 56% (307/551) in the last 5 years. Use
of the irRC (established in 2009) also increased, but only
reached 25% (135/551) of trials. A total of 38% (234/622) of
Figure 1. Radiological and immune biomarker monitoring in T-cell
checkpoint-targeted cancer immunotherapy trials. All 685 T-cell
checkpoint-targeted cancer immunotherapy trials registered on the
U.S. NIH trial registry between 2001 and 2015 were categorized
according to year of registration and registered imaging and immune
biomarker outcomemeasures (left) and radiological response criteria
(right). Six trials used the Response Assessment in Neuro-Oncology
criteria (not shown). Immune biomarkers included monitoring of any
immune-related parameter, including via immunohistochemistry,
immune cell counts, cytokine analysis, and humoral/cellular immune
responses. Univariate analysis for data presented was performed
using the Cochran-Armitage test for trend. *, p< .05; ***, p< .001.
Abbreviations: irRC, immune-related response criteria; RECIST,
Response Evaluation Criteria in Solid Tumors; WHO, World Health
Organization.
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trials registered use of an imaging endpoint without specifying
imaging criteria. Overall, only 38% (259/685) of trials included
immunological biomarker monitoring, and this proportion
decreased significantly (p 5 .011) over three consecutive
5-year periods (Figure 1).
These findings highlight three areas of concern. Firstly,
underutilization of the irRC may be associated with an underes-
timation of treatment response [2, 5]. This impact may be
dependent on tumor type or checkpoint-targeted agent [6].
However, prospective inclusion of radiological criteria that
accommodate unconventional response kinetics is essential in
order to avoid future misclassification of response and inappro-
priate cessation of effective therapy. Secondly, the failure to
incorporate immunological, and emerging host-centric [7], bio-
marker monitoring presents a missed opportunity to establish
surrogate markers of response and/or resistance [3, 4]. Thirdly,
specification and/or metrics of imaging outcome measures
were found wanting in 234 trials, an omission that should be
addressed, particularly in view of recent regulations [8].
The underutilization of recommended radiographic and
immunological monitoring identified by these data, together
with suboptimal dose finding identified by others [9], may
limit the interpretation of clinical trial results and thereby
the development of effective cancer immunotherapies and
consensus guidelines for their use. Increasing the incorpora-
tion of these measures will help answer the call for greater
accountability in the design of clinical trials to optimize the
value of data generated [4, 8]. This will improve our knowl-
edge, and application, of immunotherapy for the benefit of
patients with cancer.
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Mongolia, the country with the highest prevalence of viral hepatitis and the highest liver 28 
cancer mortality in the world, initiated a national Hepatitis Prevention, Control, and 29 
Elimination (HPCE) Program in 2016. This program aims to eliminate hepatitis C virus 30 
(HCV) nationwide by the end of 2020, ahead of the World Health Organization global 31 
target of 2030. This study quantifies the impact of the HPCE Program on the prevalence 32 




We performed two randomized cross-sectional surveys in the adult population of 37 
Ulaanbaatar. The first survey was conducted in 2013 and the second in 2018, prior to and 38 
after implementation of the HPCE Program respectively. Anti-HCV antibody (HCV 39 
antibody) positivity as a marker of HCV exposure and HCV-RNA detectability as a marker 40 
of disease activity were determined. 41 
 42 
Results 43 
Screening for HCV was conducted in 571 individuals in 2013 and in 579 individuals in 44 
2018. HCV antibody positivity remained unchanged between 2013 and 2018, at 7.7% and 45 
7.8% respectively. The fraction of HCV antibody positive individuals with detectable HCV-46 
RNA decreased from 79.1% in 2013 to 35.3% in 2018. The largest absolute decrease 47 
was seen in women over the age of 50 years. 48 
 49 
Conclusions 50 
Between 2013 and 2018, the burden of active HCV infection in the adult population of 51 
Ulaanbaatar has fallen markedly, in concordance with the intent of the HPCE program. 52 
HCV elimination in Mongolia appears to be a realistic goal. 53 
